<SEC-DOCUMENT>0001005286-24-000081.txt : 20240701
<SEC-HEADER>0001005286-24-000081.hdr.sgml : 20240701
<ACCEPTANCE-DATETIME>20240701082058
ACCESSION NUMBER:		0001005286-24-000081
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240628
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240701
DATE AS OF CHANGE:		20240701

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIFECORE BIOMEDICAL, INC. \DE\
		CENTRAL INDEX KEY:			0001005286
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				943025618
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0528

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-27446
		FILM NUMBER:		241088243

	BUSINESS ADDRESS:	
		STREET 1:		3515 LYMAN BOULEVARD
		CITY:			CHASKA
		STATE:			MN
		ZIP:			55318
		BUSINESS PHONE:		9523684300

	MAIL ADDRESS:	
		STREET 1:		3515 LYMAN BOULEVARD
		CITY:			CHASKA
		STATE:			MN
		ZIP:			55318

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LANDEC CORP \CA\
		DATE OF NAME CHANGE:	19951222
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lndc-20240628.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9de62c0c-edcd-4a54-9604-66eca7237ca7,g:0bc9d023-c4e8-4328-9407-a0fa005fd734,d:4bc551fa1d664482942b3212a1c2e56b-->
<html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lndc-20240628</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-21">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001005286</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lndc-20240628.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001005286</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-28</xbrli:startDate><xbrli:endDate>2024-06-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4bc551fa1d664482942b3212a1c2e56b_1"></div><div style="min-height:29.25pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="padding-left:9pt;padding-right:9pt"><span><br/></span></div><div style="padding-left:9pt;padding-right:9pt"><span><br/></span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><span><br/></span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the</span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</span></div><div style="padding-left:9pt;padding-right:9pt"><span><br/></span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">June 28, 2024</ix:nonNumeric></span></div><div style="padding-left:9pt;padding-right:9pt"><span><br/></span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">LIFECORE BIOMEDICAL, INC.</ix:nonNumeric></span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><span><br/></span></div><div style="padding-left:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.694%"><tr><td style="width:1.0%"/><td style="width:36.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.702%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.702%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-27446</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">94-3025618</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission file number)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.694%"><tr><td style="width:1.0%"/><td style="width:23.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.676%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">3515 Lyman Boulevard</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Chaska,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Minnesota</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">55318</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span><br/></span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">952</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">368-4300</ix:nonNumeric></span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Not Applicable</span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="padding-left:9pt;padding-right:9pt"><span><br/></span></div><div style="padding-left:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="padding-left:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div style="padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div style="padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div style="padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"/><td style="width:33.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.754%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">LFCR</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-left:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="padding-left:9pt;padding-right:9pt"><span><br/></span></div><div style="padding-left:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company &#160; <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span></div><div style="padding-left:9pt;padding-right:9pt"><span><br/></span></div><div style="padding-left:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160; &#9744;</span></div><div style="padding-left:9pt"><span><br/></span></div><div id="i4bc551fa1d664482942b3212a1c2e56b_7"></div><div style="text-align:justify"><span><br/></span></div><div style="height:29.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:29.25pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 1.01 Entry into a Material Definitive Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">22NW Cooperation Agreement </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 28, 2024, Lifecore Biomedical, Inc., a Delaware corporation (the &#8220;Company&#8221;), entered into a Cooperation Agreement (the &#8220;22NW Cooperation Agreement&#8221;) with 22NW Fund, LP, 22NW, LP, 22NW Fund GP, LLC, 22NW GP, Inc., Aron R. English, Bryson O. Hirai-Hadley, and Nathaniel Calloway (each, a &#8220;22NW Investor&#8221; and collectively, the &#8220;22NW Investor Group&#8221;) and Matthew Korenberg and Jason Aryeh, who are independent of the 22NW Investor Group. As of the date of the 22NW Cooperation Agreement, the 22NW Investor Group has represented to the Company that it is deemed to beneficially own 4,099,529 shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;) (which includes 2,344,368 shares of Common Stock issuable upon the conversion of Preferred Shares (as defined below)) and 16,436 shares of the Company&#8217;s Series A Convertible Preferred Stock, par value $0.001 per share (the &#8220;Preferred Shares&#8221;), totaling, in the aggregate, approximately 12.3% of the Company&#8217;s outstanding voting securities on an as-converted to Common Stock basis.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the 22NW Cooperation Agreement, 22NW agreed to irrevocably withdraw (i) its notice to the Company, dated May 16, 2024, of its intention to submit director nominees at the Company&#8217;s 2023 annual meeting of stockholders (the &#8220;2023 Annual Meeting&#8221;), and (ii) its written demand of the Company, dated June 11, 2024, for a special meeting of the stockholders of the Company to be held on August 14, 2024. Additionally, the Board has agreed to submit to the stockholders of the Company at the 2023 Annual Meeting a proposal to approve an amendment of the Company&#8217;s Amended and Restated Certificate of Incorporation to provide for the phased-in declassification of the Board, with Class 1 directors being elected annually beginning at the Company&#8217;s 2024 annual meeting of stockholders (the &#8220;2024 Annual Meeting&#8221;) and with Class 2 directors being elected annually beginning at the Company&#8217;s 2025 annual meeting of stockholders (the &#8220;2025 Annual Meeting&#8221;), such that the Board would be fully declassified at the time of the 2025 Annual Meeting (the &#8220;Declassification Proposal&#8221;).</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, pursuant to the 22NW Cooperation Agreement, the Board of Directors of the Company (the &#8220;Board&#8221;) will invite Messrs. Korenberg and Aryeh, Humberto Antunes, and Paul Johnson (the &#8220;Board Observers&#8221;) to the Board as Board observers within 10 days of the execution of the 22NW Cooperation Agreement. The Board Observers will be removed as Board observers at the conclusion of the 2023 Annual Meeting. Mr. Aryeh will also be nominated for election to the Board as a Class 2 director by the holders of the Preferred Shares at the 2023 Annual Meeting, with a term expiring at the Company&#8217;s 2025 annual meeting of stockholders (the &#8220;2025 Annual Meeting&#8221;). Additionally, immediately following the 2023 Annual Meeting, the Board will appoint Messrs. Korenberg and Antunes to the Board effective as of immediately following the 2023 Annual Meeting, with Messrs. Korenberg and Antunes to serve as Class 1 directors on the Board, with a term expiring at the 2024 Annual Meeting.  The Board will also nominate Messrs. Korenberg and Antunes for election to the Board at the 2024 Annual Meeting, with a term expiring at the Company&#8217;s 2026 annual meeting of stockholders (the &#8220;2026 Annual Meeting&#8221;) (or, if the Declassification Proposal is approved by the Company&#8217;s stockholders at the 2023 Annual Meeting, with a term expiring at the 2025 Annual Meeting). Further, immediately following the 2023 Annual Meeting, the Board will appoint Mr. Johnson to the Board effective as of immediately following the 2023 Annual Meeting, to serve as a Class 2 director on the Board, with a term expiring at the 2025 Annual Meeting.  The Board will also nominate Mr. Johnson for election to the Board at the 2025 Annual Meeting, with a term expiring at the Company&#8217;s 2027 annual meeting of stockholders (the &#8220;2027 Annual Meeting&#8221;) (or, if the Declassification Proposal is approved by the Company&#8217;s stockholders at the 2023 Annual Meeting, with a term expiring at the 2026 Annual Meeting).</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the 22NW Cooperation Agreement, the Company has agreed that, following the 2023 Annual Meeting and if elected, Mr. Aryeh will be appointed as a member of the Nominating and Corporate Governance Committee (the &#8220;Nominating Committee&#8221;). Mr. Korenberg will be appointed as a member of the Audit Committee upon appointment to the Board immediately following the 2023 Annual Meeting. Additionally, if the Audit Committee chair vacates their position during the Standstill Period (as defined below), then Mr. Korenberg will become chair of the Audit Committee. Moreover, immediately following the 2023 Annual Meeting, the Board will add two directors who are not affiliated with nor previously nominated by the holders of Preferred Shares to a Special Committee of the Board to address certain matters set forth in the 22NW Cooperation Agreement.  </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, pursuant to the 22NW Cooperation Agreement, the Board agrees to (i) reduce the size of the Board from nine seats to eight seats immediately prior to the 2023 Annual Meeting, (ii) increase the size of the Board from eight seats to eleven seats immediately following the 2023 Annual Meeting, (iii) reduce the size of the Board from eleven seats to nine seats upon the earlier of (A) immediately prior to the 2024 Annual Meeting or (B) November 30, 2024, and (iv) following reduction in size of the Board described in (iii) above, during the Standstill Period, the size of the Board may be increased by the Board by no more than two seats only pursuant to an agreement with an investor in or debt financing provider to the Company in connection with such equity or debt transaction.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the 22NW Cooperation Agreement, the 22NW Investor Group has agreed to certain customary standstill provisions with respect to the 22NW Investor Group&#8217;s actions with regard to the Company, the Common Stock, and the Preferred Shares for the duration of the Standstill Period. The Standstill Period begins as of the date of the 22NW Cooperation Agreement and ends upon the earlier of immediately after the Company&#8217;s 2025 annual meeting of stockholders or October 31, 2025; provided however, that the Standstill Period may expire earlier upon the occurrence of certain actions or inactions, including the termination of or uncured material breach of the Legion Cooperation Agreement or Wynnefield Cooperation Agreement (each as defined below).</span></div><div><span><br/></span></div><div style="height:29.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:29.25pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the 22NW Cooperation Agreement, the 22NW Investor Group has agreed that during the pendency of the Standstill Period, the 22NW Investor Group will take certain actions, including to vote, or cause to be voted, all shares of Common Stock and Preferred Shares beneficially owned by each member of the 22NW Investor Group in favor of (a) each of the directors nominated by the Board and recommended by the Board in the election of directors (and not in favor of any other nominees to serve on the Board), and (b) each of the stockholder proposals listed on the Company&#8217;s proxy card or voting instruction form as identified in the Company&#8217;s proxy statement in accordance with the Board&#8217;s recommendations, including in favor of all other matters recommended for stockholder approval by the Board; provided, however, that in the event that Institutional Shareholder Services Inc. (&#8220;ISS&#8221;) recommends otherwise with respect to any proposals (other than the election or removal of directors or any proposed increase in the authorized shares of the Company), each of the 22NW Investors shall be permitted to vote in accordance with the ISS recommendations; provided, further, that each of the 22NW Investors shall be permitted to vote in their sole discretion with respect to any publicly announced proposals relating to a merger, acquisition, disposition of all or substantially all of the assets of the Company, or other business combination involving the Company requiring a vote of stockholders of the Company.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The 22NW Cooperation Agreement also contains certain customary confidentiality, non-disparagement, and other undertakings by the 22NW Investor Group and the Company. In addition, the parties have made customary representations and warranties.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The foregoing description of the 22NW Cooperation Agreement is qualified in its entirety by reference to the full text of the 22NW Cooperation Agreement, which is filed herewith as Exhibit 10.1 and incorporated herein by reference. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Legion Cooperation Agreements </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 28, 2024, the Company entered into a Cooperation Agreement with Legion Partners, L.P. I, Legion Partners, L.P. II, Legion Partners, LLC, Legion Partners Asset Management, LLC, Legion Partners Holdings, LLC, Christopher S. Kiper and Raymond T. White (each, a &#8220; Legion Investor&#8221; and collectively, the &#8220;Legion Investor Group&#8221;) (the &#8220;Legion Cooperation Agreement&#8221;). As of the date of the Legion Cooperation Agreement, the Legion Investor Group has represented to the Company that it is deemed to beneficially own 4,961,814 shares of the Company&#8217;s Common Stock (which includes 1,993,405 shares of Common Stock issuable upon the conversion of Preferred Shares) and 13,954 shares of the Company&#8217;s Preferred Shares, totaling, in the aggregate, approximately 15.2% of the Company&#8217;s outstanding voting securities on an as-converted to Common Stock basis.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the terms of the Legion Cooperation Agreement, Mr. Kiper will be nominated for election to the Board as a Class 1 director by the holders of the Preferred Shares at the 2024 Annual Meeting, with a term expiring at the 2026 Annual Meeting (or, if the Declassification Proposal is approved by the Company&#8217;s stockholders at the 2023 Annual Meeting, with a term expiring at the 2025 Annual Meeting and, in such event, Mr. Kiper will also be nominated for election to the Board as a director by the holders of the Preferred Shares at the 2025 Annual Meeting, with a term expiring at the 2026 Annual Meeting). </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the Legion Cooperation Agreement, the Legion Investor Group has agreed to certain customary standstill provisions with respect to the Legion Investor Group&#8217;s actions with regard to the Company, the Common Stock, and the Preferred Shares for the duration of the Standstill Period. The Standstill Period begins as of the date of the Legion Cooperation Agreement and ends upon the earlier of immediately after the Company&#8217;s 2025 annual meeting of stockholders or October 31, 2025; provided however, that the Standstill Period may expire earlier upon the occurrence of certain actions or inactions, including the termination of or uncured material breach of the 22NW Cooperation Agreement or Wynnefield Cooperation Agreement (as defined below).</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the Legion Cooperation Agreement, the Legion Investor Group has agreed that during the pendency of the Standstill Period, the Legion Investor Group will take certain actions, including to vote, or cause to be voted, all shares of Common Stock and Preferred Shares beneficially owned by each member of the Legion Investor Group in favor of (a) each of the directors nominated by the Board and recommended by the Board in the election of directors (and not in favor of any other nominees to serve on the Board), and (b) each of the other proposals listed on the Company&#8217;s proxy card or voting instruction form as identified in the Company&#8217;s proxy statement in accordance with the Board&#8217;s recommendations; provided, however, that in the event that ISS or Glass Lewis &amp; Co., LLC (&#8220;Glass Lewis&#8221;) recommends otherwise with respect to any proposals (other than the election or removal of directors or any proposed increase in the authorized shares of the Company), each of the Legion Investors shall be permitted to vote in accordance with the ISS or Glass Lewis recommendations; provided, further, that each of the Legion Investors shall be permitted to vote in their sole discretion with respect to any publicly announced proposals relating to a merger, acquisition, disposition business combination, amalgamation, recapitalization, restructuring, distribution, spin-off, joint venture, any tender or exchange offer, any dissolution, liquidation, or reorganization of the Company, any debt or equity issuances or financings, the implementation of takeover defenses not in existence as of the date of the Legion Cooperation Agreement, or any other similar extraordinary matters involving the Company requiring a vote of stockholders of the Company.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Legion Cooperation Agreement also contains certain customary confidentiality, non-disparagement, and other undertakings by the Legion Investor Group and the Company. In addition, the parties have made customary representations and warranties.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The foregoing description of the Legion Cooperation Agreement is qualified in its entirety by reference to the full text of the Cooperation Agreement, which is filed herewith as Exhibit 10.2 and incorporated herein by reference. </span></div><div style="height:29.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:29.25pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Wynnefield Cooperation Agreement</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 28, 2024, the Company entered into a Cooperation Agreement (the &#8220;Wynnefield Cooperation Agreement&#8221; and, together with the 22NW Cooperation Agreement and the Legion Cooperation Agreement, the &#8220;Cooperation Agreements&#8221;) with Wynnefield Partners Small Cap Value, L.P. I, Wynnefield Partners Small Cap Value, L.P., Wynnefield Small Cap Value Offshore Fund, Ltd., Wynnefield Capital Inc. Profit Sharing &amp; Money Purchase Plan, Wynnefield Capital Management, LLC, Wynnefield Capital, Inc., Nelson Obus, and Joshua Landes (each, a &#8220;Wynnefield Investor&#8221; and collectively, the &#8220;Wynnefield Investor Group&#8221;). As of the date of the Wynnefield Cooperation Agreement, the Wynnefield Investor Group has represented to the Company that it is deemed to beneficially own 5,007,666 shares of the Company&#8217;s Common Stock (which includes 507,946 shares of Common Stock issuable upon the conversion of Preferred Shares) and 3,561 shares of the Company&#8217;s Preferred Shares, totaling, in the aggregate, approximately 16.0% of the Company&#8217;s outstanding voting securities on an as-converted to Common Stock basis.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the terms of the Wynnefield Cooperation Agreement, the Board agrees to nominate Mr. Obus to the Board as a Class 1 director at the 2024 Annual Meeting, with a term expiring at the 2026 Annual Meeting (or, if the Declassification Proposal is approved by the Company&#8217;s stockholders at the 2023 Annual Meeting, with a term expiring at the 2025 Annual Meeting).</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the Wynnefield Cooperation Agreement, the Wynnefield Investor Group has agreed to certain customary standstill provisions with respect to the Wynnefield Investor Group&#8217;s actions with regard to the Company, the Common Stock, and the Preferred Shares for the duration of the Standstill Period. The Standstill Period begins as of the date of the Wynnefield Cooperation Agreement and ends upon the earlier of immediately after the Company&#8217;s 2025 annual meeting of stockholders or October 31, 2025; provided however, that the Standstill Period may expire earlier upon the occurrence of certain actions or inactions, including the involuntary removal of Nelson Obus as a member of the Board&#8217;s Nominating Committee or Compensation Committee and the termination of or uncured material breach of the 22NW Cooperation Agreement or Legion Cooperation Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the Wynnefield Cooperation Agreement, the Wynnefield Investor Group has agreed that during the pendency of the Standstill Period, the Wynnefield Investor Group will take certain actions, including to vote, or cause to be voted, all shares of Common Stock and Preferred Shares beneficially owned by each member of the Wynnefield Investor Group in favor of (a) each of the directors nominated by the Board and recommended by the Board in the election of directors (and not in favor of any other nominees to serve on the Board), and (b) each of the stockholder proposals listed on the Company&#8217;s proxy card or voting instruction form as identified in the Company&#8217;s proxy statement in accordance with the Board&#8217;s recommendations; provided, however, that in the event that ISS or Glass Lewis recommends otherwise with respect to any proposals (other than the election or removal of directors or any proposed increase in the authorized shares of the Company), each of the Wynnefield Investors shall be permitted to vote in accordance with the ISS or Glass Lewis recommendations; provided, further, that each of the Wynnefield Investors shall be permitted to vote in their sole discretion with respect to any publicly announced proposals relating to a merger, acquisition, disposition of all or substantially all of the assets of the Company, or other business combination involving the Company requiring a vote of stockholders of the Company.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Wynnefield Cooperation Agreement also contains certain customary confidentiality, non-disparagement, and other undertakings by the Wynnefield Investor Group and the Company. In addition, the parties have made customary representations and warranties.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The foregoing description of the Wynnefield Cooperation Agreement is qualified in its entirety by reference to the full text of the Wynnefield Cooperation Agreement, which is filed herewith as Exhibit 10.3 and incorporated herein by reference. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 28, 2024, pursuant to the 22NW Cooperation Agreement, the Board, upon the recommendation of the Nominating Committee, appointed Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors, effective immediately following the conclusion of the 2023 Annual Meeting. Messrs. Korenberg and Antunes will serve as independent directors on the Board, with a term expiring at the 2024 Annual Meeting and Mr. Johnson will serve as an independent director until the 2025 Annual Meeting of Stockholders, until their respective successors are duly elected and qualified or until their earlier death, disqualification, resignation or removal. In accordance with the 22NW Cooperation Agreement, Mr. Korenberg will be appointed as a member of the Audit Committee upon appointment to the Board immediately following the 2023 Annual Meeting. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Messrs. Johnson, Antunes, and Korenberg will be compensated for their service as directors on the same basis as other non-employee directors of the Company. The Company&#8217;s non-employee director compensation, including certain benefits and grants of restricted stock units, is described under the heading &#8220;Corporate Governance&#8212;Compensation of Directors&#8221; in Lifecore&#8217;s proxy statement for the 2022 Annual Meeting filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on September 19, 2022. In addition, prior to joining the Board, the Company will enter into indemnification agreements with Messrs. Korenberg, Antunes, and Johnson on the form previously approved by the Board and entered into with the Company&#8217;s other directors.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are no arrangements or understandings between Messrs. Johnson, Antunes, and Korenberg and any other persons pursuant to which each was appointed as a director of the Company, and neither has direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K promulgated by the SEC.</span></div><div style="height:29.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:29.25pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 7.01 Regulation FD Disclosure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A copy of the press release issued by the Company on July 1, 2024 announcing the execution of the Cooperation Agreements is attached hereto as Exhibit 99.1 and incorporated herein by reference.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information furnished in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d) Exhibits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following exhibits are furnished as part of this report:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.040%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101-lifecorexcooper.htm">10.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101-lifecorexcooper.htm">Cooperation Agreement, effective as of June 28, 2024, by and among Lifecore Biomedical, Inc., Jason Aryeh, Matthew Korenberg and certain 22NW Investors specified therein.</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102-lifecorexcooper.htm">10.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit102-lifecorexcooper.htm">Cooperation Agreement, effective as of June 28, 2024, between Lifecore Biomedical, Inc. and certain Legion Investors specified therein.</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit103-lifecorexcooper.htm">10.3</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit103-lifecorexcooper.htm">Cooperation Agreement, effective as of June 28, 2024, between Lifecore Biomedical, Inc. and certain Wynnefield Investors specified therein.</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991-lifecorexprcoop.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit991-lifecorexprcoop.htm">Press Release dated July 1, 2024, of Lifecore Biomedical, Inc..</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i4bc551fa1d664482942b3212a1c2e56b_10"></div><div style="text-align:center"><span><br/></span></div><div style="height:29.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:29.25pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SIGNATURE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Date: July 1, 2024</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.111%"><tr><td style="width:1.0%"/><td style="width:16.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.959%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LIFECORE BIOMEDICAL, INC.</span></td></tr><tr style="height:13pt"><td colspan="9" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:13pt"><td colspan="9" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By:</span></div></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John D. Morberg</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John D. Morberg</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:29.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101-lifecorexcooper.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ide3d9fc7199c4f148ae428e47841b595_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COOPERATION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Cooperation Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made and entered into as of June 28, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by and among Lifecore Biomedical, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Lifecore</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and each of the persons listed on Exhibit&#160;A hereto (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investor Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Company and each of the Investors are each herein referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;. Unless otherwise defined herein, capitalized terms shall have the meanings given to them in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, on March 21, 2024 the Company disclosed on a Form 8-K that Craig Barbarosh notified the Company that he has elected not to stand for re-election to serve as a director of the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) at the Company&#8217;s annual meeting of stockholders for the 2023 fiscal year, which is scheduled to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">take place on August 15, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2023 Annual Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and that the Board approved the appointment of Katrina L. Houde as Chairperson of the Board, effective as of the 2023 Annual Meeting&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, each of the Investors beneficially owns the number of shares of (i) the Company&#8217;s common stock, par value $0.001 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and (ii) the Company&#8217;s Series A Convertible Preferred Stock, par value $0.001 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Series A Preferred Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), each as listed on Exhibit&#160;A hereto&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, on May 16, 2024, 22NW Fund, LP (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">22NW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) delivered to the Company a notice of intent to submit director nominations (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nomination Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) at the 2023 Annual Meeting&#894;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, on May 20, 2024, 22NW filed a Schedule 13D&#47;A with the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) disclosing its intention to nominate certain individuals to the Board, as set forth in the Nomination Notice&#894; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, on June 11, 2024, 22NW delivered to the Company a written demand for a special meeting of the stockholders of the Company to be held on August 14, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Special Meeting Demand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#894;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, on June 11, 2024, 22NW filed a Schedule 13D&#47;A with the SEC disclosing the Special Meeting Demand&#894; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, concurrent with the entry of this Agreement, Legion Partners Holdings, LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Legion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (and its Affiliates) and Wynnefield Capital Management, LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Wynnefield</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (and its Affiliates) have entered into similar agreements with the Company, complete copies of which have been delivered to the Investors prior to the execution herewith (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Other Investor Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#894; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Company </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">has reached an agreement with the Investors with respect to the composition of the Board and certain other matters as provided in this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Investor Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Irrevocable Withdrawals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. 22NW hereby irrevocably withdraws the Nomination Notice and the Special Meeting Demand.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Board </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Composition and Other Company Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Board Observers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">Within ten (10) days of the Effective Date, the Board, and all applicable committees of the Board, shall take all actions necessary to invite and appoint Humberto Antunes, Jason Aryeh, Paul Johnson and Matthew Korenberg to serve as non-voting observers to the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board Observers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) subject to delivery to the Company from each of the Board Observers an executed version of the undertaking to the Company in the form set forth on Exhibit B hereto. The Board Observers shall be entitled to attend, participate in discussions, and provide input at any portion of Board meetings and meetings of any Board committee (including via telephone, videoconference, or other electronic medium) at which business operations, financial results, capital allocation, financing alternatives, investor communications, board composition matters, stockholder value enhancement initiatives, strategic transactions, acquisitions, dispositions and&#47;or any other material corporate transactions are discussed (any of the foregoing topics, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Approved Topic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; and all such topics collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Approved Topics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in a non-voting observer capacity and, in this respect, shall (except to the extent that the Board Observers have been excluded therefrom pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2(a)(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> below) receive copies of the applicable portion of such notices, minutes, consents, and other materials and information relating to an Approved Topic or the Approved Topics (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Relevant Materials and Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that the Company provides to the directors on the applicable committees and&#47;or the Board at the same time and in the same manner as provided to such directors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">Until the Board Observers are appointed to the Board pursuant to the provisions of this Agreement or as otherwise elected at a meeting of stockholders of the Company, in no event shall the Board Observers&#58; (A) be deemed to be members of the Board or any committee thereof&#59; (B) be counted for purposes of voting, quorum, or any other reason&#59; (C) have the right to vote on any matter under consideration by the Board or any committee or otherwise have any power to cause the Company to take, or not to take, any action&#59; or (D) except as expressly set forth in this Agreement, have or be deemed to have, or otherwise be subject to, any duties (fiduciary or otherwise) to the Company or its stockholders or any duties (fiduciary or otherwise) otherwise applicable to the directors of the Company. Notwithstanding the foregoing, the Investor Group and the Board Observers understand and acknowledge that the Board Observers are required to comply with all policies, processes, procedures, codes, rules, standards, and guidelines applicable to members of the Board, as in effect from time to time, including, without limitation, the Company&#8217;s Corporate Governance Guidelines, Code of Business </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Conduct, and policies on stock trading, stock ownership, hedging and pledging of Company securities, public disclosures and confidentiality, and agree to strictly preserve the confidentiality of Company business and information, including the discussion of any matters considered in meetings of the Board or Board committees whether or not the matters relate to material non-public information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">If a meeting of the Board or any of the committees relating to an Approved Topic is conducted via telephone, videoconference, or other electronic medium, the Board Observers may attend the portion of such meeting at which an Approved Topic is to be discussed via the same medium&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that it shall be a material breach of this Agreement by the Board Observers to provide any other person access to such meeting without the Company&#8217;s express prior written consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">The Company reserves the right to withhold any information and to exclude the Board Observers from any meeting or portion thereof of the Board or any committee thereof (A) where an Approved Topic is not intended to be discussed, (B) if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel, violate any agreement between the Company and a third-party, violate any applicable law or regulation, or result in the disclosure of trade secrets or a conflict of interest, if any Investor, the Board Observers, or any of their respective Affiliates is or becomes a competitor of the Company, (C) with respect to Jason Aryeh, if such meeting or portion thereof involves a potential conflict of interest between the Company and the holders of Series A Preferred Shares, or (D) if such meeting or portion thereof is an executive session of the Board, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that no binding actions are taken or submitted to the Board with respect to an Approved Topic at any such executive sessions under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2(a)(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Board Observers other than Jason Aryeh shall be removed from their position as Board Observers upon the conclusion of the 2023 Annual Meeting, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, such Board Observers are appointed to serve on the Board upon the conclusion of the 2023 Annual Meeting as contemplated by this Agreement (as long as such Board Observers are available and qualified for such appointment at such time). Jason Aryeh shall be removed from his position as a Board Observer upon the conclusion of the 2023 Annual Meeting. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Recommendation of Class 1 Series A Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Pursuant to Section 13(c) of that certain Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of Lifecore Biomedical, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Series A Certificate of Designation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), 22NW, one of the two largest holders of shares of Series A Preferred Shares as of the Effective Date, designates Christopher Kiper (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Class 1 Series A Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for election to the Board as a Series A Preferred Director (as defined in the Series A Certificate of Designation) at the Company&#8217;s annual meeting of stockholders for the 2024 fiscal year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2024 Annual Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Board hereby, on a one-time basis, waives compliance with the notice deadline established in Section 2.5 of the Amended and Restated Bylaws of Lifecore Biomedical, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Bylaws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in connection with such designation.  Subject to, and conditioned upon, (i) receipt by the Company of a written designation of Christopher Kiper by the other largest holder of Series </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A Preferred Shares as of the Effective Date and (ii) the satisfaction of the Preferred Stock Director Designation Right Condition (as defined in the Series A Certificate of Designation) as of immediately prior to the 2024 Annual Meeting (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Class 1 Series A Director Qualification Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Board, and all applicable committees of the Board, shall (A) take all necessary actions to nominate the Class 1 Series A Director as a director (or Class 1 director if applicable at such time) and as a Series A Preferred Director (as defined in the Series A Certificate of Designation) for election to the Board by the holders of the Series A Preferred Shares, voting separately as a class, at the 2024 Annual Meeting with a term expiring at the Company&#8217;s annual meeting of stockholders for the 2026 fiscal year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2026 Annual Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and until his or her successor is duly elected and qualified (or, if the Declassification Proposal (as defined below) is approved by the Company&#8217;s stockholders at the 2023 Annual Meeting and the Declassification Amendment (as defined below) is subsequently filed and accepted by the Secretary of State of the State of Delaware prior to the 2024 Annual Meeting, with a term expiring at the Company&#8217;s annual meeting of stockholders for the 2025 fiscal year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2025 Annual Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and until his or her successor is duly elected and qualified), (B) to list the Class 1 Series A Director in the Company&#8217;s proxy statement and proxy card prepared, filed with the SEC and delivered to the Company&#8217;s stockholders in connection with the 2024 Annual Meeting and to solicit proxies for the election of the Class 1 Series A Director at the 2024 Annual Meeting in the same manner (except for differences related to the fact that the Class 1 Series A Director is subject to a separate class vote of the holders of the Series A Preferred Shares) as it solicits proxies for the election of the Company&#8217;s other director nominees and (C) subject to the good faith exercise of the Board&#8217;s, and all applicable committees of the Board&#8217;s, fiduciary duties under applicable law, recommend for the election of the Class 1 Series A Director at the 2024 Annual Meeting in the same manner (except for the fact that the Class 1 Series A Director is subject to a separate class vote of the holders of the Series A Preferred Shares) as it recommends for the election of the Company&#8217;s other director nominees. The Class 1 Series A Director agrees that he or she will recuse himself or herself from such portions of meetings of the Board or committees of the Board, if any, involving potential conflicts of interest between the Company and the holders of Series A Preferred Shares. Further, in the event the Declassification Proposal is approved by the Company&#8217;s stockholders at the 2023 Annual Meeting and the Declassification Amendment is subsequently filed and accepted by the Secretary of State of the State of Delaware prior to the 2024 Annual Meeting, all obligations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall apply with respect to the 2025 Annual Meeting in all respects.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Recommendation of Class 2 Series A Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Pursuant to Section 13(c) of the Series A Certificate of Designation, 22NW, one of the two largest holders of shares of Series A Preferred Shares as of the Effective Date, designates Jason Aryeh (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Class 2 Series A Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for election to the Board as a Series A Preferred Director (as defined in the Series A Certificate of Designation) at the 2023 Annual Meeting.  The Board hereby, on a one-time basis, waives compliance with the notice deadline established in Section 2.5 of the Amended and Restated Bylaws of Lifecore Biomedical, Inc. in connection with such designation.  Subject to, and conditioned upon, (i) receipt by the Company of a written designation of Jason Aryeh by the other largest holder of Series A Preferred Shares as of the Effective Date and (ii) the satisfaction of the Preferred Stock Director Designation Right Condition (as defined in the Series A Certificate of Designation) as of immediately prior to the 2023 Annual Meeting (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Class 2 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Series A Director Qualification Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Board, and all applicable committees of the Board, shall (A) take all necessary actions to nominate the Class 2 Series A Director as a Class 2 director and as a Series A Preferred Director (as defined in the Series A Certificate of Designation) for election to the Board by the holders of the Series A Preferred Shares, voting separately as a class, at the 2023 Annual Meeting with a term expiring at the 2025 Annual Meeting, and until his or her successor is duly elected and qualified, (B) to list the Class 2 Series A Director in the Company&#8217;s proxy statement and proxy card prepared, filed with the SEC and delivered to the Company&#8217;s stockholders in connection with the 2023 Annual Meeting and to solicit proxies for the election of the Class 2 Series A Director at the 2023 Annual Meeting in the same manner (except for differences related to the fact that the Class 2 Series A Director is subject to a separate class vote of the holders of the Series A Preferred Shares) as it solicits proxies for the election of the Company&#8217;s other director nominees and (C) subject to the good faith exercise of the Board&#8217;s, and all applicable committees of the Board&#8217;s, fiduciary duties under applicable law, recommend for the election of the Class 2 Series A Director at the 2023 Annual Meeting in the same manner (except for the fact that the Class 2 Series A Director is subject to a separate class vote of the holders of the Series A Preferred Shares) as it recommends for the election of the Company&#8217;s other director nominees. The Class 2 Series A Director agrees that he or she will recuse himself or herself from such portions of meetings of the Board or committees of the Board, if any, involving potential conflicts of interest between the Company and the holders of Series A Preferred Shares. Further, all obligations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall apply with respect to the 2025 Annual Meeting in all respects.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Class 1 Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Prior to the execution of this Agreement (i) the Board&#8217;s Nominating and Governance Committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nominating Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)  has reviewed and approved the qualifications of Matthew Korenberg (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">First Additional Class 1 Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Humberto Antunes (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Class 1 Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to serve as Class 1 members of the Board and Nelson Obus to continue to serve as a Class 1 member of the Board (collectively with the Additional Class 1 Directors, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Specified Class 1 Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and (ii) the Board has determined that the Specified Class 1 Directors are &#8220;independent&#8221; as defined by the listing standards of the Nasdaq. The Board, and all applicable committees of the Board, shall, subject to the good faith exercise of the Board&#8217;s, and all applicable committees of the Board&#8217;s, fiduciary duties under applicable law, take all necessary actions to appoint the Additional Class 1 Directors to serve as Class 1 directors on the Board effective as of immediately following the 2023 Annual Meeting (and, if the Declassification Proposal is approved by the Company&#8217;s stockholders at the 2023 Annual Meeting, prior to the filing of the Declassification Amendment with the Secretary of State of the State of Delaware), with a term expiring at the 2024 Annual Meeting, and until his or her successor is duly elected and qualified. The Board, and all applicable committees of the Board, shall (A) take all necessary actions to nominate the Specified Class 1 Directors as directors (or Class 1 directors if applicable at such time) for election to the Board at the 2024 Annual Meeting with a term expiring at the 2026 Annual Meeting, and until his or her successor is duly elected and qualified (or, if the Declassification Proposal is approved by the Company&#8217;s stockholders at the 2023 Annual Meeting and the Declassification Amendment is subsequently filed and accepted by the Secretary of State of the State of Delaware prior to the 2024 Annual Meeting, with a term expiring at the 2025 Annual Meeting, and until his or her successor is duly elected and qualified), (B) to list the Specified </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Class 1 Directors in the Company&#8217;s proxy statement and proxy card prepared, filed with the SEC and delivered to the Company&#8217;s stockholders in connection with the 2024 Annual Meeting and to solicit proxies for the election of the Specified Class 1 Directors at the 2024 Annual Meeting in the same manner as it solicits proxies for the election of the Company&#8217;s other director nominees and (C) subject to the good faith exercise of the Board&#8217;s, and all applicable committees of the Board&#8217;s, fiduciary duties under applicable law, recommend for the election of the Specified Class 1 Directors at the 2024 Annual Meeting in the same manner as it recommends for the election of the Company&#8217;s other director nominees. Further, in the event the Declassification Proposal is approved by the Company&#8217;s stockholders at the 2023 Annual Meeting and the Declassification Amendment is subsequently filed and accepted by the Secretary of State of the State of Delaware prior to the 2024 Annual Meeting, all obligations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall apply with respect to the 2025 Annual Meeting in all respects.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Appointment of New Class 2 Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Prior to the execution of this Agreement (i) the Nominating Committee has reviewed and approved the qualifications of Paul Johnson (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Class 2 Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, and together with the Class 1 Series A Director, the Class 2 Series A Director and the Specified Class 1 Directors, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Specified Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to serve as a Class 2 member of the Board, and (ii) the Board has determined that the Additional Class 2 Director is &#8220;independent&#8221; as defined by the listing standards of the Nasdaq. The Board, and all applicable committees of the Board, shall, subject to the good faith exercise of the Board&#8217;s, and all applicable committees of the Board&#8217;s, fiduciary duties under applicable law, take all necessary actions to appoint the Additional Class 2 Director to serve as a Class 2 director on the Board effective as of immediately following the 2023 Annual Meeting (and, if the Declassification Proposal is approved by the Company&#8217;s stockholders at the 2023 Annual Meeting, prior to the filing of the Declassification Amendment with the Secretary of State of the State of Delaware), with a term expiring at the 2025 Annual Meeting, and until his or her successor is duly elected and qualified. The Board, and all applicable committees of the Board, shall (A) take all necessary actions to nominate the Additional Class 2 Director as a director (or a Class 2 director if applicable at such time) for election to the Board at the 2025 Annual Meeting with a term expiring at the 2027 Annual Meeting, and until his or her successor is duly elected and qualified (or, if the Declassification Proposal is approved by the Company&#8217;s stockholders at the 2023 Annual Meeting and the Declassification Amendment is subsequently filed and accepted by the Secretary of State of the State of Delaware prior to the 2025 Annual Meeting, with a term expiring at the 2026 Annual Meeting, and until his or her successor is duly elected and qualified), (B) to list the Additional Class 2 Director in the Company&#8217;s proxy statement and proxy card prepared, filed with the SEC and delivered to the Company&#8217;s stockholders in connection with the 2025 Annual Meeting and to solicit proxies for the election of the Additional Class 2 Director at the 2024 Annual Meeting in the same manner as it solicits proxies for the election of the Company&#8217;s other director nominees and (C) subject to the good faith exercise of the Board&#8217;s, and all applicable committees of the Board&#8217;s, fiduciary duties under applicable law, recommend for the election of the Additional Class 2 Director at the 2025 Annual Meeting in the same manner as it recommends for the election of the Company&#8217;s other director nominees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Board Size</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Board, and all applicable committees of the Board, shall, subject to the good faith exercise of the Board&#8217;s, and all applicable committees of the Board&#8217;s, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">fiduciary duties under applicable law, take all necessary actions to (i) reduce the size of the Board from nine (9) seats to eight (8) seats immediately prior to the 2023 Annual Meeting, (ii) increase the size of the Board from eight (8) seats to eleven (11) seats immediately following the 2023 Annual Meeting, (iii) reduce the size of the Board from eleven (11) seats to nine (9) seats upon the earlier of (A) immediately prior to the 2024 Annual Meeting or (B) November 30, 2024, and (iv) following reduction in size of the Board described in clause (iii), during the Standstill Period, the size of the Board may be increased by the Board by no more than two (2) seats only pursuant to an agreement with an investor in or debt financing provider to the Company in connection with such equity or debt transaction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Committees of the Board and Chairman</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company agrees that the Board and all applicable committees of the Board shall, subject to the good faith exercise of the Board&#8217;s, and all applicable committees of the Board&#8217;s, fiduciary duties under applicable law, take all necessary actions to (i) appoint the First Additional Class 1 Director to the Audit Committee of the Board upon joining the Board immediately following the 2023 Annual Meeting (as long as the First Additional Class 1 Director is available and qualified for such appointment at such time) and as the Chairperson of the Audit Committee within five (5) business days after a vacancy in such position arises during the Standstill Period (as long as the First Class 1 Additional Director is available and qualified for such appointment at such time), (ii) appoint the Class 2 Series A Director to the Nominating Committee upon joining the Board immediately following the 2023 Annual Meeting (as long as the Class 2 Series A Director is available and qualified for such appointment at such time), and (iii) appoint two directors as additional members (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Additional SC Members</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to that certain Special Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Special Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to address the matters set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto immediately following the 2023 Annual Meeting who (x) are not affiliates of any holder of the Series A Preferred Shares, (y) is not the Class 2 Series A Director nor the First Additional Class 1 Director, or (z) are not current members of the Special Committee (as long as at least two directors are available and qualified for such appointment at such time). Notwithstanding the foregoing and until the Termination Date, the Specified Directors will be considered along with all other Board members for Board committee assignments in connection with the Board&#8217;s regular review of committee composition&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that with respect to any such committee appointment, the applicable New Director is eligible at all applicable times to serve as a member of such committee pursuant to applicable law and the listing standards and rules of any stock exchange that are applicable to the composition of such committee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Board Policies and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as otherwise permitted in this Agreement, all members of the Board, including the Specified Directors, are required to comply with all policies, processes, procedures, codes, rules, standards, and guidelines applicable to members of the Board, as in effect from time to time, including, without limitation, the Company&#8217;s Corporate Governance Guidelines, Code of Business Conduct, and policies on stock trading, stock ownership, hedging and pledging of Company securities, public disclosures and confidentiality, and that the Class 2 Series A Director is required to strictly preserve the confidentiality of Company business and information, including the discussion of any matters considered in meetings of the Board or Board committees whether or not the matters relate to material non-public information. The Specified Directors shall provide the Company with such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">information concerning the Specified Directors as is required to be disclosed under applicable law or stock exchange regulations, including the completion of the Company&#8217;s standard directors&#8217; and officers&#8217; questionnaire upon request, in each case as promptly as necessary to enable the timely filing of the Company&#8217;s proxy statement and other periodic reports with the SEC. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt;text-decoration:underline">Replacement Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company agrees that if, during the Standstill Period (and so long as no Investor has breached its obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereof), the First Additional Class 1 Director (or his or her replacement appointed pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) is unable to serve as a director, resigns, or is removed as a director prior to the end of the term of office set forth above (other than on account of (i) the failure of the First Additional Class 1 Director to be elected or re-elected by the stockholders at an annual meeting of the Company&#8217;s stockholders or a special meeting of stockholders held in lieu thereof or (ii) the First Additional Class 1 Director not being nominated to serve as a director in accordance with the terms of this Agreement at an annual meeting of the Company&#8217;s stockholders or a special meeting of stockholders held in lieu thereof), and at such time the Investor Group beneficially owns in the aggregate at least the lesser of (A) ten percent (10%) of the Company&#8217;s then outstanding voting securities on an as-converted to Common Stock basis or (B) the Company&#8217;s then outstanding voting securities on an as-converted to Common Stock basis beneficially owned by the Investors as of the Effective Date and as set forth on Exhibit&#160;A hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investor Group Minimum Ownership Threshold</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then the Investor Group shall have the ability to recommend a substitute person, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that any such substitute person so recommended shall qualify as &#8220;independent&#8221; pursuant to Nasdaq&#8217;s listing standards, be independent from the Investors, have the relevant financial and business experience to fill the resulting vacancy, made himself or herself available for one or more interviews with the Nominating Committee and other members of the Board, agreed to a customary background check by the Company and completed the Company&#8217;s standard directors&#8217; and officers&#8217; questionnaire (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Qualification Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). In the event that the Nominating Committee does not accept a substitute person so recommended, then the Investor Group shall have the right to recommend an additional substitute person for consideration by the Nominating Committee. Either the original candidate or the substitute person recommended shall be accepted by the Nominating</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Committee, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that after reasonable review by the Nominating Committee of the Qualification Information, both such candidates were, in the reasonable judgement of the Nominating Committee, qualified to serve on the Board&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Investor Group may continue to recommend additional substitute persons until two candidates are so accepted by the Nominating Committee at which time the Nominating Committee shall accept one of the two such candidates. Upon acceptance of a replacement director nominee by the Nominating Committee, the Board and all applicable committees of the Board, shall, subject to the good faith exercise of the Board&#8217;s, and all applicable committees of the Board&#8217;s, fiduciary duties under applicable law, take all necessary actions to appoint such replacement director to the Board no later than ten (10) business days after the Nominating Committee&#8217;s recommendation. Following the appointment of any replacement director in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, any reference to the First Additional Class 1 Director in this Agreement shall be deemed to refer to such replacement director.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt;text-decoration:underline">Rights and Benefits of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Specified Directors. The Specified Directors shall receive (i) the same benefits of director and officer insurance, and any indemnity and exculpation arrangements available generally to the directors on the Board, (ii) the same compensation for his or her service as a director as the compensation received by other non-management directors on the Board with similar Board assignments, and (iii) such other benefits on the same basis as all other non-management directors on the Board. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Stockholder Proposal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Board, and all applicable committees of the Board, shall take all necessary actions to submit to the stockholders of the Company at the 2023 Annual Meeting a proposal to approve an amendment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Declassification Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of Article VI of the Amended and Restated Certificate of Incorporation of the Company, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Certificate of Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), to provide for the phased-in declassification of the Board, with Class 1 directors being elected annually beginning at the 2024 Annual Meeting and with Class 2 directors being elected annually beginning at the 2025 Annual Meeting, such that the Board would be fully declassified at the time of the 2025 Annual Meeting (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Declassification Proposal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and subject to the good faith exercise of the Board&#8217;s, and all applicable committees of the Board&#8217;s, fiduciary duties under applicable law, to recommend in favor of the Declassification Proposal in the Company&#8217;s proxy statement and proxy card prepared, filed with the SEC and delivered to the Company&#8217;s stockholders in connection with the 2023 Annual Meeting (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2023 Annual Meeting Proxy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and, upon the approval of the Declassification Proposal, shall promptly file the Declassification Amendment with the Secretary of State of the State of Delaware upon such approval. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt;text-decoration:underline">Company Rights Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If the Board determines to cause the Company to conduct a rights offering during the Standstill Period pursuant to which the Company would distribute to holders of Common Stock subscription rights to purchase shares of Common Stock, and that is subject to a backstop or standby commitment, and either Legion or Wynnefield is offered the right to participate in such backstop or standby commitment, 22NW will be offered the right to participate in such backstop or standby commitment with respect to the same aggregate amount of unsubscribed shares as Legion or Wynnefield, subject, in each case, to (A) applicable law (including the Board&#8217;s fiduciary duties) and the applicable rules or requirements of the Nasdaq and (B) at the time of such rights offering the Investor Group beneficially owns in the aggregate at least the Investor Group Minimum Ownership Threshold. All such purchase rights shall not be subject to the ownership limitations set forth in Section 4(a)(iii) hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">The covenants set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall terminate and be of no further force or effect immediately on the earliest of (i) the Termination Date, or (ii) the date at which the Investor Group no longer satisfies the Investor Group Minimum Ownership Threshold.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Voting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. At each annual or special meeting of stockholders held during the Standstill Period, each of the Investors agrees to (i) appear at such stockholders&#8217; meeting or otherwise cause all shares of Common Stock and Series A Preferred Shares then beneficially owned by each Investor and their respective Affiliates and Associates to be counted as present thereat for purposes of establishing a quorum&#59; and (ii) vote, or cause to be voted, all shares of Common Stock and Series A Preferred Shares beneficially owned by each Investor and their </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">respective Affiliates and Associates on the Company&#8217;s proxy card or voting instruction form in favor of (a) each of the directors nominated by the Board and recommended by the Board, including such directors nominated and recommended by the Board pursuant to this Agreement and the Other Investor Agreements, in the election of directors (and not in favor of any other nominees to serve on the Board), and (b) each of the other proposals listed on the Company&#8217;s proxy card or voting instruction form as identified in the Company&#8217;s proxy statement prepared, filed with the SEC and delivered to the Company&#8217;s stockholders in accordance with the Board&#8217;s recommendations&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in the event that Institutional Shareholder Services Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ISS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) recommends otherwise with respect to any proposals (other than the election or removal of directors or any proposed increase in the authorized shares of the Company), each of the Investors shall be permitted to vote in accordance with the ISS recommendation&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that each of the Investors shall be permitted to vote in their sole discretion with respect to any publicly announced proposals relating to a merger, acquisition, disposition of all or substantially all of the assets of the Company, or other business combination involving the Company requiring a vote of stockholders of the Company. No later than two (2) business days prior to each such meeting of stockholders, each Investor shall, and shall cause each of its Associates and Affiliates to, vote any shares of Common Stock and Series A Preferred Shares beneficially owned by such Investors in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No Investor nor any of its Affiliates, Associates, nor any person under its direction or control shall take any position, make any statement, or take any action inconsistent with the foregoing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Standstill</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Each Investor agrees that, except as expressly permitted elsewhere in this Agreement or as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto, from the Effective Date until the Termination Date, without the prior written approval of the Board, neither it nor any of its controlled Affiliates nor any of its Associates shall, directly or indirectly, alone or in concert with others, in any manner&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">propose or publicly announce or otherwise disclose an intent to propose or enter into or agree to enter into, singly or with any other person, directly or indirectly, (A) any form of business combination or acquisition or other transaction relating to a material amount of assets or securities of the Company or any of its subsidiaries, (B) any form of restructuring, recapitalization or similar transaction with respect to the Company or any of its subsidiaries, or (C) any form of tender or exchange offer for the Common Stock or the Series A Preferred Shares, whether or not such transaction involves a Change of Control of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">engage in any solicitation of proxies or written consents to vote any voting securities of the Company, or conduct any non-binding referendum with respect to any voting securities of the Company, or knowingly encourage, assist or participate in any other way, directly or indirectly, in any solicitation of proxies (or written consents) with respect to any voting securities of the Company, or otherwise become a &#8220;participant&#8221; in a &#8220;solicitation,&#8221; as such terms are defined in Instruction 3 of Item 4 of Schedule&#160;14A and Rule 14a-1 of Regulation 14A, respectively, under the Exchange Act, to vote any securities of the Company in opposition to any recommendation or proposal of the Board&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">acquire, offer, or propose to acquire, or agree to acquire, directly or indirectly, by purchase or otherwise, beneficial ownership of any (A) interests in any of the Company&#8217;s indebtedness, or (B) Common Stock, Series A Preferred Shares, or other equity interests in the Company (including any rights decoupled from the underlying securities of the Company, but excluding Common Stock issued in connection with a stock split, stock dividend or similar corporate action initiated by the Company with respect to any securities beneficially owned by any of the Investors and&#47;or any Affiliate or Associate thereof) representing in the aggregate (amongst all of the Investors and any Affiliate or Associate thereof) in excess of 14.54% of the shares of Common Stock and Series A Preferred Shares outstanding (on an as converted to common basis), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, any purchases pursuant to Section 2(l) hereof shall be excluded from the limitations provided herein&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">acquire or agree, offer, seek, or propose to acquire, or cause to be acquired, ownership (including beneficial ownership) of any of the assets or business of the Company or any rights or options to acquire any such assets or business from any person, in each case other than securities of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">seek to advise, encourage, support or influence any person with respect to the voting of (or execution of a written consent in respect of) or disposition of any securities of the Company, other than in a manner consistent with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">engage in (A) any short sale or (B) any purchase, sale or grant of any option, warrant, convertible security, stock appreciation right, or other similar right (including, without limitation, any put or call option or &#8220;swap&#8221; transaction) with respect to any security (other than a broad-based market basket or index) that includes, relates to or derives any significant part of its value from a decline in the market price or value of the securities of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.36pt">intentionally pledge, hypothecate, or put any liens against the Company&#8217;s capital stock&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">nothing herein shall prevent any Investor from </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">partaking in customary margin transactions with a broker regulated by FINRA or holding its securities of the Company in a margin account&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">take any action in support of or make any proposal or request that constitutes&#58; (A) advising, controlling, changing, or influencing the Board or management of the Company or its subsidiaries, including any plans or proposals to change the number or term of directors, to elect directors, to fill any vacancies on the Board, or to remove directors, (B) any material change in the capitalization, stock repurchase programs and practices, capital allocation programs and practices or dividend policy of the Company or its subsidiaries, (C)&#160;any other material change in the Company&#8217;s management, business, or corporate or governance structure, (D)&#160;seeking to have the Company waive or make amendments or modifications to the Company&#8217;s Certificate of Incorporation or Bylaws, operations, business, corporate strategy, corporate structure, capital structure or allocation, share repurchase or dividend policies or other actions that may impede or facilitate the acquisition of control of the Company by any person, (E) causing a class of securities of the Company to be delisted from, or to cease to be authorized to be quoted on, any securities exchange&#59; or (F) causing a class of securities of the Company to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">become eligible for termination of registration pursuant to Section&#160;12(g)(4) of the Exchange Act, in each case except as permitted expressly by this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">initiate, propose, or otherwise &#8220;solicit&#8221; stockholders of the Company for the approval of any stockholder proposals (whether pursuant to Rule 14a-8 under the Exchange Act or otherwise) other than in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">communicate with stockholders of the Company or others pursuant to Rule 14a-1(l)(2)(iv) under the Exchange Act other than in a manner consistent with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">otherwise publicly act to seek to control or influence the management, the Board, or policies of the Company or initiate or take any action to obtain representation on the Board, except as permitted expressly by this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.36pt">call or seek to call, or request the call of, alone or in concert with others, any meeting of stockholders, whether or not such a meeting is permitted by the Company&#8217;s Certificate of Incorporation or Bylaws, including, but not limited to, a &#8220;town hall meeting&#59;&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xiii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">grant any proxy, consent or other authority to vote with respect to any matters (other than to the named proxies included in the Company&#8217;s proxy card for any annual meeting or special meeting of stockholders) or deposit any Common Stock or Series A Preferred Shares in any voting trust or similar arrangement or subject any Common Stock or Series A Preferred Shares to any voting agreement or pooling arrangement, other than (A) customary brokerage accounts, margin accounts and prime brokerage accounts and (B) otherwise in accordance with this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xiv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.69pt">seek, or encourage any person, to submit nominations in furtherance of a &#8220;contested solicitation&#8221; for the election or removal of directors with respect to the Company or, except as expressly provided in this Agreement, seek, encourage or take any other action with respect to the election or removal of any directors (it being acknowledged that those public communications that are permitted and those SEC filings that are required under this Agreement shall not constitute such encouragement)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.02pt">form, join or in any other way participate in any a &#8220;partnership, limited partnership, syndicate, or other group&#8221; (within the meaning of Section&#160;13(d)(3) of the Exchange Act) with respect to the securities of the Company (other than a &#8220;group&#8221; that includes all or some of the Investors, but does not include any other entities or persons that are not members of the Investor Group as of Effective Date)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that the Investor Group Schedule 13D shall not be amended to add additional members to the Investor Group other than persons that are wholly owned as of the Effective Date by an existing member of the Investor Group or an Associate of the Investor Group, so long as any such additional wholly owned member or Associate agrees to be bound by the terms and conditions of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xvi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.69pt">commence, join, encourage, or support any lawsuit, arbitration, or other legal claim against the Company or any of its officers or directors, including without </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">limitation any derivative action in the name of the Company, or any class action against the Company or any of its officers or directors </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that nothing in this clause&#160;(xvi) will in any way limit the rights of either party under this Agreement or any other agreement between the parties, including by commencing litigation to enforce such rights&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xvii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.36pt">disclose publicly, or privately in a manner that could reasonably be expected to become public, any intent, purpose, plan, or proposal with respect to the Board, the Company, its management, policies, or affairs, any of its securities or assets or this Agreement that is inconsistent with the provisions of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xviii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6.03pt">make any request or submit any proposal to amend the terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> other than through non-public communications with the Company that would not be reasonably determined to trigger public disclosure obligations for any party&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.69pt">take any action challenging the validity or enforceability of any of the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or publicly disclose, or cause or facilitate the public disclosure (including, without limitation, the filing of any document with the SEC or any other governmental agency or any disclosure to any journalist, member of the media or securities analyst) of, any intent, purpose, plan or proposal to either (A) obtain any waiver or consent under, or any amendment of, any provision of this Agreement, or (B) take any action challenging the validity or enforceability of any provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xx)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.02pt">make any public communication in opposition to (A) any merger, acquisition, amalgamation, recapitalization, restructuring, disposition, distribution, spin-off, asset sale, joint venture or other business combination or (B) any financing transaction, in each case involving the Company or any of its subsidiaries&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xxi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.69pt">call or seek to call any special meeting of the Company (other than calling or seeking to call a special meeting of the holders of the Series A Preferred Stock pursuant to the Series A Certificate of Designation) or action by consent resolutions or make any request under Section 220 of the Delaware General Corporation Law or other applicable legal provisions regarding inspection of books and records or other materials (including stocklist materials) of the Company or any of its subsidiaries&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xxii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.36pt">advise, assist, knowingly encourage, or seek to persuade any person or entity to take any action or make any statement inconsistent with any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding anything in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or elsewhere in this Agreement, nothing in this Agreement shall prohibit or restrict any Investor (including during his time as a Board Observer) from (i)&#160;communicating privately with the Board or any of the Company&#8217;s officers regarding any matter, so long as such communications are not intended to, and would not reasonably be expected to, require any public disclosure of such communications, (ii) privately communicating to any of their investors information regarding the Company based on publicly available information, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that such communications are subject to reasonable confidentiality obligations and are not otherwise reasonably expected to be publicly disclosed, (iii) communicating with stockholders of the Company and others in a manner that does not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">otherwise violate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of this Agreement, (iv) making a public statement about how such Investor intends to vote and the reasons therefor with respect to any publicly announced Change of Control transaction, (v) exchanging, tendering, or otherwise participating in any tender or exchange offer with respect to the Common Stock or Series A Preferred Shares, whether or not such transaction involves a Change of Control of the Company, on the same basis as the other stockholders of the Company, (vi) taking any action necessary to comply with any law, rule, or regulation or any action required by any governmental or regulatory authority or stock exchange that has jurisdiction over an Investor, or (vii) exercising any right permitted under the Series A Certificate of Designation and transaction documents related to the purchase of the Series A Preferred Shares, including calling upon the Company to call a special meeting for the purpose of electing Series A Preferred Directors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">As of the Effective Date, none of the Investors are engaged in any discussions or negotiations and do not have any agreements or understandings, written or oral, whether or not legally enforceable, concerning the acquisition of beneficial ownership of any securities of the Company, and have no actual knowledge that any other stockholders of the Company have any present or future intention of taking any actions that if taken by the Investors would violate any of the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt"> Except as otherwise provided in this Agreement, this Agreement shall automatically terminate upon the announcement of a transaction that will constitute a Change of Control involving the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The Class 2 Series A Director (including during his time as a Board Observer) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Recipient</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), acknowledges the confidential and proprietary nature of the Confidential Information and agrees that the Confidential Information (i) will be kept strictly confidential by Recipient, and (ii) will not be disclosed by Recipient to any person except with the specific prior written consent of the Company or except as expressly otherwise permitted by this Agreement. To the extent that Recipient is requested, required, or compelled to disclose the Confidential Information by judicial, regulatory, or administrative process pursuant to the advice of counsel or by requirements of law, the Recipient shall, to the extent legally permissible, provide the Company with (A) prompt notice to any such requested, required, or compelled disclosure to enable to the Company, at its sole expense, to seek a protective order or similar remedy, and (B) reasonable cooperation, at the Company&#8217;s sole expense, with respect to any effort by the Company to seek a protective order or similar remedy. Upon written request of the Company or the Board, the Recipient shall promptly return or destroy, at the Recipient&#8217;s option, any and all records, notes, and other written, printed, or tangible materials in its possession pertaining to the Confidential Information&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that Recipient may retain any electronic or written copies of Confidential Information as may be stored on his or her electronic records or storage system resulting from automated back-up systems or required by law, other regulatory requirements, or internal document retention policies. Any Confidential Information that is not returned or destroyed, including, without limitation, any oral Confidential Information, and all notes, analyses, compilations, studies, or other documents prepared by or for the benefit </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of the Recipient from such information, will remain subject to the confidentiality obligations set forth in this Agreement notwithstanding any termination of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Extended Confidentiality Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Notwithstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of this Agreement and except for the Extended Confidentiality Obligations, Recipient&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall survive termination or expiration of this Agreement until eighteen (18) months after the date the Recipient received the last of such Confidential Information (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidentiality Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">All Confidential Information is provided to the Recipient &#8220;as is&#8221; and the Company does not make any representation or warranty as to the accuracy or completeness of the Confidential Information or any component thereof. The Company will have no liability to the Recipient resulting from the reliance on the Confidential Information. The Recipient acknowledges that all of the Confidential Information is owned solely by the Company (or its licensors) and that the unauthorized disclosure or use of such Confidential Information would cause irreparable harm and significant injury, the degree of which may be difficult to ascertain. Therefore, in the event of any breach of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company is entitled to seek all forms of equitable relief (including an injunction and order for specific performance), in addition to all other remedies available at law or in equity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all information or data concerning the Company, whether in verbal, visual, written, electronic, or other form, which is disclosed to Recipient by the Company or any Representative of the Company (including, but not limited to, all Relevant Materials and Information that is non-public information)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall not include information that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">is or becomes generally available to the public other than as a result of disclosure of such information by the Recipient in violation of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">is independently developed by the Recipient without use of the Confidential Information provided by the Company or any Representative thereof&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">becomes available to Recipient at any time on a non-confidential basis from a third party that is not, to such recipient&#8217;s knowledge, prohibited from disclosing such information to such recipient by any contractual, legal, or fiduciary obligation to the Company&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">was known by Recipient prior to receipt from the Company or from any Representative thereof and, to Recipient&#8217;s knowledge, the source of such information was not prohibited from disclosing such information to such recipient by any contractual, legal, or fiduciary obligation to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding anything in this Agreement to the contrary, the Company acknowledges that the Recipient&#8217;s businesses include the analysis of, and investment in, securities, instruments, businesses and assets, and Confidential Information may serve to give the Recipient a deeper overall knowledge and understanding in a way that cannot be separated from </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">their other knowledge, and accordingly, subject to the Recipient&#8217;s compliance with his or her obligations under this Agreement and without in any way limiting Recipient&#8217;s obligations under this Agreement, the Company acknowledges that this Agreement is not intended to restrict the use of such overall knowledge and understanding solely for internal investment analysis purposes, including, subject to applicable law, the purchase, sale, consideration of, and decisions related to, other investments. Subject to applicable law and Recipient&#8217;s compliance with his or her obligations under this Agreement, this Agreement shall not prohibit or otherwise limit the Recipient from negotiating, evaluating and&#47;or trading, directly or indirectly, in any index fund, exchange traded fund, benchmark fund, or other basket of securities which the Recipient has no direct or indirect control over, which may contain or otherwise reflect the performance of any securities of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Acknowledgment of Obligations under Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Recipient acknowledges that he or she is aware of the restrictions imposed by the United States federal securities laws and other applicable foreign and domestic laws (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) on a person possessing material nonpublic information about a publicly traded company, including, but not limited to, restrictions that prohibit such person from purchasing or selling securities of such company, or from communicating such information to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell such securities. The Recipient acknowledges that Confidential Information shared by the Company or its Representatives with the Recipient may include information regarding material activity by the Company, and that any such information so shared or exchanged shall be subject to the confidentiality obligations set forth herein and may constitute material non-public information with respect to United States securities laws.  The Company agrees that, following the Effective Date and prior to the Confidentiality Termination Date, the Company shall promptly (and in any event, no later than the time that the Company&#8217;s directors are notified) notify the Recipient in writing as to the (i)&#160;opening of a trading window during which time all directors of the Company are permitted to trade in the Company&#8217;s securities and (ii) institution of a blackout period during which time all directors of the Company are prohibited from trading in the Company&#8217;s securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Representations and Warranties of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company represents and warrants to the Investors that (a) the Company has the corporate power and authority to execute this Agreement and to bind it thereto, (b) this Agreement has been duly and validly authorized, executed and delivered by the Company, constitutes a valid and binding obligation and agreement of the Company, and is enforceable against the Company in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles, and (c) to the actual knowledge of the executive officers of the Company, the execution, delivery, and performance of this Agreement by the Company does not and will not violate or conflict with (i) any law, rule, regulation, order, judgment or decree applicable to it, or (ii) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both could become a default) under or pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document, or any material </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">agreement, contract, commitment, understanding or arrangement to which the Company is a party or by which it is bound.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Representations and Warranties of the Investors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Investor, on behalf of itself, severally represents and warrants to the Company that (a) as of the date hereof, such Investor beneficially owns, directly or indirectly, only the number of shares of Common Stock and Series A Preferred Shares as described opposite its name on Exhibit&#160;A and Exhibit&#160;A includes all Affiliates and Associates of any Investors that own any securities of the Company beneficially or of record and reflects all shares of Common Stock and Series A Preferred Shares in which the Investors have any interest or right to acquire, whether through derivative securities, voting agreements or otherwise, (b) this Agreement has been duly and validly authorized, executed and delivered by such Investor, and constitutes a valid and binding obligation and agreement of such Investor, enforceable against such Investor in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles, (c) such Investor has the authority to execute the Agreement on behalf of itself and the applicable Investor associated with that signatory&#8217;s name, and to bind such Investor to the terms hereof, (d) each of the Investors shall cause its respective Representatives acting on its behalf to comply with the terms of this Agreement, and (e) to the actual knowledge of each Investor, the execution, delivery, and performance of this Agreement by such Investor does not and will not violate or conflict with (i) any law, rule, regulation, order, judgment or decree applicable to it, or (ii) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both could become a default) under or pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document, agreement, contract, commitment, understanding or arrangement to which such Investor is a party or by which it is bound.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Mutual Non-Disparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to applicable law, each of the parties covenants and agrees that, except with respect to the matter set forth on Schedule 4(a) hereto, during the Standstill Period, or if earlier, until such time as the other party or any of its Representatives shall have breached this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, neither it nor any of its Representatives shall in any way publicly disparage, call into disrepute or otherwise defame or slander the other party or such other party&#8217;s Representatives (including any current officer of a party or a party&#8217;s subsidiaries who no longer serves in such capacity following the execution of this Agreement and any current director of a party or a party&#8217;s subsidiaries who no longer serves in such capacity following the execution of this Agreement), or any of their businesses, products or services, in any manner that would reasonably be expected to damage the business or reputation thereof. For the avoidance of doubt, the foregoing shall not prevent the making of any factual statement in connection with any compelled testimony or production of information by legal process, subpoena, or as part of a response to a request for information from any governmental authority with purported jurisdiction over the party from whom information is sought.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Public Announcements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Promptly following the execution of this Agreement, the Company shall issue a mutually agreeable press release (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Press Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) announcing this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Agreement, substantially in the form attached as Exhibit&#160;C hereto. Prior to the issuance of the Press Release, neither the Company nor any of the Investors nor any of their respective Representatives shall issue any press release or make any public announcement regarding this Agreement or take any action that would require public disclosure thereof without the prior written consent of the other party. No party nor any of its Representatives shall make any public statement (including, without limitation, in any filing required under the Exchange Act) concerning the subject matter of this Agreement inconsistent with this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">SEC Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">No later than four (4) business days following the execution of this Agreement, the Company shall file a Current Report on Form 8-K with the SEC reporting entry into this Agreement and appending or incorporating by reference this Agreement as an exhibit thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">No later than two (2) business days following the execution of this Agreement, the Investor Group shall file an amendment to its Schedule&#160;13D with respect to the Company that has been filed with the SEC, reporting the entry into this Agreement, amending applicable items to conform to their obligations hereunder and appending or incorporating by reference this Agreement as an exhibit thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Not a Group with any Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Nothing contained in this Agreement shall be deemed or construed as creating a group, joint venture or partnership between the Investors and any other stockholders of the Company including those stockholders who are entering into Other Investor Agreements concurrently with this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each of the Company and the Investors shall be responsible for its own fees and expenses incurred in connection with the negotiation, execution, and effectuation of this Agreement and the matters contemplated hereby, including, but not limited to attorneys&#8217; fees incurred in connection with the negotiation and execution of this Agreement and all other activities related to the foregoing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company will reimburse the 22NW for its reasonable, document out-of-pocket fees and expenses (including reasonable, documented legal expenses) incurred solely in connection with the preparation and delivery of the Nomination Notice, the Special Meeting Demand and the negotiation and execution of this Agreement in an amount not to exceed $150,000, which amount shall be paid in six equal monthly installments by the Company commencing on the first business day of the month after which the 22NW provides reasonable documentation of such expenses to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As used in this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Rule 12b-2 promulgated by the SEC under the Exchange Act&#894; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that, for purposes of this Agreement, no Investor shall be deemed an Affiliate of the Company and the Company shall not be deemed an Affiliate of any Investor&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Associate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Rule 12b-2 promulgated by the SEC under the Exchange Act&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the terms &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">beneficial owner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">beneficial ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the same meanings as set forth in Rule 13d-3 promulgated by the SEC under the Exchange Act&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">business day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any day that is not a Saturday, Sunday, or other day on which commercial banks in the State of New York are authorized or obligated to be closed by applicable law&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the sale of all or substantially all the assets of the Company&#59; any merger, consolidation, or acquisition of the Company with, by or into another corporation, entity, or person&#59; or any change in the ownership of more than 50% of the voting capital stock of the Company in one or more related transactions&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S.&#160;Securities Exchange Act of 1934, as amended&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the terms &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">proxy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; (and any plurals thereof) have the meanings ascribed to such terms under the Exchange Act and the rules and regulations promulgated thereunder, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that the meaning of &#8220;solicitation&#8221; shall be without regard to the exclusions set forth in Rules 14a-1(l)(2)(iv) and 14a-2 under the Exchange Act&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the terms &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any individual, corporation (including not-for-profit), general or limited partnership, limited liability company, joint venture, estate, trust, association, organization, or other entity of any kind or nature&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (i) a person&#8217;s Affiliates and Associates, and (ii) its and their respective directors, officers, employees, partners, members, managers, consultants, legal or other advisors, agents, and other representatives acting in a capacity on behalf of, in concert with or at the direction of such person or its Affiliates or Associates&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">the term, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S.&#160;Securities and Exchange Commission&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt"> the term, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Standstill Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the period commencing on the Effective Date and ending upon the earlier to occur of (X) the day immediately after the 2025 Annual Meeting or (Y) October 31, 2025</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or, if earlier, upon the occurrence of any of the following&#58; (i) termination of any Other Investor Agreement or material breach of any Other Investor Agreement by any party to such Other Investor Agreement that is not cured within thirty (30) days&#8217; written notice thereof, (ii)  if the Class 2 Series A Director Qualification Conditions are satisfied immediately prior to the 2023 Annual Meeting (or 2025 Annual Meeting, as applicable) and the Board has not recommended for, or has withdrawn the recommendation for, the election of the Class 2 Series A Director at the 2023 Annual Meeting (or 2025 Annual Meeting, as applicable) (as long as such Class 2 Series A Director is available and qualified for such applicable election), (iii) if the Board has not appointed the Additional Class 1 Directors or the Additional Class 2 Director to the Board immediately following the 2023 Annual Meeting (as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">long as such Additional Class 1 Directors or the Additional Class 2 Director, as applicable, is available and qualified for such appointment), (iv) if the Board has not recommended for, or has withdrawn the recommendation for, the election of the Specified Class 1 Directors at the 2024 Annual Meeting or, if applicable, the 2025 Annual Meeting (as long as such Specified Class 1 Directors are available and qualified for such election), (v) if the Board has not recommended for, or has withdrawn the recommendation for, the election of the Additional Class 2 Director at the 2025 Annual Meeting (as long as the Additional Class 2 Director is available and qualified for such election), (vi) if the size of the Board is not eight (8) or fewer seats immediately prior to the 2023 Annual Meeting, (vii) if size of the Board is not eleven (11) seats on the day after the 2023 Annual Meeting, (viii) if size of the Board is not nine (9) or fewer seats upon the earlier of (x) immediately prior to the 2024 Annual Meeting and (y) December 1, 2024, (ix) if the size of the Board is increased after it is decreased from eleven (11) seats to nine (9) seats (except for any increase permitted pursuant to Section 2(f)(iv)), (x) if upon joining the Board immediately following the 2023 Annual Meeting, Matthew Korenberg is not appointed to the Audit Committee of the Board (as long as Matthew Korenberg is available and qualified for such appointment), (xi) if Matthew Korenberg is not appointed as Chairperson of the Audit Committee of the Board within five (5) business days after a vacancy in such position arises (as long as Matthew Korenberg is available and qualified for such appointment), (xii) if upon joining the Board immediately following the 2023 Annual Meeting, Jason Aryeh is not appointed to the Nominating Committee (as long as Jason Aryeh is available and qualified for such appointment), (xiii) if upon joining the Board immediately following the 2023 Annual Meeting, the Additional SC Members are not appointed to the Special Committee (as long as such Additional SC Members are available and qualified for such appointment), (xiv) if the Investor Group Minimum Ownership Threshold is satisfied at the applicable time and the Board does not appoint a replacement nominee pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> no later than ten (10) business days after the Nominating Committee&#8217;s recommendation, (xv) if the Company does not include the Declassification Proposal in the 2023 Annual Meeting Proxy or if the Board does not recommend in favor of the adoption of such proposal in the 2023 Annual Meeting Proxy, (xvi) if the Declassification Proposal is approved, the Board does not file the Declassification Amendment with the Secretary of State of Delaware within five (5) business days following certification of stockholder approval, or (xvii) the 2024 Annual Meeting is not held on or prior to November 30, 2024 (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if any of clauses (ii), (iv), (v), or (xv) occur, the Company shall (1) notify the Investor Group in writing of such determination as promptly as practicable, and in any event within one (1) business day thereafter&#59; and (2) agree to delay the 2023 Annual Meeting, the 2024 Annual Meeting, or the 2025 Annual Meeting, as applicable, by at least 75 calendar days to permit the members of the Investor Group (and their Affiliates) to seek the election of the applicable Specified Director (or any replacement candidate) as a director of the Company or submit a stockholder proposal to declassify the Board, as applicable, and engage in a solicitation of proxies with respect to the election of such applicable Specified Director (or any replacement candidate) as a director of the Company or such stockholder proposal, as applicable&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">third party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; refers to any person that is not a party, a member of the Board, a director or officer of the Company, or legal counsel to either party.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Specific Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each of the Investors, on the one hand, and the Company, on the other hand, acknowledges and agrees that irreparable injury to the other party hereto may occur in the event any of the provisions of this Agreement are not performed in accordance with their specific terms or are otherwise breached and that such injury would not be adequately compensable in monetary damages. It is accordingly agreed that the Investors or any Investor, on the one hand, and the Company, on the other hand (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Moving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), shall each be entitled to seek specific enforcement of, and injunctive or other equitable relief to prevent any violation of, the terms hereof, and the other party hereto will not take action, directly or indirectly, in opposition to the Moving Party seeking such relief on the grounds that any other remedy or relief is available at law or in equity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any notices, consents, determinations, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered&#58; (i) upon receipt, when delivered personally&#59; (ii) upon confirmation of receipt, when sent by email (provided such confirmation is not automatically generated)&#59; or (iii)&#160;one (1) business day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same. The addresses for such communications shall be&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If to the Company&#58;</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lifecore Biomedical, Inc.</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3515 Lyman Boulevard</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chaska, MN 55318</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; John.Morberg&#64;lifecore.com</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; John D. Morberg</font></div><div style="padding-left:108pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With copies (which shall not constitute notice) to&#58;</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Latham &#38; Watkins LLP</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">650 Town Center Dr. Floor 20</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Costa Mesa, CA 92626</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; Darren.Guttenberg&#64;lw.com&#59; Christopher.Drewry&#64;lw.com&#59; Tessa.Bernhardt&#64;lw.com</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Darren Guttenberg&#59; Christopher Drewry&#59; Tessa Bernhardt</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If to any Investor&#58;</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22NW, LP</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">590 1st Avenue S, Unit C1</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Seattle, WA 98104</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; English&#64;englishcap.com</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Aron R. English</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With copies (which shall not constitute notice) to&#58;</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Baker &#38; Hostetler LLP</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45 Rockefeller Plaza</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">New York, NY 10111</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; afinerman&#64;bakerlaw.com</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Adam W. Finerman</font></div><div style="text-indent:108pt"><font><br></font></div><div style="text-indent:108pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement shall be governed in all respects, including validity, interpretation, and effect, by, and construed in accordance with, the laws of the State of Delaware, without giving effect to the principles of conflicts of law or choice of law thereof or of any other jurisdiction to the extent that such principles would require or permit the application of the laws of another jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each party to this Agreement agrees, on behalf of itself and its Affiliates and Associates, that any actions, suits or proceedings arising out of or relating to this Agreement or the transactions contemplated by this Agreement will be brought solely and exclusively in any state or federal court in the State of Delaware (and the parties agree not to commence any action, suit or proceeding relating to this Agreement or the transactions contemplated by this Agreement except in such courts), and further agrees that service of any process, summons, notice or document by U.S. registered mail to the respective addresses set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be effective service of process for any such action, suit or proceeding brought against any party in any such court. Each party, on behalf of itself and its Affiliates and Associates, irrevocably and unconditionally waives any objection to the laying of venue of any action, suit or proceeding arising out of this Agreement or the transactions contemplated by this Agreement, in any state or federal court in the State of Delaware, and further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an improper or inconvenient forum.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION, (B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D)&#160;SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SECTION&#160;19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Investor hereby irrevocably appoints 22NW as its attorney-in-fact and representative, in such Investor&#8217;s place and stead, to do any and all things and to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">execute any and all documents and give and receive any and all notices or instructions in connection with this Agreement and the transactions contemplated hereby. The Company shall be entitled to rely, as being binding on each Investor, upon any action taken by 22NW or upon any document, notice, instruction, or other writing given or executed by 22NW.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement constitutes the full and entire understanding and agreement among the parties with regard to the subject matter hereof, and supersedes all prior and contemporaneous agreements, understandings, and representations, whether oral or written, of the parties with respect to the subject matter hereof. There are no restrictions, agreements, promises, representations, warranties, covenants, or undertakings, oral or written, between the parties other than those expressly set forth herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The section&#160;headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No failure on the part of any party to exercise, and no delay in exercising, any right, power, or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such party preclude any other or further exercise thereof or the exercise of any other right, power, or remedy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All remedies hereunder are cumulative and are not exclusive of any other remedies provided by law or equity. In the event of litigation relating to this Agreement, if a court of competent jurisdiction determines in a final, non-appealable order that this Agreement has been breached by either party, then the breaching party shall reimburse the other party for its costs and expenses (including, without limitation, reasonable legal fees and expenses) incurred in connection with all such litigation, including any appeal therefrom.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Receipt of Adequate Information&#59; No Reliance&#59; Representation by Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each party acknowledges that it has received adequate information to enter into this Agreement, that it has had adequate opportunity to make whatever investigation or inquiry it may deem necessary or desirable in connection with the subject matter of this Agreement prior to the execution hereof, and that it has not relied on any promise, representation, or warranty, express, or implied not contained in this Agreement. Each of the parties hereto acknowledges that it has been represented by counsel of its choice throughout all negotiations that have preceded the execution of this Agreement, and that it has executed the same with the advice of said independent counsel. Each party cooperated and participated in the drafting and preparation of this Agreement and the documents referred to herein, and any and all drafts relating thereto exchanged among the parties shall be deemed the work product of all of the parties and may not be construed against any party by reason of its drafting or preparation. Accordingly, any rule of law or any legal decision that would require interpretation of any ambiguities in this Agreement against any party that drafted or prepared it is of no application and is hereby expressly waived by each of the parties hereto, and any controversy over interpretations of this Agreement shall be decided without regards to events of drafting or preparation. Further, any rule of law or any legal decision that would provide any party with a defense to the enforcement of the terms of this Agreement against such party shall have no application and is expressly waived. The provisions </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of the Agreement shall be interpreted in a reasonable manner so as to effect the intent of the parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. When a reference is made in this Agreement to a section, such reference shall be to a section&#160;of this Agreement, unless otherwise indicated. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation.&#8221; The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The word &#8220;will&#8221; shall be construed to have the same meaning as the word &#8220;shall.&#8221; The words &#8220;dates hereof&#8221; will refer to the Effective Date. The word &#8220;or&#8221; is not exclusive. The use of any gender shall be applicable to all genders. The definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms. Any agreement, instrument, law, rule, or statute defined or referred to herein means, unless otherwise indicated, such agreement, instrument, law, rule, or statute as from time to time amended, modified, or supplemented. For purposes of this Agreement, where an obligation of the Company or the Board (or any committee thereof) is qualified by the phrase &#8220;subject to the good faith exercise of the Board of its fiduciary duties under applicable law,&#8221; compliance with such obligation shall not be required if the Board (or, in the case of an obligation that is to be fulfilled by a committee of the Board, such committee), after receipt of advice from counsel regarding the same, determines in good faith that such compliance would violate the Board&#8217;s (or, as the case may be, such committee&#8217;s) fiduciary duties under applicable law.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If any provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Agreement shall remain in full force and effect. Any provision of this Agreement held invalid or unenforceable only in part or degree shall remain in full force and effect to the extent not held invalid or unenforceable. The parties further agree to replace such invalid or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the purposes of such invalid or unenforceable provision.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement may be modified, amended, or otherwise changed only in a writing signed by all of the parties hereto, or in the case of the Investors, the 22NW Representative, or their respective successors or assigns. Prior to the Termination Date, the Company shall not agree to any amendment to either of the Other Investor Agreements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The terms and conditions of this Agreement shall be binding upon and be enforceable by the parties hereto and the respective successors, heirs, executors, legal representatives and permitted assigns of the parties, and inure to the benefit of any successor, heir, executor, legal representative or permitted assign of any of the parties&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that no party may assign this Agreement or any rights or obligations hereunder without, with respect to any Investor, the express prior written consent of the Company (with such consent specifically authorized by a majority of the Board), and with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">respect to the Company, the prior written consent of the 22NW Representative, and any assignment in contravention of the foregoing shall be null and avoid.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">No Third-Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The representations, warranties, and agreements of the parties contained herein are intended solely for the benefit of the party to whom such representations, warranties, and&#47;or agreements are made, and shall confer no rights, benefits, remedies, obligations, or liabilities hereunder, whether legal or equitable, in any other person or entity, and no other person or entity shall be entitled to rely thereon.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">31.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Counterparts&#59; Facsimile &#47; PDF Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement and any amendments hereto may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become effective when each party hereto shall have received a counterpart hereof signed by the other parties hereto. In the event that any signature to this Agreement or any amendment hereto is delivered by facsimile transmission or by e-mail delivery of a portable document format (.pdf or similar format) data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &#8220;.pdf&#8221; signature page were an original thereof. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">32.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as otherwise provided in this Agreement or as otherwise mutually agreed in writing by each party, this Agreement shall terminate on the Termination Date. Notwithstanding the foregoing, the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> through this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the Extended Confidentiality Obligations shall survive the termination of this Agreement and Recipient&#8217;s other obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall survive the termination of this Agreement until the Confidentiality Termination Date. No termination of this Agreement shall relieve any party from liability for any breach of this Agreement prior to such termination.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;REMAINDER OF PAGE INTENTIONALLY LEFT BLANK&#93;<br>&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><div id="ide3d9fc7199c4f148ae428e47841b595_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF the parties have duly executed and delivered this Agreement as of the date first above written.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIFECORE BIOMEDICAL, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Paul Josephs&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Paul Josephs</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page to Cooperation Agreement&#93;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22NW FUND, LP</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; 22NW Fund GP, LLC, its General Partner</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Aron R. English&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Aron R. English</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Manager</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22NW, LP</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; 22NW GP, Inc., its General Partner</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Aron R. English&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Aron R. English</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; President and Sole Shareholder</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">22NW FUND GP, LLC</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Aron R. English&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Aron R. English</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Manager</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">22NW GP, INC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Aron R. English&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Aron R. English</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; President and Sole Shareholder</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page to Cooperation Agreement&#93;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.602%"><tr><td style="width:0.1%"></td><td style="width:1.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.043%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Aron R. English&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARON R. ENGLISH</font></td></tr><tr style="height:17pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Bryson O. Hirai-Hadley&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;BRYSON O. HIRAI-HADLEY</font></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Nathaniel Calloway&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NATHANIEL CALLOWAY</font></td></tr><tr style="height:17pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jason Aryeh&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;JASON ARYEH</font></td></tr><tr style="height:17pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Matthew Korenberg&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MATTHEW KORENBERG</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page to Cooperation Agreement&#93;</font></div><div><font><br></font></div></div></div><div id="ide3d9fc7199c4f148ae428e47841b595_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVESTOR GROUP OWNERSHIP</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.629%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Investor</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Shares of Common Stock Beneficially Owned</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Shares of Series A Preferred Shares Beneficially Owned</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22NW Fund, LP<br>22NW, LP<br>22NW Fund GP, LLC<br>22NW GP, Inc.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1,755,161</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16,436.420103</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Aron R. English</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1,755,161*</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;16,436.420103*</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Bryson O. Hirai-Hadley</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">583</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NONE</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nathaniel Calloway</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28,069</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NONE </font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Jason Aryeh</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NONE</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NONE</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Matthew Korenberg</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NONE</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NONE</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*   Mr. English, as the portfolio manager of 22NW, LP, manager of 22NW Fund GP, LLC and president and sole shareholder of 22NW GP, Inc., may be deemed to beneficially own the shares beneficially owned by 22NW Fund, LP.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ide3d9fc7199c4f148ae428e47841b595_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><br>FORM OF BOARD OBSERVER UNDERTAKING</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">June 28, 2024</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Board of Directors<br>Lifecore Biomedical, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3515 Lyman Boulevard</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chaska, MN 55318</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">BOARD OBSERVER UNDERTAKING</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ladies and Gentlemen&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Reference is made to that certain Cooperation Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreemen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">t&#8221;), dated as of June 28, 2024, by and among Lifecore Biomedical, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and each of the persons listed on Exhibit A to the Cooperation Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investor Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).&#160; Capitalized terms used herein but not defined shall have the meaning set forth in the Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I hereby irrevocably undertake that, while I serve as a Board Observer, I will be governed by, and will comply with, all policies, processes, procedures, codes, rules, standards, and guidelines applicable to members of the Board, as in effect from time to time, including, without limitation, the Company&#8217;s Corporate Governance Guidelines, Code of Business Conduct, and policies on stock trading, stock ownership, hedging and pledging of Company securities, public disclosures and confidentiality (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Policies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and agree to strictly preserve the confidentiality of Company business and information, including the discussion of any matters considered in meetings of the Board or Board committees whether or not the matters relate to material non-public information.  Furthermore, I irrevocably undertake that I will not share any Confidential Information with the Investor Group or any other person in respect of the Company which I learn in my capacity as an Observer, including discussions or matters considered in meetings of the Board or any Board committee, at any time, for any reason, without the Company&#8217;s prior consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If appointed as an Observer, I hereby irrevocably offer to resign from my position as the Observer, effective immediately upon notice from the Company that I have materially breached this Observer Undertaking (including a material breach of any of the Company Policies) or, if I am party to the Agreement, the Agreement&#894; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that I need not offer to resign if any such breach is capable of being cured and I have cured such breach within ten (10) calendar days following written notice of such breach from the Company.&#160; It shall be in the Board&#8217;s sole discretion whether to accept or reject such resignation.&#160; Further, I hereby acknowledge that I will no longer be an Observer upon the conclusion of the 2023 Annual Meeting.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Yours truly,</font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_________________________</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT C</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><br>FORM OF PRESS RELEASE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(see attached)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit102-lifecorexcooper.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic32337fa5efd4b538fe17dd1d785e973_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COOPERATION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Cooperation Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made and entered into as of June 28, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by and among Lifecore Biomedical, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Lifecore</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and each of the persons listed on Exhibit A hereto (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investor Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Company and each of the Investors are each herein referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;. Unless otherwise defined herein, capitalized terms shall have the meanings given to them in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, on March 21, 2024 the Company disclosed on a Form 8-K that Craig Barbarosh notified the Company that he has elected not to stand for re-election to serve as a director of the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) at the Company&#8217;s annual meeting of stockholders for the 2023 fiscal year, which is scheduled to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">take place on August 15, 2024  (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2023 Annual Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and that the Board approved the appointment of Katrina L. Houde as Chairperson of the Board, effective as of the 2023 Annual Meeting&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, each of the Investors beneficially owns the number of shares of (i) the Company&#8217;s common stock, par value $0.001 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and (ii) the Company&#8217;s Series A Convertible Preferred Stock, par value $0.001 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Series A Preferred Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), each as listed on Exhibit&#160;A hereto&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, on May 16, 2024, 22NW Fund, LP (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">22NW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) delivered to the Company a notice of intent to submit director nominations (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nomination Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) at the 2023 Annual Meeting&#894;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, on May 20, 2024, 22NW filed a Schedule 13D&#47;A with the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) disclosing its intention to nominate certain individuals to the Board, as set forth in the Nomination Notice&#894; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, on June 11, 2024, 22NW delivered to the Company a written demand for a special meeting of the stockholders of the Company to be held on August 14, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Special Meeting Demand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#894;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, on June 11, 2024, 22NW filed a Schedule 13D&#47;A with the SEC disclosing the Special Meeting Demand&#894;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, concurrent with the entry of this Agreement, 22NW (and its Affiliates) and Wynnefield Capital Management, LLC (together with its Affiliates, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Wynnefield</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) have entered into similar agreements with the Company, complete copies of which have been delivered to the Investors prior to the execution herewith (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Other Investor Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#894; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Company </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">has reached an agreement with the Investors with respect to the composition of the Board and certain other matters as provided in this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Board </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Composition and Other Company Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Recommendation of Class 1 Series A Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Pursuant to Section 13(c) of that certain Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of Lifecore Biomedical, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Series A Certificate of Designation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Legion Partners, L.P. I (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">LP I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), one of the two largest holders of shares of Series A Preferred Shares as of the Effective Date, designates Christopher Kiper (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Class 1 Series A Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for election to the Board as a Series A Preferred Director (as defined in the Series A Certificate of Designation) at the Company&#8217;s annual meeting of stockholders for the 2024 fiscal year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2024 Annual Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Board hereby, on a one-time basis, waives compliance with the notice deadline established in Section 2.5 of the Amended and Restated Bylaws of Lifecore Biomedical, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Bylaws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in connection with such designation.  Subject to, and conditioned upon, (i) receipt by the Company of a written designation of Christopher Kiper by the other largest holder of Series A Preferred Shares as of the Effective Date and (ii) the satisfaction of the Preferred Stock Director Designation Right Condition (as defined in the Series A Certificate of Designation) as of immediately prior to the 2024 Annual Meeting (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Class 1 Series A Director Qualification Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Board, and all applicable committees of the Board, shall (A) take all necessary actions to nominate the Class 1 Series A Director as a director (or Class 1 director if applicable at such time) and as a Series A Preferred Director (as defined in the Series A Certificate of Designation) for election to the Board by the holders of the Series A Preferred Shares, voting separately as a class, at the 2024 Annual Meeting with a term expiring at the Company&#8217;s annual meeting of stockholders for the 2026 fiscal year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2026 Annual Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and until his or her successor is duly elected and qualified (or, if the Declassification Proposal (as defined below) is approved by the Company&#8217;s stockholders at the 2023 Annual Meeting and the Declassification Amendment (as defined below) is subsequently filed and accepted by the Secretary of State of the State of Delaware prior to the 2024 Annual Meeting, with a term expiring at the 2025 Annual Meeting, and until his or her successor is duly elected and qualified), (B) to list the Class 1 Series A Director in the Company&#8217;s proxy statement and proxy card prepared, filed with the SEC and delivered to the Company&#8217;s stockholders in connection with the 2024 Annual Meeting and to solicit proxies for the election of the Class 1 Series A Director at the 2024 Annual Meeting in the same manner (except for differences related to the fact that the Class 1 Series A Director is subject to a separate class vote of the holders of the Series A Preferred Shares) as it solicits proxies for the election of the Company&#8217;s other director nominees and (C) subject to the good faith exercise of the Board&#8217;s, and all applicable committees of the Board&#8217;s, fiduciary duties under applicable law, recommend for the election of the Class 1 Series A Director at the 2024 Annual Meeting in the same manner (except for the fact that the Class 1 Series A Director is subject to a separate class vote of the holders of the Series A Preferred Shares) as it recommends for the election of the Company&#8217;s other director nominees.  The Class 1 Series A Director agrees that he or she will recuse himself or herself from such portions of meetings of the Board or committees of the Board, if any, involving actual conflicts </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of interest between the Company and the holders of Series A Preferred Shares.  Further, in the event the Declassification Proposal is approved by the Company&#8217;s stockholders at the 2023 Annual Meeting and the Declassification Amendment is subsequently filed and accepted by the Secretary of State of the State of Delaware prior to the 2024 Annual Meeting, all obligations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall apply with respect to the 2025 Annual Meeting in all respects.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Recommendation of Class 2 Series A Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Pursuant to Section 13(c) of the Series A Certificate of Designation, LP I, one of the two largest holders of shares of Series A Preferred Shares as of the Effective Date, designates Jason Aryeh (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Class 2 Series A Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for election to the Board as a Series A Preferred Director (as defined in the Series A Certificate of Designation) at the 2023 Annual Meeting.  The Board hereby, on a one-time basis, waives compliance with the notice deadline established in Section 2.5 of the Amended and Restated Bylaws of Lifecore Biomedical, Inc. in connection with such designation.  Subject to, and conditioned upon, (i) receipt by the Company of a written designation of Jason Aryeh by the other largest holder of Series A Preferred Shares as of the Effective Date and (ii) the satisfaction of the Preferred Stock Director Designation Right Condition (as defined in the Series A Certificate of Designation) as of immediately prior to the 2023 Annual Meeting (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Class 2 Series A Director Qualification Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Board, and all applicable committees of the Board, shall, (A) take all necessary actions to nominate the Class 2 Series A Director as a Class 2 director and as a Series A Preferred Director (as defined in the Series A Certificate of Designation) for election to the Board by the holders of the Series A Preferred Shares, voting separately as a class, at the 2023 Annual Meeting with a term expiring at the 2025 Annual Meeting, and until his or her successor is duly elected and qualified, (B) to list the Class 2 Series A Director in the Company&#8217;s proxy statement and proxy card prepared, filed with the SEC and delivered to the Company&#8217;s stockholders in connection with the 2023 Annual Meeting and to solicit proxies for the election of the Class 2 Series A Director at the 2023 Annual Meeting in the same manner (except for differences related to the fact that the Class 2 Series A Director is subject to a separate class vote of the holders of the Series A Preferred Shares) as it solicits proxies for the election of the Company&#8217;s other director nominees and (C) subject to the good faith exercise of the Board&#8217;s, and all applicable committees of the Board&#8217;s, fiduciary duties under applicable law, recommend for the election of the Class 2 Series A Director at the 2023 Annual Meeting in the same manner (except for the fact that the Class 2 Series A Director is subject to a separate class vote of the holders of the Series A Preferred Shares) as it recommends for the election of the Company&#8217;s other director nominees. The Class 2 Series A Director agrees that he or she will recuse himself or herself from such portions of meetings of the Board or committees of the Board, if any, involving actual conflicts of interest between the Company and the Investor Group. Further, all obligations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall apply with respect to the 2025 Annual Meeting in all respects. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Board Size</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Board, and all applicable committees of the Board, shall, subject to the good faith exercise of the Board&#8217;s, and all applicable committees of the Board&#8217;s, fiduciary duties under applicable law, take all necessary actions to (i) reduce the size of the Board from nine (9) seats to eight (8) seats immediately prior to the 2023 Annual Meeting, (ii) increase the size of the Board from eight (8) seats to eleven (11) seats immediately following the 2023 Annual Meeting, (iii) reduce the size of the Board from eleven (11) seats to nine (9) seats </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">upon the earlier of (A) immediately prior to the 2024 Annual Meeting or (B) November 30, 2024, and (iv) following reduction in size of the Board described in clause (iii), during the Standstill Period, the size of the Board may be increased by the Board by no more than two (2) seats only pursuant to an agreement with an investor in or debt financing provider to the Company in connection with such equity or debt transaction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Board Policies and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as otherwise permitted in this Agreement, all members of the Board, including the Class 1 Series A Director, are required to comply with all policies, processes, procedures, codes, rules, standards, and guidelines applicable to members of the Board, as in effect from time to time, including, without limitation, the Company&#8217;s Corporate Governance Guidelines, Code of Business Conduct, and policies on stock trading, stock ownership, hedging and pledging of Company securities, public disclosures and confidentiality, and that the Class 1 Series A Director is required to strictly preserve the confidentiality of Company business and information, including the discussion of any matters considered in meetings of the Board or Board committees whether or not the matters relate to material non-public information. The Class 1 Series A Director shall provide the Company with such information concerning the Class 1 Series A Director as is required to be disclosed under applicable law or stock exchange regulations, including the completion of the Company&#8217;s standard directors&#8217; and officers&#8217; questionnaire upon request, in each case as promptly as necessary to enable the timely filing of the Company&#8217;s proxy statement and other periodic reports with the SEC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Rights and Benefits of the Class 1 Series A Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Class 1 Series A Director shall receive (i) the same benefits of director and officer insurance, and any indemnity and exculpation arrangements available generally to the directors on the Board, (ii) the same compensation for his or her service as a director as the compensation received by other non-management directors on the Board with similar Board assignments, and (iii) such other benefits on the same basis as all other non-management directors on the Board. Notwithstanding the foregoing, (A) the Company shall not be responsible for the preparation or filing of any Forms 3, 4, and 5 under Section 16 of the Exchange Act (as defined below) that are required to be filed by the Class 1 Series A Director, and (B) the Company agrees to provide timely notice to the Class 1 Series A Director of any expected SEC filing requirements applicable to directors of the Company and reasonably cooperate with the Class 1 Series A Director and his or her counsel in the preparation of any Forms 3, 4, and 5 under Section 16 of the Exchange Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Stockholder Proposal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Board, and all applicable committees of the Board, shall, take all necessary actions  to submit to the stockholders of the Company at the 2023 Annual Meeting a proposal to approve an amendment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Declassification Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of Article VI of the Amended and Restated Certificate of Incorporation of the Company, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Certificate of Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), to provide for the phased-in declassification of the Board, with Class 1 directors being elected annually beginning at the 2024 Annual Meeting and with Class 2 directors being elected annually beginning at the 2025 Annual Meeting, such that the Board would be fully declassified at the time of the 2025 Annual Meeting (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Declassification Proposal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and subject to the good faith exercise of the Board&#8217;s and all applicable committees of the Board&#8217;s, fiduciary duties under applicable law, to recommend in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">favor of the Declassification Proposal in the Company&#8217;s proxy statement and proxy card prepared, filed with the SEC and delivered to the Company&#8217;s stockholders in connection with the 2023 Annual Meeting (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2023 Annual Meeting Proxy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and, upon the approval of the Declassification Proposal, shall promptly file the Declassification Amendment with the Secretary of State of the State of Delaware upon such approval.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Company Rights Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If the Board determines to cause the Company to conduct a rights offering during the Standstill Period pursuant to which the Company would distribute to holders of Common Stock subscription rights to purchase shares of Common Stock, and that is subject to a backstop or standby commitment, and either 22NW or Wynnefield is offered the right to participate in such backstop or standby commitment, the Investor Group will be offered the right to participate in such backstop or standby commitment with respect to the same aggregate amount of unsubscribed shares as 22NW or Wynnefield, subject, in each case, to (A) applicable law (including the Board&#8217;s fiduciary duties) and the applicable rules or requirements of the Nasdaq and (B) at the time of such rights offering the Investor Group beneficially owns in the aggregate at least the lesser of (A) ten percent (10%) of the Company&#8217;s then outstanding voting securities on an as-converted to Common Stock basis or (B) the Company&#8217;s then outstanding voting securities on an as-converted to Common Stock basis beneficially owned by the Investors as of the Effective Date and as set forth on Exhibit&#160;A hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investor Group Minimum Ownership Threshold</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). All such purchase rights shall not be subject to the ownership limitations set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(a)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The covenants set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall terminate and be of no further force or effect immediately on the earliest of (i) the Termination Date, or (ii) the date at which the Investor Group no longer satisfies the Investor Group Minimum Ownership Threshold.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Voting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. At each annual or special meeting of stockholders held during the Standstill Period, each of the Investors agrees to (i) appear at such stockholders&#8217; meeting or otherwise cause all shares of Common Stock and Series A Preferred Shares then beneficially owned by each Investor and their respective Affiliates to be counted as present thereat for purposes of establishing a quorum&#59; and (ii) vote, or cause to be voted, all shares of Common Stock and Series A Preferred Shares then beneficially owned by each Investor and their respective Affiliates on the Company&#8217;s proxy card or voting instruction form in favor of (a) each of the directors nominated by the Board and recommended by the Board, including such directors nominated and recommended by the Board pursuant to this Agreement and the Other Investor Agreements, in the election of directors (and not in favor of any other nominees to serve on the Board), and (b) each of the other proposals listed on the Company&#8217;s proxy card or voting instruction form as identified in the Company&#8217;s proxy statement prepared, filed with the SEC and delivered to the Company&#8217;s stockholders in accordance with the Board&#8217;s recommendations&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in the event in the event that Institutional Shareholder Services Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ISS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) or Glass Lewis &#38; Co., LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Glass Lewis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) recommends otherwise with respect to any proposals (other than the election or removal of directors or any proposed increase in the authorized shares of the Company), each of the Investors shall be permitted to vote in accordance with the ISS or Glass Lewis recommendation&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that each of the Investors shall be permitted to vote in their sole discretion with respect to any publicly announced proposals </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">relating to a merger, acquisition, disposition, business combination, amalgamation, recapitalization, restructuring,  distribution, spin-off, joint venture, any tender or exchange offer, any dissolution, liquidation, or reorganization of the Company, any debt or equity issuances or financings, the implementation of takeover defenses not in existence as of the date of this Agreement, or any other similar extraordinary matters involving the Company requiring a vote of stockholders of the Company. No later than two (2) business days prior to each such meeting of stockholders, each Investor shall, and shall cause each of its Affiliates to, vote any shares of Common Stock and Series A Preferred Shares beneficially owned by such Investors in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No Investor nor any of its Affiliates, nor any person under its direction or control shall take any position, make any statement, or take any action inconsistent with the foregoing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Standstill</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Each Investor agrees that, except as expressly permitted elsewhere in this Agreement, from the Effective Date until the Termination Date, without the prior written approval of the Board, neither it nor any of its controlled Affiliates shall, directly or indirectly, alone or in concert with others, in any manner&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">publicly announce or otherwise disclose an intent to propose or enter into or agree to enter into, singly or with any other person, directly or indirectly, (A) any form of business combination or acquisition or other transaction relating to a material amount of assets or securities of the Company or any of its subsidiaries, (B) any form of restructuring, recapitalization or similar transaction with respect to the Company or any of its subsidiaries, or (C) any form of tender or exchange offer for the Common Stock or the Series A Preferred Shares, whether or not such transaction involves a Change of Control of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">engage in any solicitation of proxies or written consents to vote any voting securities of the Company, or conduct any non-binding referendum with respect to any voting securities of the Company, or knowingly encourage, assist or participate in any other way, directly or indirectly, in any solicitation of proxies (or written consents) with respect to any voting securities of the Company, or otherwise become a &#8220;participant&#8221; in a &#8220;solicitation,&#8221; as such terms are defined in Instruction 3 of Item 4 of Schedule&#160;14A and Rule 14a-1 of Regulation 14A, respectively, under the Exchange Act, to vote any securities of the Company in opposition to any recommendation or proposal of the Board&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">acquire, offer, or propose to acquire, or agree to acquire, directly or indirectly, by purchase or otherwise, beneficial ownership of any interests in any of the Company&#8217;s indebtedness, Common Stock, Series A Preferred Shares, or other equity interests in the Company (including any rights decoupled from the underlying securities of the Company, but excluding Common Stock issued in connection with a stock split, stock dividend or similar corporate action initiated by the Company with respect to any securities beneficially owned by any of the Investors and&#47;or any Affiliate), in each case, if such acquisition, offer, proposal or agreement would result in the Investors acquiring beneficial ownership (amongst all of the Investors and any Affiliate) in excess of 17.20% of the shares of Common Stock and Series A </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preferred Shares outstanding (on an as converted to common basis)&#59; provided, however, any purchase pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereof shall be excluded from the limitations provided herein&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">acquire or agree, offer, seek, or propose to acquire, or cause to be acquired, ownership (including beneficial ownership) in one or a series of related transactions, a majority or more of the assets or business of the Company or any rights or options to acquire any such assets or business from any person, in each case other than securities of the Company&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">seek to advise, encourage, support or influence any person with respect to the voting of (or execution of a written consent in respect of) or disposition of any securities of the Company, other than in a manner consistent with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">take any public action in support of or make any public proposal or request that constitutes&#58; (A) advising, controlling, changing, or influencing the Board or management of the Company or its subsidiaries, including any plans or proposals to change the number or term of directors, to elect directors, to fill any vacancies on the Board, or to remove directors, (B) any material change in the capitalization, stock repurchase programs and practices, capital allocation programs and practices or dividend policy of the Company or its subsidiaries, (C)&#160;any other material change in the Company&#8217;s management, business, or corporate or governance structure, (D)&#160;seeking to have the Company waive or make amendments or modifications to the Company&#8217;s Certificate of Incorporation or Bylaws, operations, business, corporate strategy, corporate structure, capital structure or allocation, share repurchase or dividend policies or other actions that may impede or facilitate the acquisition of control of the Company by any person, (E) causing a class of securities of the Company to be delisted from, or to cease to be authorized to be quoted on, any securities exchange&#59; or (F) causing a class of securities of the Company to become eligible for termination of registration pursuant to Section&#160;12(g)(4) of the Exchange Act, in each case except as permitted expressly by this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.36pt">initiate, propose, or otherwise &#8220;solicit&#8221; stockholders of the Company for the approval of any stockholder proposals (whether pursuant to Rule 14a-8 under the Exchange Act or otherwise) other than in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">communicate with stockholders of the Company or others pursuant to Rule 14a-1(l)(2)(iv) under the Exchange Act other than in a manner consistent with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">call or seek to call, or request the call of, alone or in concert with others, any meeting of stockholders, whether or not such a meeting is permitted by the Company&#8217;s Certificate of Incorporation or Bylaws, including, but not limited to, a &#8220;town hall meeting&#59;&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">grant any proxy, consent or other authority to vote with respect to any matters (other than to the named proxies included in the Company&#8217;s proxy card for any annual meeting or special meeting of stockholders) or deposit any Common Stock or Series A Preferred Shares in any voting trust or similar arrangement or subject any Common Stock or Series A Preferred Shares to any voting agreement or pooling arrangement, other than (A) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">customary brokerage accounts, margin accounts and prime brokerage accounts and (B) otherwise in accordance with this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">seek, or encourage any person, to submit nominations in furtherance of a &#8220;contested solicitation&#8221; for the election or removal of directors with respect to the Company or, except as expressly provided in this Agreement, seek, encourage or take any other action with respect to the election or removal of any directors (it being acknowledged that those public communications that are permitted and those SEC filings that are required under this Agreement shall not constitute such encouragement)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.36pt">form, join or in any other way participate in any a &#8220;partnership, limited partnership, syndicate, or other group&#8221; (within the meaning of Section&#160;13(d)(3) of the Exchange Act) with respect to the securities of the Company (other than a &#8220;group&#8221; that includes all or some of the Investors, but does not include any other entities or persons that are not members of the Investor Group as of Effective Date)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that the Investor Group Schedule 13D shall not be amended to add additional members to the Investor Group other than persons that are wholly owned as of the Effective Date by an existing member of the Investor Group, so long as any such additional wholly owned member agrees to be bound by the terms and conditions of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xiii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">commence, join, encourage, or support any lawsuit, arbitration, or other legal claim against the Company or any of its officers or directors, including without limitation any derivative action in the name of the Company, or any class action against the Company or any of its officers or directors </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that nothing in this clause&#160;(xii) will in any way limit the rights of either party under this Agreement or any other agreement between the parties, including by (A) commencing litigation to enforce such rights, or (B) making counterclaims with respect to any proceeding initiated by, or on behalf of, the Company against an Investor&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xiv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.69pt">disclose publicly, or privately in a manner that could reasonably be expected to become public, any intent, purpose, plan, or proposal with respect to the Board, the Company, its management, policies, or affairs, any of its securities or assets or this Agreement that is inconsistent with the provisions of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.02pt">make any request or submit any proposal to amend the terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> other than through non-public communications with the Company that would not be reasonably determined to trigger public disclosure obligations for any party&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xvi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.69pt">take any action challenging the validity or enforceability of any of the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or publicly disclose, or cause or facilitate the public disclosure (including, without limitation, the filing of any document with the SEC or any other governmental agency or any disclosure to any journalist, member of the media or securities analyst) of, any intent, purpose, plan or proposal to either (A) obtain any waiver or consent under, or any amendment of, any provision of this Agreement, or (B) take any action challenging the validity or enforceability of any provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xvii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.36pt">make any public communication in opposition to (A) any merger, acquisition, amalgamation, recapitalization, restructuring, disposition, distribution, spin-off, asset sale, joint venture or other business combination or (B) any financing transaction, in each case involving the Company or any of its subsidiaries&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xviii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6.03pt">call or seek to call any special meeting of the Company (other than calling or seeking to call a special meeting of the holders of the Series A Preferred Shares pursuant to the Series A Certificate of Designation) or action by consent resolutions or make any request under Section 220 of the Delaware General Corporation Law or other applicable legal provisions regarding inspection of books and records or other materials (including stocklist materials) of the Company or any of its subsidiaries&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.69pt">advise, assist, knowingly encourage, or seek to persuade any person or entity to take any action or make any statement inconsistent with any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding anything in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or elsewhere in this Agreement, nothing in this Agreement shall prohibit or restrict any Investor or the Class 1 Series A Director from (i)&#160;communicating privately with any director on the Board or any of the Company&#8217;s officers regarding any matter, so long as such communications are not intended to, and would not reasonably be expected to, require any public disclosure of such communications, (ii) identifying potential director candidates to serve on the Board so long as such actions do not create a public disclosure obligation for the Investor Group or the Company, are not publicly disclosed by the Investor Group or its Affiliates and are undertaken on a basis reasonably designed to be confidential, (iii) privately communicating to any of their investors or potential investors information regarding the Company based on publicly available information, provided, that such communications are subject to reasonable confidentiality obligations and are not otherwise reasonably expected to be publicly disclosed, (iv) communicating with stockholders of the Company and others in a manner that does not otherwise violate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of this Agreement, (v) making a public statement about how such Investor intends to vote and the reasons therefor with respect to any publicly announced Change of Control transaction, (vi) exchanging, tendering, or otherwise participating in any tender or exchange offer with respect to the Common Stock or Series A Preferred Shares, whether or not such transaction involves a Change of Control of the Company, on the same basis as the other stockholders of the Company, (vii) taking any action necessary to comply with any law, rule, or regulation or any action required by any governmental or regulatory authority or stock exchange that has jurisdiction over an Investor, or (viii) exercising any right permitted under the Series A Certificate of Designation and transaction documents related to the purchase of the Series A Preferred Shares, including calling upon the Company to call a special meeting for the purpose of electing Series A Preferred Directors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">As of the Effective Date, none of the Investors are engaged in any discussions or negotiations and do not have any agreements or understandings, written or oral, whether or not legally enforceable, concerning the acquisition of beneficial ownership of any securities of the Company, and have no actual knowledge that any other stockholders of the Company have any present or future intention of taking any actions that if taken by the Investors would violate any of the terms of this Agreement. For the avoidance of doubt, nothing in this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Agreement shall be deemed to limit the exercise in good faith by the Class 1 Series A Director of his fiduciary duties in his capacity as a director of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Except as otherwise provided in this Agreement, this Agreement shall automatically terminate upon the public announcement of a transaction that will constitute a Change of Control involving the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Information Sharing with Investor Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The Class 1 Series A Director may, if he wishes to do so, provide Confidential Information to other members of the Investor Group and their Representatives who need to know such information in connection with the Investor Group&#8217;s investment in the Company (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Recipient</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Investor Group shall (i) inform each Recipient of the confidential nature of the Confidential Information and (ii) cause each Recipient not to disclose any Confidential Information to any Person other than to Recipients in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and not to use any Confidential Information other than in connection with (A) the Class 1 Series A Director&#8217;s duties as a director of the Company and (B) evaluating or monitoring the Investor Group&#8217;s investment in the Company. The Investor Group shall be jointly and severally responsible for any breach of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> by any Recipient who receives Confidential Information from the Class 1 Series A Director hereunder. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">If any Recipient is (i) legally compelled, by deposition, interrogatory, request for documents, subpoena, civil investigation, demand, order or similar process, to disclose any Confidential Information or (ii) determines (on the advice of outside legal counsel) that it is required by law or regulation to disclose any Confidential Information, prior to making such disclosure, such Recipient must, to the extent practicable and legally permissible, (A) promptly notify the Company of the circumstances surrounding such requirement or request and (B) reasonably cooperate with the Company, at the Company&#8217;s sole expense, in any attempt it may make to obtain a protective order, other appropriate remedy, or an appropriate assurance that confidential treatment will be afforded to its Confidential Information. If a protective order or other appropriate remedy or assurance is not obtained, the Recipient agrees to only disclose (or cause to be disclosed, as applicable) that portion of the Confidential Information that is legally required to be disclosed (on the advice of outside legal counsel). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Upon the expiration of the Standstill Period, each member of the Investor Group agrees to (and agrees to cause any Recipient to, if applicable) (i) promptly (and in any event within five business days of such expiration) return or destroy (and upon request, confirm in writing such return or destruction to the Company) all Confidential Information of the Company and its Affiliates and any other material containing or reflecting any of the Confidential Information, (ii) not to retain any copies, extracts or other reproductions in whole or in part, mechanical or electronic, of such written material, and (iii) to destroy all computer records, documents, memoranda, notes and other writings prepared by the Class 1 Series A Director or a Recipient based on the Confidential Information of the Company or any of its Affiliates&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Investor Group that receive Confidential Information shall be entitled to retain one copy of all such Confidential Information in restricted access legal files or pursuant to automatic electronic archiving and back-up procedures for use solely in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">connection with any regulatory action&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that any Confidential Information so retained shall remain subject to the confidentiality obligations hereunder for so long as it so retained, notwithstanding any termination of this Agreement or the confidentiality obligations pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">All Confidential Information is provided to any Recipient &#8220;as is&#8221; and the Company does not make any representation or warranty as to the accuracy or completeness of the Confidential Information or any component thereof. The Company will have no liability to any Recipient resulting from the reliance on the Confidential Information. The Investor Group acknowledges that all of the Confidential Information is owned solely by the Company (or its licensors) and that the unauthorized disclosure or use of such Confidential Information would cause irreparable harm and significant injury, the degree of which may be difficult to ascertain. Therefore, in the event of any breach of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company is entitled to seek all forms of equitable relief (including an injunction and order for specific performance), in addition to all other remedies available at law or in equity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all information or data concerning the Company, whether in verbal, visual, written, electronic, or other form, which is disclosed to any Recipient by the Company or any Representative of the Company (including, but not limited to, all Relevant Materials and Information that is non-public information)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall not include information that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">is or becomes generally available to the public other than as a result of disclosure of such information by any Recipient in violation of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">is independently developed by any Recipient without use of the Confidential Information provided by the Company or any Representative thereof&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">becomes available to any Recipient at any time on a non-confidential basis from a third party that is not, to such recipient&#8217;s knowledge, prohibited from disclosing such information to such recipient by any contractual, legal, or fiduciary obligation to the Company&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">was known by any Recipient prior to receipt from the Company or from any Representative thereof and, to Recipient&#8217;s knowledge, the source of such information was not prohibited from disclosing such information to such recipient by any contractual, legal, or fiduciary obligation to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">Notwithstanding anything in this Agreement to the contrary, the Company acknowledges that the Investor Group&#8217;s businesses include the analysis of, and investment in, securities, instruments, businesses and assets, and Confidential Information may serve to give any natural person who is an Investor Group party a deeper overall knowledge and understanding in a way that cannot be separated from his or her other knowledge, and accordingly, subject to such Investor Group party&#8217;s compliance with his or her obligations under this Agreement and without in any way limiting the Investor Group&#8217;s obligations under this Agreement, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company acknowledges that this Agreement is not intended to restrict the use of such overall knowledge and understanding solely for internal investment analysis purposes, including, subject to applicable law, the purchase, sale, consideration of, and decisions related to, other investments. Subject to applicable law and the Investor Group&#8217;s compliance with its obligations under this Agreement, this Agreement shall not prohibit or otherwise limit the Investor Group from negotiating, evaluating and&#47;or trading, directly or indirectly, in any index fund, exchange traded fund, benchmark fund, or other basket of securities which the Investor Group has no direct or indirect control over, which may contain or otherwise reflect the performance of any securities of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the confidentiality and use obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall terminate 18 months after the date any Recipient received the last of such Confidential Information (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidentiality Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Acknowledgment of Obligations under Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Each member of the Investor Group acknowledges that he or she is aware of the restrictions imposed by the United States federal securities laws and other applicable foreign and domestic laws (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) on a person possessing material nonpublic information about a publicly traded company, including, but not limited to, restrictions that prohibit such person from purchasing or selling securities of such company, or from communicating such information to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell such securities. The Investor Group acknowledges that Confidential Information shared by the Company or its Representatives with any Recipient may include information regarding material activity by the Company, and that any such information so shared or exchanged shall be subject to the confidentiality obligations set forth herein and may constitute material non-public information with respect to United States securities laws.  The Company agrees that, following the Effective Date and prior to the Confidentiality Termination Date, the Company shall promptly (and in any event, no later than the time that the Company&#8217;s directors are notified) notify the Investor Group in writing as to the (i)&#160;opening of a trading window during which time all directors of the Company are permitted to trade in the Company&#8217;s securities and (ii) institution of a blackout period during which time all directors of the Company are prohibited from trading in the Company&#8217;s securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Representations and Warranties of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company represents and warrants to the Investors that (a) the Company has the corporate power and authority to execute this Agreement and to bind it thereto, (b) this Agreement has been duly and validly authorized, executed and delivered by the Company, constitutes a valid and binding obligation and agreement of the Company, and is enforceable against the Company in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles, and (c) to the actual knowledge of the executive officers of the Company, the execution, delivery, and performance of this Agreement by the Company does not and will not violate or conflict with (i) any law, rule, regulation, order, judgment or decree applicable to it, or (ii) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both could become a default) under or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document, or any material agreement, contract, commitment, understanding or arrangement to which the Company is a party or by which it is bound.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Representations and Warranties of the Investors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Investor, on behalf of itself, severally represents and warrants to the Company that (a) as of the date hereof, such Investor beneficially owns, directly or indirectly, only the number of shares of Common Stock and Series A Preferred Shares as described opposite its name on Exhibit&#160;A and Exhibit&#160;A includes all Affiliates of any Investors that own any securities of the Company beneficially or of record and reflects all shares of Common Stock and Series A Preferred Shares in which the Investors have any interest or right to acquire, whether through derivative securities, voting agreements or otherwise, (b) this Agreement has been duly and validly authorized, executed and delivered by such Investor, and constitutes a valid and binding obligation and agreement of such Investor, enforceable against such Investor in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles, (c) such Investor has the authority to execute the Agreement on behalf of itself and the applicable Investor associated with that signatory&#8217;s name, and to bind such Investor to the terms hereof, (d) each of the Investors shall cause its respective Representatives acting on its behalf to comply with the terms of this Agreement, and (e) to the actual knowledge of each Investor, the execution, delivery, and performance of this Agreement by such Investor does not and will not violate or conflict with (i) any law, rule, regulation, order, judgment or decree applicable to it, or (ii) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both could become a default) under or pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document, agreement, contract, commitment, understanding or arrangement to which such Investor is a party or by which it is bound.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Mutual Non-Disparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to applicable law, each of the parties covenants and agrees that, during the Standstill Period, or if earlier, until such time as the other party or any of its Representatives shall have breached this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, neither it nor any of its Representatives shall in any way publicly disparage, call into disrepute or otherwise defame or slander the other party or such other party&#8217;s Representatives (including any current officer of a party or a party&#8217;s subsidiaries who no longer serves in such capacity following the execution of this Agreement and any current director of a party or a party&#8217;s subsidiaries who no longer serves in such capacity following the execution of this Agreement), or any of their businesses, products or services, in any manner that would reasonably be expected to damage the business or reputation thereof. For the avoidance of doubt, the foregoing shall not prevent the making of any factual statement in connection with any compelled testimony or production of information by legal process, subpoena, or as part of a response to a request for information from any governmental authority with purported jurisdiction over the party from whom information is sought.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Public Announcements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Promptly following the execution of this Agreement, the Company shall issue a mutually agreeable press release (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Press Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) announcing this Agreement, substantially in the form attached as Exhibit B hereto. Prior to the issuance of the Press Release, neither the Company nor any of the Investors nor any of their respective Representatives shall issue any press release or make any public announcement regarding this Agreement or take any action that would require public disclosure thereof without the prior written consent of the other party. No party nor any of its Representatives shall make any public statement (including, without limitation, in any filing required under the Exchange Act) concerning the subject matter of this Agreement inconsistent with this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">SEC Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">No later than four (4) business days following the execution of this Agreement, the Company shall file a Current Report on Form 8-K with the SEC reporting entry into this Agreement and appending or incorporating by reference this Agreement as an exhibit thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">No later than two (2) business days following the execution of this Agreement, the Investor Group shall file an amendment to its Schedule&#160;13D with respect to the Company that has been filed with the SEC, reporting the entry into this Agreement, amending applicable items to conform to their obligations hereunder and appending or incorporating by reference this Agreement as an exhibit thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Not a Group with any Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Nothing contained in this Agreement shall be deemed or construed as creating a group, joint venture or partnership between the Investors and any other stockholders of the Company including those stockholders who are entering into Other Investor Agreements concurrently with this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each of the Company and the Investors shall be responsible for its own fees and expenses incurred in connection with the negotiation, execution, and effectuation of this Agreement and the matters contemplated hereby, including, but not limited to attorneys&#8217; fees incurred in connection with the negotiation and execution of this Agreement and all other activities related to the foregoing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company will reimburse the Investor Group for its reasonable, document out-of-pocket fees and expenses (including reasonable, documented legal expenses) incurred solely in connection with the negotiation and execution of this Agreement and related filings in an amount not to exceed $37,500, which amount shall be paid in three equal monthly installments by the Company commencing on the first business day of the month after which the Investor Group provides reasonable documentation of such expenses to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As used in this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Rule 12b-2 promulgated by the SEC under the Exchange Act&#894; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that, for purposes of this Agreement, no Investor shall be deemed an Affiliate of the Company and the Company shall not be deemed an Affiliate of any Investor&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the terms &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">beneficial owner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">beneficial ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the same meanings as set forth in Rule 13d-3 promulgated by the SEC under the Exchange Act&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">business day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any day that is not a Saturday, Sunday, or other day on which commercial banks in the State of New York are authorized or obligated to be closed by applicable law&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the sale of all or substantially all the assets of the Company&#59; any merger, consolidation, or acquisition of the Company with, by or into another corporation, entity, or person&#59; or any change in the ownership of more than 50% of the voting capital stock of the Company in one or more related transactions&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S.&#160;Securities Exchange Act of 1934, as amended&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">the terms &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">proxy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; (and any plurals thereof) have the meanings ascribed to such terms under the Exchange Act and the rules and regulations promulgated thereunder, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that the meaning of &#8220;solicitation&#8221; shall be without regard to the exclusions set forth in Rules 14a-1(l)(2)(iv) and 14a-2 under the Exchange Act&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the terms &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any individual, corporation (including not-for-profit), general or limited partnership, limited liability company, joint venture, estate, trust, association, organization, or other entity of any kind or nature&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (i) a person&#8217;s Affiliates, and (ii) its and their respective directors, officers, employees, partners, members, managers, consultants, legal or other advisors, agents, and other representatives acting in a capacity on behalf of, in concert with or at the direction of such person or its Affiliates&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">the term, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S.&#160;Securities and Exchange Commission&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt"> the term, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Standstill Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the period commencing on the Effective Date and ending upon the earlier to occur of (X) the day immediately after the 2025 Annual Meeting or (Y) October 31, 2025</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or, if earlier, upon the occurrence of any of the following&#58; (i) termination of any Other Investor Agreement or material breach of any Other Investor Agreement by any party to such Other Investor Agreement that is not cured within thirty (30) days&#8217; written notice thereof, (ii) if the Class 1 Series A Director Qualification Conditions are satisfied immediately prior to the 2024 Annual Meeting (or 2025 Annual Meeting if applicable) and the Board has not recommended for, or has withdrawn the recommendation for, the election of the Class 1 Series A Director at the 2024 Annual Meeting (as long as such Class 1 Series A Director is available and qualified for such election), (iii) if the size of the Board is not eight (8) or fewer seats immediately prior to the 2023 Annual Meeting, (iv) if size of the Board is not eleven (11) seats on the day after the 2023 Annual Meeting, (v) if size of the Board is not nine (9) or fewer seats upon the earlier of (x) immediately prior to the 2024 Annual Meeting and (y) December 1, 2024, (vi) if the size of the Board is increased after it is decreased from eleven (11) seats to nine (9) seats (except for any increase permitted pursuant to Section 1(c)(iv)), (vii) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">if the Company does not include the Declassification proposal in the 2023 Annual Meeting Proxy or if the Board does not recommend in favor of the adoption of such proposal in the 2023 Annual Meeting Proxy, (viii) if the Declassification Proposal is approved, the Board does not file the Declassification Amendment with the Secretary of State of Delaware within five (5) business days following certification of stockholder approval, or (ix) the 2024 Annual Meeting is not held on or prior to November 30, 2024 (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if either of clauses (ii) or (vi) occurs, the Company shall (1) notify the Investor Group in writing of such determination as promptly as practicable, and in any event within one (1) business day thereafter&#59; and (2) agree to delay the 2023 Annual Meeting, the 2024 Annual Meeting, or the 2025 Annual Meeting, as applicable, by at least 75 calendar days to permit the members of the Investor Group (and their Affiliates) to seek the election of the Class 1 Series A Director (or any replacement candidate) as a director of the Company or submit a stockholder proposal to declassify the Board, as applicable, and engage in a solicitation of proxies with respect to the election of the Class 1 Series A Director (or any replacement candidate) as a director of the Company or such stockholder proposal, as applicable&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">third party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; refers to any person that is not a party, a member of the Board, a director or officer of the Company, or legal counsel to either party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Specific Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each of the Investors, on the one hand, and the Company, on the other hand, acknowledges and agrees that irreparable injury to the other party hereto may occur in the event any of the provisions of this Agreement are not performed in accordance with their specific terms or are otherwise breached and that such injury would not be adequately compensable in monetary damages. It is accordingly agreed that the Investors or any Investor, on the one hand, and the Company, on the other hand (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Moving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), shall each be entitled to seek specific enforcement of, and injunctive or other equitable relief to prevent any violation of, the terms hereof, and the other party hereto will not take action, directly or indirectly, in opposition to the Moving Party seeking such relief on the grounds that any other remedy or relief is available at law or in equity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any notices, consents, determinations, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered&#58; (i) upon receipt, when delivered personally&#59; (ii) upon confirmation of receipt, when sent by email (provided such confirmation is not automatically generated)&#59; or (iii)&#160;one (1) business day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same. The addresses for such communications shall be&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If to the Company&#58;</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lifecore Biomedical, Inc.</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3515 Lyman Boulevard</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chaska, MN 55318</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; John.Morberg&#64;lifecore.com</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; John D. Morberg</font></div><div style="padding-left:108pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With copies (which shall not constitute notice) to&#58;</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Latham &#38; Watkins LLP</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">650 Town Center Dr. Floor 20</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Costa Mesa, CA 92626</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; Darren.Guttenberg&#64;lw.com&#59; Christopher.Drewry&#64;lw.com&#59; Tessa.Bernhardt&#64;lw.com</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Darren Guttenberg&#59; Christopher Drewry&#59; Tessa Bernhardt</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If to any Investor&#58;</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c&#47;o Legion Partners Holdings, LLC</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12121 Wilshire Boulevard, Suite 1240</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Los Angeles, California 90025</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; CKiper&#64;legionpartners.com</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Christopher S. Kiper</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With copies (which shall not constitute notice) to&#58;</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Olshan Frome Wolosky LLP</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1325 Avenue of the Americas</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">New York, New York 10019</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; EGonzalez&#64;olshanlaw.com</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Elizabeth Gonzalez-Sussman </font></div><div style="text-indent:108pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement shall be governed in all respects, including validity, interpretation, and effect, by, and construed in accordance with, the laws of the State of Delaware, without giving effect to the principles of conflicts of law or choice of law thereof or of any other jurisdiction to the extent that such principles would require or permit the application of the laws of another jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each party to this Agreement agrees, on behalf of itself and its Affiliates, that any actions, suits or proceedings arising out of or relating to this Agreement or the transactions contemplated by this Agreement will be brought solely and exclusively in any state or federal court in the State of Delaware (and the parties agree not to commence any action, suit or proceeding relating to this Agreement or the transactions contemplated by this Agreement except in such courts), and further agrees that service of any process, summons, notice or document by U.S. registered mail to the respective addresses set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be effective service of process for any such action, suit or proceeding brought against any party in any such court. Each party, on behalf of itself and its Affiliates, irrevocably and unconditionally waives any objection to the laying of venue of any action, suit or proceeding arising out of this Agreement or the transactions contemplated by this Agreement, in any state or federal court in the State of Delaware, and further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an improper or inconvenient forum.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION, (B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D)&#160;SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SECTION&#160;18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Investor hereby irrevocably appoints Legion Partners Asset Management, LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">LPAM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) as its attorney-in-fact and representative, in such Investor&#8217;s place and stead, to do any and all things and to execute any and all documents and give and receive any and all notices or instructions in connection with this Agreement and the transactions contemplated hereby. The Company shall be entitled to rely, as being binding on each Investor, upon any action taken by LPAM or upon any document, notice, instruction, or other writing given or executed by LPAM.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement constitutes the full and entire understanding and agreement among the parties with regard to the subject matter hereof, and supersedes all prior and contemporaneous agreements, understandings, and representations, whether oral or written, of the parties with respect to the subject matter hereof. There are no restrictions, agreements, promises, representations, warranties, covenants, or undertakings, oral or written, between the parties other than those expressly set forth herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The section&#160;headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No failure on the part of any party to exercise, and no delay in exercising, any right, power, or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such party preclude any other or further exercise thereof or the exercise of any other right, power, or remedy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All remedies hereunder are cumulative and are not exclusive of any other remedies provided by law or equity. In the event of litigation relating to this Agreement, if a court of competent jurisdiction determines in a final, non-appealable order that this Agreement has been breached by either party, then the breaching party shall reimburse the other party for its costs and expenses (including, without limitation, reasonable legal fees and expenses) incurred in connection with all such litigation, including any appeal therefrom.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Receipt of Adequate Information&#59; No Reliance&#59; Representation by Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each party acknowledges that it has received adequate information to enter into this Agreement, that it has had adequate opportunity to make whatever investigation or inquiry it may deem necessary or desirable in connection with the subject matter of this Agreement prior to the execution hereof, and that it has not relied on any promise, representation, or warranty, express, or implied not contained in this Agreement. Each of the parties hereto acknowledges that it has been represented by counsel of its choice throughout all negotiations that have preceded the execution of this Agreement, and that it has executed the same with the advice of said independent counsel. Each party cooperated and participated in the drafting and preparation of this Agreement and the documents referred to herein, and any and all drafts relating thereto exchanged among the parties shall be deemed the work product of all of the parties and may not be construed against any party by reason of its drafting or preparation. Accordingly, any rule of law or any legal decision that would require interpretation of any ambiguities in this Agreement against any party that drafted or prepared it is of no application and is hereby expressly waived by each of the parties hereto, and any controversy over interpretations of this Agreement shall be decided without regards to events of drafting or preparation. Further, any rule of law or any legal decision that would provide any party with a defense to the enforcement of the terms of this Agreement against such party shall have no application and is expressly waived. The provisions of the Agreement shall be interpreted in a reasonable manner so as to effect the intent of the parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. When a reference is made in this Agreement to a section, such reference shall be to a section&#160;of this Agreement, unless otherwise indicated. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation.&#8221; The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The word &#8220;will&#8221; shall be construed to have the same meaning as the word &#8220;shall.&#8221; The words &#8220;dates hereof&#8221; will refer to the Effective Date. The word &#8220;or&#8221; is not exclusive. The use of any gender shall be applicable to all genders. The definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms. Any agreement, instrument, law, rule, or statute defined or referred to herein means, unless otherwise indicated, such agreement, instrument, law, rule, or statute as from time to time amended, modified, or supplemented. For purposes of this Agreement, where an obligation of the Company or the Board (or any committee thereof) is qualified by the phrase &#8220;subject to the good faith exercise of the Board of its fiduciary duties under applicable law,&#8221; compliance with such obligation shall not be required if the Board (or, in the case of an obligation that is to be fulfilled by a committee of the Board, such committee), after receipt of advice from counsel regarding the same, determines in good faith that such compliance would violate the Board&#8217;s (or, as the case may be, such committee&#8217;s) fiduciary duties under applicable law. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If any provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Agreement shall remain in full force and effect. Any provision of this Agreement held invalid or unenforceable only in part </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or degree shall remain in full force and effect to the extent not held invalid or unenforceable. The parties further agree to replace such invalid or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the purposes of such invalid or unenforceable provision.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement may be modified, amended, or otherwise changed only in a writing signed by all of the parties hereto, or in the case of the Investors, the LPAM Representative, or their respective successors or assigns. Prior to the Termination Date, the Company shall not agree to any amendment to either of the Other Investor Agreements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The terms and conditions of this Agreement shall be binding upon and be enforceable by the parties hereto and the respective successors, heirs, executors, legal representatives and permitted assigns of the parties, and inure to the benefit of any successor, heir, executor, legal representative or permitted assign of any of the parties&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that no party may assign this Agreement or any rights or obligations hereunder without, with respect to any Investor, the express prior written consent of the Company (with such consent specifically authorized by a majority of the Board), and with respect to the Company, the prior written consent of the LPAM Representative, and any assignment in contravention of the foregoing shall be null and avoid.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">No Third-Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The representations, warranties, and agreements of the parties contained herein are intended solely for the benefit of the party to whom such representations, warranties, and&#47;or agreements are made, and shall confer no rights, benefits, remedies, obligations, or liabilities hereunder, whether legal or equitable, in any other person or entity, and no other person or entity shall be entitled to rely thereon.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Counterparts&#59; Facsimile &#47; PDF Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement and any amendments hereto may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become effective when each party hereto shall have received a counterpart hereof signed by the other parties hereto. In the event that any signature to this Agreement or any amendment hereto is delivered by facsimile transmission or by e-mail delivery of a portable document format (.pdf or similar format) data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &#8220;.pdf&#8221; signature page were an original thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">31.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as otherwise provided in this Agreement or as otherwise mutually agreed in writing by each party, this Agreement shall terminate on the Termination Date. Notwithstanding the foregoing, the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> through this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall survive the termination of this Agreement and any Recipient&#8217;s obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall survive the termination of this Agreement until the Confidentiality Termination Date. No termination of this Agreement shall relieve any party from liability for any breach of this Agreement prior to such termination.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;REMAINDER OF PAGE INTENTIONALLY LEFT BLANK&#93;<br>&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><div id="ic32337fa5efd4b538fe17dd1d785e973_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF the parties have duly executed and delivered this Agreement as of the date first above written.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIFECORE BIOMEDICAL, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Paul Josephs&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Paul Josephs</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page to Cooperation Agreement&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.442%"><tr><td style="width:1.0%"></td><td style="width:11.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Legion Partners, L.P. I</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Legion Partners Asset Management, LLC</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Investment Advisor</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher S. Kiper</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Christopher S. Kiper</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Managing Director </font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.442%"><tr><td style="width:1.0%"></td><td style="width:11.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Legion Partners, L.P. II</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Legion Partners Asset Management, LLC</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Investment Advisor</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher S. Kiper</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Christopher S. Kiper</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Managing Director </font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.442%"><tr><td style="width:1.0%"></td><td style="width:11.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Legion Partners, LLC</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Legion Partners Holdings, LLC</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Managing Member </font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher S. Kiper</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Christopher S. Kiper</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Managing Member </font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.442%"><tr><td style="width:1.0%"></td><td style="width:11.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Legion Partners Asset Management, LLC</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher S. Kiper</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Christopher S. Kiper</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Managing Director </font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page to Cooperation Agreement&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.442%"><tr><td style="width:1.0%"></td><td style="width:11.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Legion Partners Holdings, LLC</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher S. Kiper</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Christopher S. Kiper</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Managing Member</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.282%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher S. Kiper</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Christopher S. Kiper</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Raymond T. White </font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Raymond T. White </font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page to Cooperation Agreement&#93;</font></div></div></div><div id="ic32337fa5efd4b538fe17dd1d785e973_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVESTOR GROUP OWNERSHIP</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.629%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Investor</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Shares of Common Stock Beneficially Owned</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Shares of Series A Preferred Shares Beneficially Owned</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Legion Partners, L.P. I</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2,772,956</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12,742</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Legion Partners, L.P. II</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">167,184</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1,212</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Legion Partners, LLC</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2,940,140</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13,954</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Legion Partners Asset Management, LLC</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2,968,209</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13,954</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Legion Partners Holdings, LLC</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2,968,409</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13,954</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Christopher S. Kiper</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2,968,409</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13,954</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Raymond T. White</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2,968,409</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13,954</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><div id="ic32337fa5efd4b538fe17dd1d785e973_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><br>FORM OF PRESS RELEASE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(see attached)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>exhibit103-lifecorexcooper.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i46c8d8777bc043cb9188c1d643cfe281_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COOPERATION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Cooperation Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made and entered into as of June 28, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by and among Lifecore Biomedical, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Lifecore</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and each of the persons listed on Exhibit A hereto (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investor Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Company and each of the Investors are each herein referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;. Unless otherwise defined herein, capitalized terms shall have the meanings given to them in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, on March 21, 2024 the Company disclosed on a Form 8-K that Craig Barbarosh notified the Company that he has elected not to stand for re-election to serve as a director of the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) at the Company&#8217;s annual meeting of stockholders for the 2023 fiscal year, which is scheduled to take place on August 15, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2023 Annual Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and that the Board approved the appointment of Katrina L. Houde as Chairperson of the Board, effective as of the 2023 Annual Meeting&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, each of the Investors beneficially owns the number of shares of (i) the Company&#8217;s common stock, par value $0.001 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and (ii) the Company&#8217;s Series A Convertible Preferred Stock, par value $0.001 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Series A Preferred Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), each as listed on Exhibit&#160;A hereto&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, on May 16, 2024, 22NW Fund, LP (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">22NW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) delivered to the Company a notice of intent to submit director nominations (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Nomination Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) at the 2023 Annual Meeting&#894;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, on May 20, 2024, 22NW filed a Schedule 13D&#47;A with the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) disclosing its intention to nominate certain individuals to the Board, as set forth in the Nomination Notice&#894; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, on June 11, 2024, 22NW delivered to the Company a written demand for a special meeting of the stockholders of the Company to be held on August 14, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Special Meeting Demand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#894;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, on June 11, 2024, 22NW filed a Schedule 13D&#47;A with the SEC disclosing the Special Meeting Demand&#894;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, concurrent with the entry of this Agreement, 22NW (and its Affiliates) and Legion Partners Asset Management, LLC (together with its Affiliates, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Legion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) have entered into similar agreements with the Company, complete copies of which have been delivered to the Investors prior to the execution herewith (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Other Investor Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#894; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Company </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">has reached an agreement with the Investors with respect to the composition of the Board and certain other matters as provided in this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Board </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Composition and Other Company Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Recommendation of Class 1 Series A Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Pursuant to Section 13(c) of that certain Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of Lifecore Biomedical, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Series A Certificate of Designation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Wynnefield Capital Management, LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">WCM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) designates Christopher Kiper (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Class 1 Series A Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for election to the Board as a Series A Preferred Director (as defined in the Series A Certificate of Designation) at the Company&#8217;s annual meeting of stockholders for the 2024 fiscal year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2024 Annual Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Board hereby, on a one-time basis, waives compliance with the notice deadline established in Section 2.5 of the Amended and Restated Bylaws of Lifecore Biomedical, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Bylaws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in connection with such designation.  Subject to, and conditioned upon, (i) receipt by the Company of a written designation of Christopher Kiper by the two largest holders of Series A Preferred Shares as of the Effective Date and (ii) the satisfaction of the Preferred Stock Director Designation Right Condition (as defined in the Series A Certificate of Designation) as of immediately prior to the 2024 Annual Meeting (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Class 1 Series A Director Qualification Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Board, and all applicable committees of the Board, shall (A) take all necessary actions to nominate the Class 1 Series A Director as a director (or Class 1 director if applicable at such time) and as a Series A Preferred Director (as defined in the Series A Certificate of Designation) for election to the Board by the holders of the Series A Preferred Shares, voting separately as a class, at the 2024 Annual Meeting with a term expiring at the Company&#8217;s annual meeting of stockholders for the 2026 fiscal year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2026 Annual Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and until his or her successor is duly elected and qualified (or, if the Declassification Proposal (as defined below) is approved by the Company&#8217;s stockholders at the 2023 Annual Meeting and the Declassification Amendment (as defined below) is subsequently filed and accepted by the Secretary of State of the State of Delaware prior to the 2024 Annual Meeting, with a term expiring at the 2025 Annual Meeting, and until his or her successor is duly elected and qualified), (B) to list the Class 1 Series A Director in the Company&#8217;s proxy statement and proxy card prepared, filed with the SEC and delivered to the Company&#8217;s stockholders in connection with the 2024 Annual Meeting and to solicit proxies for the election of the Class 1 Series A Director at the 2024 Annual Meeting in the same manner (except for differences related to the fact that the Class 1 Series A Director is subject to a separate class vote of the holders of the Series A Preferred Shares) as it solicits proxies for the election of the Company&#8217;s other director nominees and (C) subject to the good faith exercise of the Board&#8217;s, and all applicable committees of the Board&#8217;s, fiduciary duties under applicable law, recommend for the election of the Class 1 Series A Director at the 2024 Annual Meeting in the same manner (except for the fact that the Class 1 Series A Director is subject to a separate class vote of the holders of the Series A Preferred Shares) as it recommends for the election of the Company&#8217;s other director nominees.  The Class 1 Series A Director agrees that he or she will recuse himself or herself from such portions of meetings of the Board or committees of the Board, if any, involving actual conflicts of interest between the Company and the holders of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Series A Preferred Shares. Further, in the event the Declassification Proposal is approved by the Company&#8217;s stockholders at the 2023 Annual Meeting and the Declassification Amendment is subsequently filed and accepted by the Secretary of State of the State of Delaware prior to the 2024 Annual Meeting, all obligations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall apply with respect to the 2025 Annual Meeting in all respects.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Recommendation of Class 2 Series A Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Pursuant to Section 13(c) of the Series A Certificate of Designation, WCM designates Jason Aryeh (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Class 2 Series A Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for election to the Board as a Series A Preferred Director (as defined in the Series A Certificate of Designation) at the 2023 Annual Meeting.  The Board hereby, on a one-time basis, waives compliance with the notice deadline established in Section 2.5 of the Amended and Restated Bylaws of Lifecore Biomedical, Inc. in connection with such designation.  Subject to, and conditioned upon, (i) receipt by the Company of a written designation of Jason Aryeh by the two largest holders of Series A Preferred Shares as of the Effective Date and (ii) the satisfaction of the Preferred Stock Director Designation Right Condition (as defined in the Series A Certificate of Designation) as of immediately prior to the 2023 Annual Meeting (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Class 2 Series A Director Qualification Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Board, and all applicable committees of the Board, shall, (A) take all necessary actions to nominate the Class 2 Series A Director as a Class 2 director and as a Series A Preferred Director (as defined in the Series A Certificate of Designation) for election to the Board by the holders of the Series A Preferred Shares, voting separately as a class, at the 2023 Annual Meeting with a term expiring at the 2025 Annual Meeting, and until his or her successor is duly elected and qualified, (B) to list the Class 2 Series A Director in the Company&#8217;s proxy statement and proxy card prepared, filed with the SEC and delivered to the Company&#8217;s stockholders in connection with the 2023 Annual Meeting and to solicit proxies for the election of the Class 2 Series A Director at the 2023 Annual Meeting in the same manner (except for differences related to the fact that the Class 2 Series A Director is subject to a separate class vote of the holders of the Series A Preferred Shares) as it solicits proxies for the election of the Company&#8217;s other director nominees and (C) subject to the good faith exercise of the Board&#8217;s, and all applicable committees of the Board&#8217;s, fiduciary duties under applicable law, recommend for the election of the Class 2 Series A Director at the 2023 Annual Meeting in the same manner (except for the fact that the Class 2 Series A Director is subject to a separate class vote of the holders of the Series A Preferred Shares) as it recommends for the election of the Company&#8217;s other director nominees. The Class 2 Series A Director agrees that he or she will recuse himself or herself from such portions of meetings of the Board or committees of the Board, if any, involving actual conflicts of interest between the Company and the Investor Group. Further, all obligations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall apply with respect to the 2025 Annual Meeting in all respects. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Continuing Class 1 Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Prior to the execution of this Agreement (i) the Board&#8217;s Nominating and Governance Committee has reviewed and approved the qualifications of Nelson Obus to continue to serve as a Class 1 member of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Continuing Class 1 Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and (ii) the Board has determined that the Continuing Class 1 Director is &#8220;independent&#8221; as defined by the listing standards of the Nasdaq. The Board, and all applicable committees of the Board, shall (A) take all necessary actions to nominate the Continuing Class 1 Director as a director (or a Class 1 director if applicable at such time) for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">election to the Board at the 2024 Annual Meeting with a term expiring at the 2026 Annual Meeting, and until his or her successor is duly elected and qualified (or, if the Declassification Proposal is approved by the Company&#8217;s stockholders at the 2023 Annual Meeting and the Declassification Amendment is subsequently filed and accepted by the Secretary of State of the State of Delaware prior to the 2024 Annual Meeting, with a term expiring at the 2025 Annual Meeting, and until his or her successor is duly elected and qualified), (B) to list the Continuing Class 1 Director in the Company&#8217;s proxy statement and proxy card prepared, filed with the SEC and delivered to the Company&#8217;s stockholders in connection with the 2024 Annual Meeting and to solicit proxies for the election of the Continuing Class 1 Director at the 2024 Annual Meeting in the same manner as it solicits proxies for the election of the Company&#8217;s other director nominees and (C) subject to the good faith exercise of the Board&#8217;s, and all applicable committees of the Board&#8217;s, fiduciary duties under applicable law, recommend for the election of the Continuing Class 1 Director at the 2024 Annual Meeting in the same manner as it recommends for the election of the Company&#8217;s other director nominees. Further, in the event the Declassification Proposal is approved by the Company&#8217;s stockholders at the 2023 Annual Meeting and the Declassification Amendment is subsequently filed and accepted by the Secretary of State of the State of Delaware prior to the 2024 Annual Meeting, all obligations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall apply with respect to the 2025 Annual Meeting in all respects. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Board Size</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Board, and all applicable committees of the Board, shall, subject to the good faith exercise of the Board&#8217;s, and all applicable committees of the Board&#8217;s, fiduciary duties under applicable law, take all necessary actions to (i) reduce the size of the Board from nine (9) seats to eight (8) seats immediately prior to the 2023 Annual Meeting, (ii) increase the size of the Board from eight (8) seats to eleven (11) seats immediately following the 2023 Annual Meeting, (iii) reduce the size of the Board from eleven (11) seats to nine (9) seats upon the earlier of (A) immediately prior to the 2024 Annual Meeting or (B) November 30, 2024, and (iv) following reduction in size of the Board described in clause (iii), during the Standstill Period, the size of the Board may be increased by the Board by no more than two (2) seats only pursuant to an agreement with an investor in or debt financing provider to the Company in connection with such equity or debt transaction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Board Policies and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as otherwise permitted in this Agreement, all members of the Board, including the Continuing Class 1 Director, are required to comply with all policies, processes, procedures, codes, rules, standards, and guidelines applicable to members of the Board, as in effect from time to time, including, without limitation, the Company&#8217;s Corporate Governance Guidelines, Code of Business Conduct, and policies on stock trading, stock ownership, hedging and pledging of Company securities, public disclosures and confidentiality, and that the Continuing Class 1 Director is required to strictly preserve the confidentiality of Company business and information, including the discussion of any matters considered in meetings of the Board or Board committees whether or not the matters relate to material non-public information. The Continuing Class 1 Director shall provide the Company with such information concerning the Continuing Class 1 Director as is required to be disclosed under applicable law or stock exchange regulations, including the completion of the Company&#8217;s standard directors&#8217; and officers&#8217; questionnaire upon request, in each case as promptly as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">necessary to enable the timely filing of the Company&#8217;s proxy statement and other periodic reports with the SEC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Replacement Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company agrees that if, during the Standstill Period (and so long as no Investor has breached its obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereof), the Continuing Class 1 Director (or his or her replacement appointed pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) is unable to serve as a director, resigns, or is removed as a director prior to the end of the term of office set forth above (other than on account of (i) the failure of the Continuing Class 1 Director to be elected or re-elected by the stockholders at an annual meeting of the Company&#8217;s stockholders or a special meeting of stockholders held in lieu thereof or (ii) the Continuing Class 1 Director not being nominated to serve as a director in accordance with the terms of this Agreement at an annual meeting of the Company&#8217;s stockholders or a special meeting of stockholders held in lieu thereof), and at such time the Investor Group beneficially owns in the aggregate at least the lesser of (A) ten percent (10%) of the Company&#8217;s then outstanding voting securities on an as-converted to Common Stock basis or (B) the Company&#8217;s then outstanding voting securities on an as-converted to Common Stock basis beneficially owned by the Investors as of the Effective Date and as set forth on Exhibit&#160;A hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investor Group Minimum Ownership Threshold</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then the Investor Group shall have the ability to recommend a substitute person, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that any such substitute person so recommended shall qualify as &#8220;independent&#8221; pursuant to Nasdaq&#8217;s listing standards, have the relevant financial and business experience to fill the resulting vacancy, made himself or herself available for one or more interviews with the Nominating Committee and other members of the Board, agreed to a customary background check by the Company and completed the Company&#8217;s standard directors&#8217; and officers&#8217; questionnaire (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Qualification Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). In the event that the Nominating Committee does not accept a substitute person so recommended, then the Investor Group shall have the right to recommend an additional substitute person for consideration by the Nominating Committee. Either the original candidate or the substitute person recommended shall be accepted by the Nominating</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Committee, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that after reasonable review by the Nominating Committee of the Qualification Information, both such candidates were, in the reasonable judgement of the Nominating Committee, qualified to serve on the Board&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Investor Group may continue to recommend additional substitute persons until two candidates are so accepted by the Nominating Committee at which time the Nominating Committee shall accept one of the two such candidates. Upon acceptance of a replacement director nominee by the Nominating Committee, the Board and all applicable committees of the Board, shall, subject to the good faith exercise of the Board&#8217;s, and all applicable committees of the Board&#8217;s, fiduciary duties under applicable law, take all necessary actions to appoint such replacement director to the Board no later than ten (10) business days after the Nominating Committee&#8217;s recommendation. Following the appointment of any replacement director in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, any reference to the Continuing Class 1 Director in this Agreement shall be deemed to refer to such replacement director.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Rights and Benefits of the Continuing Class 1 Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Continuing Class 1 Director shall receive (i) the same benefits of director and officer insurance, and any indemnity and exculpation arrangements available generally to the directors on the Board, (ii) the same compensation for his or her service as a director as the compensation received by other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">non-management directors on the Board with similar Board assignments, and (iii) such other benefits on the same basis as all other non-management directors on the Board. Notwithstanding the foregoing, (A) the Company shall not be responsible for the preparation or filing of any Forms 3, 4, and 5 under Section 16 of the Exchange Act (as defined below) that are required to be filed by the Continuing Class 1 Director, and (B) the Company agrees to provide timely notice to the Continuing Class 1 Director of any expected SEC filing requirements applicable to directors of the Company and reasonably cooperate with the Continuing Class 1 Director and his or her counsel in the preparation of any Forms 3, 4, and 5 under Section 16 of the Exchange Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Stockholder Proposal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Board, and all applicable committees of the Board, shall, take all necessary actions  to submit to the stockholders of the Company at the 2023 Annual Meeting a proposal to approve an amendment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Declassification Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of Article VI of the Amended and Restated Certificate of Incorporation of the Company, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Certificate of Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), to provide for the phased-in declassification of the Board, with Class 1 directors being elected annually beginning at the 2024 Annual Meeting and with Class 2 directors being elected annually beginning at the 2025 Annual Meeting, such that the Board would be fully declassified at the time of the 2025 Annual Meeting (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Declassification Proposal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and subject to the good faith exercise of the Board&#8217;s and all applicable committees of the Board&#8217;s, fiduciary duties under applicable law, to recommend in favor of the Declassification Proposal in the Company&#8217;s proxy statement and proxy card prepared, filed with the SEC and delivered to the Company&#8217;s stockholders in connection with the 2023 Annual Meeting (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2023 Annual Meeting Proxy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and, upon the approval of the Declassification Proposal, shall promptly file the Declassification Amendment with the Secretary of State of the State of Delaware upon such approval.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt;text-decoration:underline">Company Rights Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If the Board determines to cause the Company to conduct a rights offering during the Standstill Period pursuant to which the Company would distribute to holders of Common Stock subscription rights to purchase shares of Common Stock, and that is subject to a backstop or standby commitment, and either Legion or 22NW is offered the right to participate in such backstop or standby commitment, the Investor Group will be offered the right to participate in such backstop or standby commitment with respect to the same aggregate amount of unsubscribed shares as Legion or 22NW, subject, in each case, to (A) applicable law (including the Board&#8217;s fiduciary duties) and the applicable rules or requirements of the Nasdaq and (B) at the time of such rights offering the Investor Group beneficially owns in the aggregate at least the Investor Group Minimum Ownership Threshold. All such purchase rights shall not be subject to the ownership limitations set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(a)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">The covenants set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall terminate and be of no further force or effect immediately on the earliest of (i) the Termination Date, or (ii) the date at which the Investor Group no longer satisfies the Investor Group Minimum Ownership Threshold.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Voting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. At each annual or special meeting of stockholders held during the Standstill Period, each of the Investors agrees to (i) appear at such stockholders&#8217; meeting or otherwise cause all shares of Common Stock and Series A Preferred Shares then beneficially owned by each Investor and their respective Affiliates to be counted as present thereat for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">purposes of establishing a quorum&#59; and (ii) vote, or cause to be voted, all shares of Common Stock and Series A Preferred Shares then beneficially owned by each Investor and their respective Affiliates on the Company&#8217;s proxy card or voting instruction form in favor of (a) each of the directors nominated by the Board and recommended by the Board, including such directors nominated and recommended by the Board pursuant to this Agreement and the Other Investor Agreements, in the election of directors (and not in favor of any other nominees to serve on the Board), and (b) each of the other proposals listed on the Company&#8217;s proxy card or voting instruction form as identified in the Company&#8217;s proxy statement prepared, filed with the SEC and delivered to the Company&#8217;s stockholders in accordance with the Board&#8217;s recommendations&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in the event in the event that Institutional Shareholder Services Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ISS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) or Glass Lewis &#38; Co., LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Glass Lewis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) recommends otherwise with respect to any proposals (other than the election or removal of directors or any proposed increase in the authorized shares of the Company), each of the Investors shall be permitted to vote in accordance with the ISS or Glass Lewis recommendation&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that each of the Investors shall be permitted to vote in their sole discretion with respect to any publicly announced proposals relating to a merger, acquisition, disposition business combination, amalgamation, recapitalization, restructuring,  distribution, spin-off, joint venture, any tender or exchange offer, any dissolution, liquidation, or reorganization of the Company, any debt or equity issuances or financings, the implementation of takeover defenses not in existence as of the date of this Agreement, or any other similar extraordinary matters involving the Company requiring a vote of stockholders of the Company. No later than two (2) business days prior to each such meeting of stockholders, each Investor shall, and shall cause each of its Affiliates to, vote any shares of Common Stock and Series A Preferred Shares beneficially owned by such Investors in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No Investor nor any of its Affiliates, nor any person under its direction or control shall take any position, make any statement, or take any action inconsistent with the foregoing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Standstill</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Each Investor agrees that, except as expressly permitted elsewhere in this Agreement, from the Effective Date until the Termination Date, without the prior written approval of the Board, neither it nor any of its controlled Affiliates shall, directly or indirectly, alone or in concert with others, in any manner&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">publicly announce or otherwise disclose an intent to propose or enter into or agree to enter into, singly or with any other person, directly or indirectly, (A) any form of business combination or acquisition or other transaction relating to a material amount of assets or securities of the Company or any of its subsidiaries, (B) any form of restructuring, recapitalization or similar transaction with respect to the Company or any of its subsidiaries, or (C) any form of tender or exchange offer for the Common Stock or the Series A Preferred Shares, whether or not such transaction involves a Change of Control of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">engage in any solicitation of proxies or written consents to vote any voting securities of the Company, or conduct any non-binding referendum with respect to any voting securities of the Company, or knowingly encourage, assist or participate in any other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">way, directly or indirectly, in any solicitation of proxies (or written consents) with respect to any voting securities of the Company, or otherwise become a &#8220;participant&#8221; in a &#8220;solicitation,&#8221; as such terms are defined in Instruction 3 of Item 4 of Schedule&#160;14A and Rule 14a-1 of Regulation 14A, respectively, under the Exchange Act, to vote any securities of the Company in opposition to any recommendation or proposal of the Board&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">acquire, offer, or propose to acquire, or agree to acquire, directly or indirectly, by purchase or otherwise, beneficial ownership of any interests in any of the Company&#8217;s indebtedness, Common Stock, Series A Preferred Shares, or other equity interests in the Company (including any rights decoupled from the underlying securities of the Company, but excluding Common Stock issued in connection with a stock split, stock dividend or similar corporate action initiated by the Company with respect to any securities beneficially owned by any of the Investors and&#47;or any Affiliate), in each case, if such acquisition, offer, proposal or agreement would result in the Investors acquiring beneficial ownership (amongst all of the Investors and any Affiliate) in excess of 18.16% of the shares of Common Stock and Series A Preferred Shares outstanding (on an as converted to common basis), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, any purchases pursuant to Section 1(i) hereof shall be excluded from the limitations provided herein&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">acquire or agree, offer, seek, or propose to acquire, or cause to be acquired, ownership (including beneficial ownership) in one or a series of related transactions, a majority or more of the assets or business of the Company or any rights or options to acquire any such assets or business from any person, in each case other than securities of the Company&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">seek to advise, encourage, support or influence any person with respect to the voting of (or execution of a written consent in respect of) or disposition of any securities of the Company, other than in a manner consistent with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">take any public action in support of or make any public proposal or request that constitutes&#58; (A) advising, controlling, changing, or influencing the Board or management of the Company or its subsidiaries, including any plans or proposals to change the number or term of directors, to elect directors, to fill any vacancies on the Board, or to remove directors, (B) any material change in the capitalization, stock repurchase programs and practices, capital allocation programs and practices or dividend policy of the Company or its subsidiaries, (C)&#160;any other material change in the Company&#8217;s management, business, or corporate or governance structure, (D)&#160;seeking to have the Company waive or make amendments or modifications to the Company&#8217;s Certificate of Incorporation or Bylaws, operations, business, corporate strategy, corporate structure, capital structure or allocation, share repurchase or dividend policies or other actions that may impede or facilitate the acquisition of control of the Company by any person, (E) causing a class of securities of the Company to be delisted from, or to cease to be authorized to be quoted on, any securities exchange&#59; or (F) causing a class of securities of the Company to become eligible for termination of registration pursuant to Section&#160;12(g)(4) of the Exchange Act, in each case except as permitted expressly by this Agreement&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.36pt">initiate, propose, or otherwise &#8220;solicit&#8221; stockholders of the Company for the approval of any stockholder proposals (whether pursuant to Rule 14a-8 under the Exchange Act or otherwise) other than in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">communicate with stockholders of the Company or others pursuant to Rule 14a-1(l)(2)(iv) under the Exchange Act other than in a manner consistent with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">call or seek to call, or request the call of, alone or in concert with others, any meeting of stockholders, whether or not such a meeting is permitted by the Company&#8217;s Certificate of Incorporation or Bylaws, including, but not limited to, a &#8220;town hall meeting&#59;&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">grant any proxy, consent or other authority to vote with respect to any matters (other than to the named proxies included in the Company&#8217;s proxy card for any annual meeting or special meeting of stockholders) or deposit any Common Stock or Series A Preferred Shares in any voting trust or similar arrangement or subject any Common Stock or Series A Preferred Shares to any voting agreement or pooling arrangement, other than (A) customary brokerage accounts, margin accounts and prime brokerage accounts and (B) otherwise in accordance with this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">seek, or encourage any person, to submit nominations in furtherance of a &#8220;contested solicitation&#8221; for the election or removal of directors with respect to the Company or, except as expressly provided in this Agreement, seek, encourage or take any other action with respect to the election or removal of any directors (it being acknowledged that those public communications that are permitted and those SEC filings that are required under this Agreement shall not constitute such encouragement)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.36pt">form, join or in any other way participate in any a &#8220;partnership, limited partnership, syndicate, or other group&#8221; (within the meaning of Section&#160;13(d)(3) of the Exchange Act) with respect to the securities of the Company (other than a &#8220;group&#8221; that includes all or some of the Investors, but does not include any other entities or persons that are not members of the Investor Group as of Effective Date)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that the Investor Group Schedule 13D shall not be amended to add additional members to the Investor Group other than persons that are wholly owned as of the Effective Date by an existing member of the Investor Group, so long as any such additional wholly owned member agrees to be bound by the terms and conditions of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xiii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">commence, join, encourage, or support any lawsuit, arbitration, or other legal claim against the Company or any of its officers or directors, including without limitation any derivative action in the name of the Company, or any class action against the Company or any of its officers or directors </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that nothing in this clause&#160;(xii) will in any way limit the rights of either party under this Agreement or any other agreement between the parties, including by (A) commencing litigation to enforce such rights, or (B) making counterclaims with respect to any proceeding initiated by, or on behalf of, the Company against an Investor&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xiv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.69pt">disclose publicly, or privately in a manner that could reasonably be expected to become public, any intent, purpose, plan, or proposal with respect to the Board, the Company, its management, policies, or affairs, any of its securities or assets or this Agreement that is inconsistent with the provisions of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.02pt">make any request or submit any proposal to amend the terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> other than through non-public communications with the Company that would not be reasonably determined to trigger public disclosure obligations for any party&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xvi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.69pt">take any action challenging the validity or enforceability of any of the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or publicly disclose, or cause or facilitate the public disclosure (including, without limitation, the filing of any document with the SEC or any other governmental agency or any disclosure to any journalist, member of the media or securities analyst) of, any intent, purpose, plan or proposal to either (A) obtain any waiver or consent under, or any amendment of, any provision of this Agreement, or (B) take any action challenging the validity or enforceability of any provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xvii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.36pt">make any public communication in opposition to (A) any merger, acquisition, amalgamation, recapitalization, restructuring, disposition, distribution, spin-off, asset sale, joint venture or other business combination or (B) any financing transaction, in each case involving the Company or any of its subsidiaries&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xviii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6.03pt">call or seek to call any special meeting of the Company (other than calling or seeking to call a special meeting of the holders of the Series A Preferred Shares pursuant to the Series A Certificate of Designation) or action by consent resolutions or make any request under Section 220 of the Delaware General Corporation Law or other applicable legal provisions regarding inspection of books and records or other materials (including stocklist materials) of the Company or any of its subsidiaries&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(xix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.69pt">advise, assist, knowingly encourage, or seek to persuade any person or entity to take any action or make any statement inconsistent with any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding anything in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or elsewhere in this Agreement, nothing in this Agreement shall prohibit or restrict any Investor or the Continuing Class 1 Director from (i)&#160;communicating privately with any director on the Board or any of the Company&#8217;s officers regarding any matter, so long as such communications are not intended to, and would not reasonably be expected to, require any public disclosure of such communications, (ii) identifying potential director candidates to serve on the Board so long as such actions do not create a public disclosure obligation for the Investor Group or the Company, are not publicly disclosed by the Investor Group or its Affiliates and are undertaken on a basis reasonably designed to be confidential, (iii) privately communicating to any of their investors or potential investors information regarding the Company based on publicly available information, provided, that such communications are subject to reasonable confidentiality obligations and are not otherwise reasonably expected to be publicly disclosed, (iv) communicating with stockholders of the Company and others in a manner that does not otherwise violate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of this Agreement, (v) making a public statement about how such Investor intends to vote and the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">reasons therefor with respect to any publicly announced Change of Control transaction, (vi) exchanging, tendering, or otherwise participating in any tender or exchange offer with respect to the Common Stock or Series A Preferred Shares, whether or not such transaction involves a Change of Control of the Company, on the same basis as the other stockholders of the Company, (vii) taking any action necessary to comply with any law, rule, or regulation or any action required by any governmental or regulatory authority or stock exchange that has jurisdiction over an Investor, or (viii) exercising any right permitted under the Series A Certificate of Designation and transaction documents related to the purchase of the Series A Preferred Shares, including calling upon the Company to call a special meeting for the purpose of electing Series A Preferred Directors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">As of the Effective Date, none of the Investors are engaged in any discussions or negotiations and do not have any agreements or understandings, written or oral, whether or not legally enforceable, concerning the acquisition of beneficial ownership of any securities of the Company, and have no actual knowledge that any other stockholders of the Company have any present or future intention of taking any actions that if taken by the Investors would violate any of the terms of this Agreement. For the avoidance of doubt, nothing in this Agreement shall be deemed to limit the exercise in good faith by the Continuing Class 1 Director of his fiduciary duties in his capacity as a director of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Except as otherwise provided in this Agreement, this Agreement shall automatically terminate upon the public announcement of a transaction that will constitute a Change of Control involving the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Information Sharing with Investor Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The Continuing Class 1 Director may, if he wishes to do so, provide Confidential Information to other members of the Investor Group and their Representatives who need to know such information in connection with the Investor Group&#8217;s investment in the Company (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Recipient</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Investor Group shall (i) inform each Recipient of the confidential nature of the Confidential Information and (ii) cause each Recipient not to disclose any Confidential Information to any Person other than to Recipients in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and not to use any Confidential Information other than in connection with (A) the Continuing Class 1 Director&#8217;s duties as a director of the Company and (B) evaluating or monitoring the Investor Group&#8217;s investment in the Company. The Investor Group shall be jointly and severally responsible for any breach of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> by any Recipient who receives Confidential Information from the Continuing Class 1 Director hereunder. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">If any Recipient is (i) legally compelled, by deposition, interrogatory, request for documents, subpoena, civil investigation, demand, order or similar process, to disclose any Confidential Information or (ii) determines (on the advice of outside legal counsel) that it is required by law or regulation to disclose any Confidential Information, prior to making such disclosure, such Recipient must, to the extent practicable and legally permissible, (A) promptly notify the Company of the circumstances surrounding such requirement or request and (B) reasonably cooperate with the Company, at the Company&#8217;s sole expense, in any attempt it may make to obtain a protective order, other appropriate remedy, or an appropriate assurance </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that confidential treatment will be afforded to its Confidential Information. If a protective order or other appropriate remedy or assurance is not obtained, the Recipient agrees to only disclose (or cause to be disclosed, as applicable) that portion of the Confidential Information that is legally required to be disclosed (on the advice of outside legal counsel). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Upon the expiration of the Standstill Period, each member of the Investor Group agrees to (and agrees to cause any Recipient to, if applicable) (i) promptly (and in any event within five business days of such expiration) return or destroy (and upon request, confirm in writing such return or destruction to the Company) all Confidential Information of the Company and its Affiliates and any other material containing or reflecting any of the Confidential Information, (ii) not to retain any copies, extracts or other reproductions in whole or in part, mechanical or electronic, of such written material, and (iii) to destroy all computer records, documents, memoranda, notes and other writings prepared by the Continuing Class 1 Director or a Recipient based on the Confidential Information of the Company or any of its Affiliates&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Investor Group that receive Confidential Information shall be entitled to retain one copy of all such Confidential Information in restricted access legal files or pursuant to automatic electronic archiving and back-up procedures for use solely in connection with any regulatory action&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that any Confidential Information so retained shall remain subject to the confidentiality obligations hereunder for so long as it so retained, notwithstanding any termination of this Agreement or the confidentiality obligations pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">All Confidential Information is provided to any Recipient &#8220;as is&#8221; and the Company does not make any representation or warranty as to the accuracy or completeness of the Confidential Information or any component thereof. The Company will have no liability to any Recipient resulting from the reliance on the Confidential Information. The Investor Group acknowledges that all of the Confidential Information is owned solely by the Company (or its licensors) and that the unauthorized disclosure or use of such Confidential Information would cause irreparable harm and significant injury, the degree of which may be difficult to ascertain. Therefore, in the event of any breach of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company is entitled to seek all forms of equitable relief (including an injunction and order for specific performance), in addition to all other remedies available at law or in equity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all information or data concerning the Company, whether in verbal, visual, written, electronic, or other form, which is disclosed to any Recipient by the Company or any Representative of the Company (including, but not limited to, all Relevant Materials and Information that is non-public information)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall not include information that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">is or becomes generally available to the public other than as a result of disclosure of such information by any Recipient in violation of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">is independently developed by any Recipient without use of the Confidential Information provided by the Company or any Representative thereof&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">becomes available to any Recipient at any time on a non-confidential basis from a third party that is not, to such recipient&#8217;s knowledge, prohibited from disclosing such information to such recipient by any contractual, legal, or fiduciary obligation to the Company&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">was known by any Recipient prior to receipt from the Company or from any Representative thereof and, to Recipient&#8217;s knowledge, the source of such information was not prohibited from disclosing such information to such recipient by any contractual, legal, or fiduciary obligation to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">Notwithstanding anything in this Agreement to the contrary, the Company acknowledges that the Investor Group&#8217;s businesses include the analysis of, and investment in, securities, instruments, businesses and assets, and Confidential Information may serve to give any natural person who is an Investor Group party a deeper overall knowledge and understanding in a way that cannot be separated from his or her other knowledge, and accordingly, subject to such Investor Group party&#8217;s compliance with his or her obligations under this Agreement and without in any way limiting the Investor Group&#8217;s obligations under this Agreement, the Company acknowledges that this Agreement is not intended to restrict the use of such overall knowledge and understanding solely for internal investment analysis purposes, including, subject to applicable law, the purchase, sale, consideration of, and decisions related to, other investments. Subject to applicable law and the Investor Group&#8217;s compliance with its obligations under this Agreement, this Agreement shall not prohibit or otherwise limit the Investor Group from negotiating, evaluating and&#47;or trading, directly or indirectly, in any index fund, exchange traded fund, benchmark fund, or other basket of securities which the Investor Group has no direct or indirect control over, which may contain or otherwise reflect the performance of any securities of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the confidentiality and use obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall terminate 18 months after the date any Recipient received the last of such Confidential Information (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidentiality Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Acknowledgment of Obligations under Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Each member of the Investor Group acknowledges that he or she is aware of the restrictions imposed by the United States federal securities laws and other applicable foreign and domestic laws (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) on a person possessing material nonpublic information about a publicly traded company, including, but not limited to, restrictions that prohibit such person from purchasing or selling securities of such company, or from communicating such information to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell such securities. The Investor Group acknowledges that Confidential Information shared by the Company or its Representatives with any Recipient may include information regarding material activity by the Company, and that any such information so shared or exchanged shall be subject to the confidentiality obligations set forth herein and may constitute material non-public information with respect to United States securities laws.  The Company agrees that, following the Effective Date and prior to the Confidentiality Termination Date, the Company shall promptly (and in any event, no later than the time that the Company&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">directors are notified) notify the Investor Group in writing as to the (i)&#160;opening of a trading window during which time all directors of the Company are permitted to trade in the Company&#8217;s securities and (ii) institution of a blackout period during which time all directors of the Company are prohibited from trading in the Company&#8217;s securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Representations and Warranties of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company represents and warrants to the Investors that (a) the Company has the corporate power and authority to execute this Agreement and to bind it thereto, (b) this Agreement has been duly and validly authorized, executed and delivered by the Company, constitutes a valid and binding obligation and agreement of the Company, and is enforceable against the Company in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles, and (c) to the actual knowledge of the executive officers of the Company, the execution, delivery, and performance of this Agreement by the Company does not and will not violate or conflict with (i) any law, rule, regulation, order, judgment or decree applicable to it, or (ii) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both could become a default) under or pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document, or any material agreement, contract, commitment, understanding or arrangement to which the Company is a party or by which it is bound.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Representations and Warranties of the Investors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Investor, on behalf of itself, severally represents and warrants to the Company that (a) as of the date hereof, such Investor beneficially owns, directly or indirectly, only the number of shares of Common Stock and Series A Preferred Shares as described opposite its name on Exhibit&#160;A and Exhibit&#160;A includes all Affiliates of any Investors that own any securities of the Company beneficially or of record and reflects all shares of Common Stock and Series A Preferred Shares in which the Investors have any interest or right to acquire, whether through derivative securities, voting agreements or otherwise, (b) this Agreement has been duly and validly authorized, executed and delivered by such Investor, and constitutes a valid and binding obligation and agreement of such Investor, enforceable against such Investor in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles, (c) such Investor has the authority to execute the Agreement on behalf of itself and the applicable Investor associated with that signatory&#8217;s name, and to bind such Investor to the terms hereof, (d) each of the Investors shall cause its respective Representatives acting on its behalf to comply with the terms of this Agreement, and (e) to the actual knowledge of each Investor, the execution, delivery, and performance of this Agreement by such Investor does not and will not violate or conflict with (i) any law, rule, regulation, order, judgment or decree applicable to it, or (ii) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both could become a default) under or pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document, agreement, contract, commitment, understanding or arrangement to which such Investor is a party or by which it is bound.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Mutual Non-Disparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to applicable law, each of the parties covenants and agrees that, during the Standstill Period, or if earlier, until such time as the other party or any of its Representatives shall have breached this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, neither it nor any of its Representatives shall in any way publicly disparage, call into disrepute or otherwise defame or slander the other party or such other party&#8217;s Representatives (including any current officer of a party or a party&#8217;s subsidiaries who no longer serves in such capacity following the execution of this Agreement and any current director of a party or a party&#8217;s subsidiaries who no longer serves in such capacity following the execution of this Agreement), or any of their businesses, products or services, in any manner that would reasonably be expected to damage the business or reputation thereof. For the avoidance of doubt, the foregoing shall not prevent the making of any factual statement in connection with any compelled testimony or production of information by legal process, subpoena, or as part of a response to a request for information from any governmental authority with purported jurisdiction over the party from whom information is sought.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Public Announcements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Promptly following the execution of this Agreement, the Company shall issue a mutually agreeable press release (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Press Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) announcing this Agreement, substantially in the form attached as Exhibit B hereto. Prior to the issuance of the Press Release, neither the Company nor any of the Investors nor any of their respective Representatives shall issue any press release or make any public announcement regarding this Agreement or take any action that would require public disclosure thereof without the prior written consent of the other party. No party nor any of its Representatives shall make any public statement (including, without limitation, in any filing required under the Exchange Act) concerning the subject matter of this Agreement inconsistent with this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">SEC Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">No later than four (4) business days following the execution of this Agreement, the Company shall file a Current Report on Form 8-K with the SEC reporting entry into this Agreement and appending or incorporating by reference this Agreement as an exhibit thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">No later than two (2) business days following the execution of this Agreement, the Investor Group shall file an amendment to its Schedule&#160;13D with respect to the Company that has been filed with the SEC, reporting the entry into this Agreement, amending applicable items to conform to their obligations hereunder and appending or incorporating by reference this Agreement as an exhibit thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Not a Group with any Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Nothing contained in this Agreement shall be deemed or construed as creating a group, joint venture or partnership between the Investors and any other stockholders of the Company including those stockholders who are entering into Other Investor Agreements concurrently with this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each of the Company and the Investors shall be responsible for its own fees and expenses incurred in connection with the negotiation, execution, and effectuation of this Agreement and the matters contemplated hereby, including, but not limited to attorneys&#8217; fees </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">incurred in connection with the negotiation and execution of this Agreement and all other activities related to the foregoing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company will reimburse the Investor Group for its reasonable, document out-of-pocket fees and expenses (including reasonable, documented legal expenses) incurred solely in connection with the negotiation and execution of this Agreement and related filings in an amount not to exceed $18,750, which amount shall be paid in three equal monthly installments by the Company commencing on the first business day of the month after which the Investor Group provides reasonable documentation of such expenses to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As used in this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Rule 12b-2 promulgated by the SEC under the Exchange Act&#894; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that, for purposes of this Agreement, no Investor shall be deemed an Affiliate of the Company and the Company shall not be deemed an Affiliate of any Investor&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the terms &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">beneficial owner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">beneficial ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the same meanings as set forth in Rule 13d-3 promulgated by the SEC under the Exchange Act&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">business day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any day that is not a Saturday, Sunday, or other day on which commercial banks in the State of New York are authorized or obligated to be closed by applicable law&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the sale of all or substantially all the assets of the Company&#59; any merger, consolidation, or acquisition of the Company with, by or into another corporation, entity, or person&#59; or any change in the ownership of more than 50% of the voting capital stock of the Company in one or more related transactions&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S.&#160;Securities Exchange Act of 1934, as amended&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">the terms &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">proxy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; (and any plurals thereof) have the meanings ascribed to such terms under the Exchange Act and the rules and regulations promulgated thereunder, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that the meaning of &#8220;solicitation&#8221; shall be without regard to the exclusions set forth in Rules 14a-1(l)(2)(iv) and 14a-2 under the Exchange Act&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the terms &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any individual, corporation (including not-for-profit), general or limited partnership, limited liability company, joint venture, estate, trust, association, organization, or other entity of any kind or nature&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (i) a person&#8217;s Affiliates, and (ii) its and their respective directors, officers, employees, partners, members, managers, consultants, legal or other advisors, agents, and other representatives acting in a capacity on behalf of, in concert with or at the direction of such person or its Affiliates&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">the term, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S.&#160;Securities and Exchange Commission&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt"> the term, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Standstill Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the period commencing on the Effective Date and ending upon the earlier to occur of (X) the day immediately after the 2025 Annual Meeting or (Y) October 31, 2025</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or, if earlier, upon the occurrence of any of the following&#58; (i) termination of any Other Investor Agreement or material breach of any Other Investor Agreement by any party to such Other Investor Agreement that is not cured within thirty (30) days&#8217; written notice thereof, (ii) if the Board has not recommended for, or has withdrawn the recommendation for, the election of the Continuing Class 1 Director at the 2024 Annual Meeting or, if applicable, the 2025 Annual Meeting (as long as such Continuing Class 1 Director is available and qualified for such appointment), (iii) if the size of the Board is not eight (8) or fewer seats immediately prior to the 2023 Annual Meeting, (iv) if size of the Board is not eleven (11) seats on the day after the 2023 Annual Meeting, (v) if size of the Board is not nine (9) or fewer seats upon the earlier of (x) immediately prior to the 2024 Annual Meeting and (y) December 1, 2024, (vi) if the size of the Board is increased after it is decreased from eleven (11) seats to nine (9) seats (except for any increase permitted pursuant to Section 1(d)(iv)), (vii) if the Company does not include the Declassification proposal in the 2023 Annual Meeting Proxy or if the Board does not recommend in favor of the adoption of such proposal in the 2023 Annual Meeting Proxy, (viii) if the Declassification Proposal is approved, the Board does not file the Declassification Amendment with the Secretary of State of Delaware within five (5) business days following certification of stockholder approval, (ix) if Nelson Obus is involuntarily removed as a member of the Nominating Committee or the Compensation Committee of the Board, or (x) the 2024 Annual Meeting is not held on or prior to November 30, 2024  (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, that if either of clauses (ii) or (vi) occurs, the Company shall (1) notify the Investor Group in writing of such determination as promptly as practicable, and in any event within one (1) business day thereafter&#59; and (2) agree to delay the 2023 Annual Meeting, the 2024 Annual Meeting, or the 2025 Annual Meeting, as applicable, by at least 75 calendar days to permit the members of the Investor Group (and their Affiliates) to seek the election of the Continuing Class 1 Director (or any replacement candidate) as a director of the Company or submit a stockholder proposal to declassify the Board, as applicable, and engage in a solicitation of proxies with respect to the election of the Continuing Class 1 Director (or any replacement candidate) as a director of the Company or such stockholder proposal, as applicable&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">third party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; refers to any person that is not a party, a member of the Board, a director or officer of the Company, or legal counsel to either party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Specific Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each of the Investors, on the one hand, and the Company, on the other hand, acknowledges and agrees that irreparable injury to the other party hereto may occur in the event any of the provisions of this Agreement are not performed in accordance with their specific terms or are otherwise breached and that such injury would not be adequately compensable in monetary damages. It is accordingly agreed that the Investors or any Investor, on the one hand, and the Company, on the other hand (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Moving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), shall each be entitled to seek specific enforcement of, and injunctive or other equitable relief to prevent any violation of, the terms hereof, and the other party hereto will not take action, directly or indirectly, in opposition to the Moving Party seeking such relief on the grounds that any other remedy or relief is available at law or in equity.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any notices, consents, determinations, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered&#58; (i) upon receipt, when delivered personally&#59; (ii) upon confirmation of receipt, when sent by email (provided such confirmation is not automatically generated)&#59; or (iii)&#160;one (1) business day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same. The addresses for such communications shall be&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If to the Company&#58;</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lifecore Biomedical, Inc.</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3515 Lyman Boulevard</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chaska, MN 55318</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; John.Morberg&#64;lifecore.com</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; John D. Morberg</font></div><div style="padding-left:108pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With copies (which shall not constitute notice) to&#58;</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Latham &#38; Watkins LLP</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">650 Town Center Dr. Floor 20</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Costa Mesa, CA 92626</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Email&#58; Darren.Guttenberg&#64;lw.com&#59; Christopher.Drewry&#64;lw.com&#59; Tessa.Bernhardt&#64;lw.com</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Darren Guttenberg&#59; Christopher Drewry&#59; Tessa Bernhardt</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If to any Investor&#58;</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c&#47;o Wynnefield Capital Management, LLC</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">450 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Avenue, Suite 509</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">New York, NY 10123</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; nobus&#64;wynnecap.com</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nelson Obus</font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With copies (which shall not constitute notice) to&#58;</font></div><div><font><br></font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Kane Kessler, P.C.</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">600 Third Avenue, 35th Floor</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">New York, NY 10016</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; rlawrence&#64;kanekessler.com</font></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Robert L. Lawrence, Esq.</font></div><div style="text-indent:108pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement shall be governed in all respects, including validity, interpretation, and effect, by, and construed in accordance with, the laws of the State of Delaware, without giving effect to the principles of conflicts of law or choice of law thereof or of any other jurisdiction to the extent that such principles would require or permit the application of the laws of another jurisdiction.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each party to this Agreement agrees, on behalf of itself and its Affiliates, that any actions, suits or proceedings arising out of or relating to this Agreement or the transactions contemplated by this Agreement will be brought solely and exclusively in any state or federal court in the State of Delaware (and the parties agree not to commence any action, suit or proceeding relating to this Agreement or the transactions contemplated by this Agreement except in such courts), and further agrees that service of any process, summons, notice or document by U.S. registered mail to the respective addresses set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be effective service of process for any such action, suit or proceeding brought against any party in any such court. Each party, on behalf of itself and its Affiliates, irrevocably and unconditionally waives any objection to the laying of venue of any action, suit or proceeding arising out of this Agreement or the transactions contemplated by this Agreement, in any state or federal court in the State of Delaware, and further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an improper or inconvenient forum.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION, (B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D)&#160;SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SECTION&#160;18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Investor hereby irrevocably appoints WCM as its attorney-in-fact and representative, in such Investor&#8217;s place and stead, to do any and all things and to execute any and all documents and give and receive any and all notices or instructions in connection with this Agreement and the transactions contemplated hereby. The Company shall be entitled to rely, as being binding on each Investor, upon any action taken by WCM or upon any document, notice, instruction, or other writing given or executed by WCM.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement constitutes the full and entire understanding and agreement among the parties with regard to the subject matter hereof, and supersedes all prior and contemporaneous agreements, understandings, and representations, whether oral or written, of the parties with respect to the subject matter hereof. There are no restrictions, agreements, promises, representations, warranties, covenants, or undertakings, oral or written, between the parties other than those expressly set forth herein.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The section&#160;headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No failure on the part of any party to exercise, and no delay in exercising, any right, power, or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such party preclude any other or further exercise thereof or the exercise of any other right, power, or remedy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All remedies hereunder are cumulative and are not exclusive of any other remedies provided by law or equity. In the event of litigation relating to this Agreement, if a court of competent jurisdiction determines in a final, non-appealable order that this Agreement has been breached by either party, then the breaching party shall reimburse the other party for its costs and expenses (including, without limitation, reasonable legal fees and expenses) incurred in connection with all such litigation, including any appeal therefrom.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Receipt of Adequate Information&#59; No Reliance&#59; Representation by Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each party acknowledges that it has received adequate information to enter into this Agreement, that it has had adequate opportunity to make whatever investigation or inquiry it may deem necessary or desirable in connection with the subject matter of this Agreement prior to the execution hereof, and that it has not relied on any promise, representation, or warranty, express, or implied not contained in this Agreement. Each of the parties hereto acknowledges that it has been represented by counsel of its choice throughout all negotiations that have preceded the execution of this Agreement, and that it has executed the same with the advice of said independent counsel. Each party cooperated and participated in the drafting and preparation of this Agreement and the documents referred to herein, and any and all drafts relating thereto exchanged among the parties shall be deemed the work product of all of the parties and may not be construed against any party by reason of its drafting or preparation. Accordingly, any rule of law or any legal decision that would require interpretation of any ambiguities in this Agreement against any party that drafted or prepared it is of no application and is hereby expressly waived by each of the parties hereto, and any controversy over interpretations of this Agreement shall be decided without regards to events of drafting or preparation. Further, any rule of law or any legal decision that would provide any party with a defense to the enforcement of the terms of this Agreement against such party shall have no application and is expressly waived. The provisions of the Agreement shall be interpreted in a reasonable manner so as to effect the intent of the parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. When a reference is made in this Agreement to a section, such reference shall be to a section&#160;of this Agreement, unless otherwise indicated. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation.&#8221; The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The word &#8220;will&#8221; shall be construed to have the same meaning as the word &#8220;shall.&#8221; The words &#8220;dates hereof&#8221; will refer to the Effective Date. The word &#8220;or&#8221; is not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">exclusive. The use of any gender shall be applicable to all genders. The definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms. Any agreement, instrument, law, rule, or statute defined or referred to herein means, unless otherwise indicated, such agreement, instrument, law, rule, or statute as from time to time amended, modified, or supplemented. For purposes of this Agreement, where an obligation of the Company or the Board (or any committee thereof) is qualified by the phrase &#8220;subject to the good faith exercise of the Board of its fiduciary duties under applicable law,&#8221; compliance with such obligation shall not be required if the Board (or, in the case of an obligation that is to be fulfilled by a committee of the Board, such committee), after receipt of advice from counsel regarding the same, determines in good faith that such compliance would violate the Board&#8217;s (or, as the case may be, such committee&#8217;s) fiduciary duties under applicable law. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If any provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Agreement shall remain in full force and effect. Any provision of this Agreement held invalid or unenforceable only in part or degree shall remain in full force and effect to the extent not held invalid or unenforceable. The parties further agree to replace such invalid or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the purposes of such invalid or unenforceable provision.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement may be modified, amended, or otherwise changed only in a writing signed by all of the parties hereto, or in the case of the Investors, the WCM Representative, or their respective successors or assigns. Prior to the Termination Date, the Company shall not agree to any amendment to either of the Other Investor Agreements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The terms and conditions of this Agreement shall be binding upon and be enforceable by the parties hereto and the respective successors, heirs, executors, legal representatives and permitted assigns of the parties, and inure to the benefit of any successor, heir, executor, legal representative or permitted assign of any of the parties&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that no party may assign this Agreement or any rights or obligations hereunder without, with respect to any Investor, the express prior written consent of the Company (with such consent specifically authorized by a majority of the Board), and with respect to the Company, the prior written consent of the WCM Representative, and any assignment in contravention of the foregoing shall be null and avoid.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">No Third-Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The representations, warranties, and agreements of the parties contained herein are intended solely for the benefit of the party to whom such representations, warranties, and&#47;or agreements are made, and shall confer no rights, benefits, remedies, obligations, or liabilities hereunder, whether legal or equitable, in any other person or entity, and no other person or entity shall be entitled to rely thereon.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Counterparts&#59; Facsimile &#47; PDF Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement and any amendments hereto may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become effective when each party hereto shall have received a counterpart hereof signed by the other parties hereto. In the event that any signature to this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Agreement or any amendment hereto is delivered by facsimile transmission or by e-mail delivery of a portable document format (.pdf or similar format) data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &#8220;.pdf&#8221; signature page were an original thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">31.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as otherwise provided in this Agreement or as otherwise mutually agreed in writing by each party, this Agreement shall terminate on the Termination Date. Notwithstanding the foregoing, the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> through this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall survive the termination of this Agreement and any Recipient&#8217;s obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall survive the termination of this Agreement until the Confidentiality Termination Date. No termination of this Agreement shall relieve any party from liability for any breach of this Agreement prior to such termination.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;REMAINDER OF PAGE INTENTIONALLY LEFT BLANK&#93;<br>&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;&#124;</font></div></div></div><div id="i46c8d8777bc043cb9188c1d643cfe281_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF the parties have duly executed and delivered this Agreement as of the date first above written.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIFECORE BIOMEDICAL, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Paul Josephs&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Paul Josephs</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page to Cooperation Agreement&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.442%"><tr><td style="width:1.0%"></td><td style="width:11.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WYNNEFIELD PARTNERS SMALL CAP VALUE, L.P. I</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Wynnefield&#160;Capital Management, LLC,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its General Partner</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Nelson Obus</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nelson Obus</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Co-Managing Member</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.442%"><tr><td style="width:1.0%"></td><td style="width:11.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WYNNEFIELD PARTNERS SMALL CAP VALUE, L.P.</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Wynnefield&#160;Capital Management, LLC,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its General Partner</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Nelson Obus</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nelson Obus</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Co-Managing Member</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.442%"><tr><td style="width:1.0%"></td><td style="width:11.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WYNNEFIELD SMALL CAP VALUE OFFSHORE FUND, LTD.</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Wynnefield&#160;Capital, Inc.,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its Investment Manager</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Nelson Obus</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nelson Obus</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.442%"><tr><td style="width:1.0%"></td><td style="width:11.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WYNNEFIELD CAPITAL INC. PROFIT SHARING &#38; MONEY PURCHASE PLAN</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Nelson Obus</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nelson Obus</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Co-Trustee</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page to Cooperation Agreement&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.442%"><tr><td style="width:1.0%"></td><td style="width:11.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WYNNEFIELD CAPITAL MANAGEMENT, LLC</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Nelson Obus</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nelson Obus</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Co-Managing Member</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.442%"><tr><td style="width:1.0%"></td><td style="width:11.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WYNNEFIELD CAPITAL, INC.</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Nelson Obus</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nelson Obus</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.282%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Nelson Obus</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nelson Obus</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Joshua Landes</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Joshua Landes</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page to Cooperation Agreement&#93;</font></div></div></div><div id="i46c8d8777bc043cb9188c1d643cfe281_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVESTOR GROUP OWNERSHIP</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.629%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Investor</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Shares of Common Stock Beneficially Owned</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Shares of Series A Preferred Shares Beneficially Owned</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WYNNEFIELD PARTNERS SMALL CAP VALUE, L.P. I</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1,972,853</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1,560</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WYNNEFIELD PARTNERS SMALL CAP VALUE, L.P.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1,233,865</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1,040</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WYNNEFIELD SMALL CAP VALUE OFFSHORE FUND, LTD.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">836,965</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">650</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WYNNEFIELD CAPITAL INC. PROFIT SHARING &#38; MONEY PURCHASE PLAN</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">367,350</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">0</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WYNNEFIELD CAPITAL MANAGEMENT, LLC</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3,206,718</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2,600</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WYNNEFIELD CAPITAL, INC.</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">836,965</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">650</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NELSON OBUS</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4,499,720</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3,250</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">JOSHUA LANDES</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4,411,033</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3,250</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div><div id="i46c8d8777bc043cb9188c1d643cfe281_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><br>FORM OF PRESS RELEASE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(see attached)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>exhibit991-lifecorexprcoop.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i6affac77a45649509a2a5a488b216c30_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 99.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Lifecore Biomedical Announces Cooperation Agreement with 22NW</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHASKA, Minn., July 1, 2024</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (GLOBE NEWSWIRE)-- Lifecore Biomedical, Inc. (NASDAQ&#58; LFCR) (&#8220;Lifecore&#8221; or the &#8220;Company&#8221;), a fully integrated contract development and manufacturing organization (&#8220;CDMO&#8221;), today announced it has reached a cooperation agreement (the &#8220;Agreement&#8221;) with 22NW, LP (&#8220;22NW&#8221;), which provides for the addition of Humberto Antunes, Jason Aryeh, Paul Johnson and Matthew Korenberg to the Board of Directors (the &#8220;Board&#8221;) of the Company effective immediately following the 2023 Annual Meeting of Stockholders (the &#8220;2023 Annual Meeting&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Katrina Houde, chair of the Board&#8217;s Nominating and Corporate Governance Committee, stated, &#8220;We are pleased to have reached this Agreement, which will allow us to avoid a costly and distracting proxy fight and focus on the execution of our business plan. The Board looks forward to working with its new members to continue overseeing efforts to build a solid foundation for Lifecore&#8217;s future success, working with our recently installed CEO, Paul Josephs. We welcome Humberto, Jason, Paul and Matt to the boardroom and believe their perspectives will be beneficial as we continue to do what is best for all stockholders.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms. Houde continued, &#8220;We have a strong Board that includes representatives of significant stockholders and individuals with experience critical to overseeing the Company&#8217;s strategy. We believe this composition reinforces alignment between the Board and our stockholders, and positions us well to deliver value for all stakeholders.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aron English, founder of 22NW stated, &#8220;We appreciate the constructive engagement we have had with the Board and believe that its new configuration will even better support Lifecore&#8217;s execution of its business plan and lead to improved stockholder value. Humberto, Jason, Paul and Matt are highly qualified and possess relevant experience and expertise that will make them important voices in the boardroom going forward.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Agreement includes the following key terms&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">22NW will withdraw its notice of nominations of director candidates at the 2023 Annual Meeting, as well as its demand for a special meeting of stockholders to vote on an advisory proposal to declassify the Board. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Nathaniel Calloway, a partner at 22NW, will resign as one of the two Series A Board designees immediately prior to the 2023 Annual Meeting.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Humberto Antunes, Jason Aryeh, Paul Johnson and Matthew Korenberg will join as Board observers within 10 days of the execution of the Agreement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Messrs. Antunes, Johnson and Korenberg will be appointed as directors immediately following the 2023 Annual Meeting and Mr. Aryeh will be added to the slate of the Company&#8217;s nominees for election at the 2023 Annual Meeting as a Series A Board designee. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mr. Korenberg will be appointed as a member of the Audit Committee and Mr. Aryeh will be appointed as a member of the Nominating and Corporate Governance Committee, in each case subject to availability and satisfaction of the required qualifications. If a vacancy were to occur in the role of the Chairperson of the Audit Committee in the future, Mr. Korenberg will also be appointed to such role, subject to availability and satisfaction of the required qualifications.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Following Mr. Barbarosh&#8217;s previously announced determination to resign on or before the 2023 Annual Meeting, the size of the Board will be reduced from nine to eight seats immediately prior to the 2023 Annual Meeting, then will increase from eight seats to 11 seats immediately following the 2023 Annual Meeting, and, finally, will be reduced from 11 to nine seats as of the earlier of the 2024 Annual Meeting of Stockholders or November 30, 2024.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Board will recommend a stockholder proposal to be voted on at the 2023 Annual Meeting to provide for the declassification of the Board, resulting in one-year terms for all directors beginning at the Company&#8217;s 2025 Annual Meeting of Stockholders. This proposal is the result of the Board&#8217;s continued evaluation of the Company&#8217;s corporate governance practices.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">22NW has signed a standstill and support agreement lasting through the 2025 Annual Meeting.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Large stockholders Legion Partners Asset Management, LLC and Wynnefield Capital, Inc., and their respective affiliates, have entered into similar support agreements. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The full text of the Agreement (and the agreements with Legion Partners and Wynnefield Capital) will be filed on Form 8-K with the SEC. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Latham &#38; Watkins LLP is acting as legal counsel to Lifecore.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humberto C. Antunes Biography</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Antunes is an entrepreneur in healthcare, with 40 years of experience in the industry. Mr. Antunes has served as a Partner at Gore Range Capital LLC, a venture capital company focused on healthcare, since May 2017. He also serves as a member of the board of directors of Novaestiq, Inc., a privately owned aesthetic medicine company, since June 2021. Mr. Antunes served as CEO and as a member of the board of directors of Nestle Skin Health S.A., from June 2014 to December 2016, a subsidiary of Nestle S.A. (SWX&#58; NESN). From April 2004 to December 2016, he served as CEO of Galderma Pharma S.A. (SWX&#58; GALD), a former joint-venture between Nestle and L&#8217;Oreal, where he also served as chairperson of its board of directors from June 2014 to December 2016. Prior to his time at Galderma, Mr. Antunes served as President, North America at Galderma Laboratories, L.P., from January 2001 to April 2004. For two decades, Mr. Antunes serves on the board of directors of the American Skin Association. Mr. Antunes received a Bachelor of Science in Business Administration from the University of Nebraska.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jason Aryeh Biography </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jason Aryeh has more than 25 years of equity investment experience focused on the life sciences industry. He is the Founder and Managing General Partner of JALAA Equities, LP, a private investment fund focused on the biotechnology and medical device sectors. He has served in such capacity since 1997. Mr. Aryeh currently serves on the Board of Directors of Ligand Pharmaceuticals (Nasdaq&#58; LGND), Anebulo Pharmaceuticals (Nasdaq&#58; ANEB), and Orchestra BioMed (Nasdaq&#58; OBIO). He serves as Chairman of Ligand&#8217;s Nominating &#38; Governance and on its Compensation Committee, as Chairman of Anebulo&#8217;s Audit and Nominating &#38; Governance Committees, and as Chairman of Orchestra&#8217;s Nominating &#38; Governance and on its Audit Committee. Since 2006, Mr. Aryeh has served as Chairman of the Board, on the Board of Directors or as a consultant to over a dozen public and private life sciences companies and charitable foundations, including the Cystic Fibrosis Foundation&#8217;s Therapeutics Board for seven years. Mr. Aryeh earned a B.A. in economics, with honors, from Colgate University, and is a member of the Omnicron Delta Epsilon Honor Society in economics.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paul H. Johnson Biography</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Johnson has significant CDMO experience, with over 30 years of broad and diverse executive management and board roles within the pharmaceutical and medical device service industries. Mr. Johnson has been a member of the board of directors of Lil&#8217; Drug Store Products, a privately owned leading supplier of healthcare products to c-stores since June 2005, where he also has served on the compensation committee since November 2018.  Mr. Johnson has also been a member of the board of directors of Tjoapack, a privately owned CDMO company, since December 2022, where he is a member of its compensation committee, as well as executive chairman. He has also served on the board of directors of Phosphorex, a privately owned CDMO company, since January 2023. Additionally, Mr. Johnson served on the board of directors of MedPharm Ltd., a privately owned CDMO company, from November 2018 to January 2024, where he served as executive chairman and was a member of its compensation committee. Since 2018, Mr. Johnson has served as an Operating Partner at Ampersand Capital Partners, a private equity firm focused on healthcare companies. Prior to joining Ampersand, Mr. Johnson was President and CEO of Renaissance Pharmaceuticals and DPT, a leading CDMO, from 2015 to 2016, and served as President from 2002 to 2015. Mr. Johnson received a Bachelor of Arts from the University of Texas El Paso, as well as a Masters in Business Administration from Southern Methodist University.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matthew Korenberg Biography</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Korenberg is a seasoned executive with significant leadership experience in the healthcare industry. He has served as the President and Chief Operating Officer of Ligand Pharmaceuticals Incorporated (Nasdaq&#58; LGND) since November 2022 and prior to that as our Chief Financial Officer since August 2015. Prior to joining Ligand, Mr. Korenberg was the founder, Chief Executive Officer and a director of NeuroCircuit Therapeutics, a company focused on developing drugs to treat genetic disorders of the brain with an initial focus on Down syndrome. Prior to founding NeuroCircuit Therapeutics, Mr. Korenberg was a Managing Director and member of the healthcare investment banking team at The Goldman Sachs Group, Inc. (NYSE&#58; GS) from July 1999 through August 2013. During his 14-year tenure at Goldman Sachs, he was focused on advising and financing companies in the biotechnology and pharmaceutical sectors and was based in New York, London and San Francisco. Mr. Korenberg serves on the board, audit and compensation committees of Qualigen Therapeutics, Inc. (Nasdaq&#58; QLGN), a company that develops and manufactures oncology-focused therapeutics and diagnostic products. Mr. Korenberg holds a B.B.A. in Finance and Accounting from the University of Michigan.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">About Lifecore Biomedical </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. As a leading manufacturer of premium, injectable grade Hyaluronic Acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the Company, visit Lifecore&#8217;s website at www.lifecore.com.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the 2023 Annual Meeting. Such forward-looking statements are based on current expectations about future events affecting Lifecore and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond Lifecore&#8217;s control and could cause its actual results to differ materially and adversely from those expressed or implied in its forward-looking statements as a result of various risk factors, including, but not limited to uncertainties regarding future actions that may be taken by 22NW, the potential cost and management distraction attendant to 22NW&#8217;s actions and factors discussed in the &#8220;Risk Factors&#8221; section of Lifecore&#8217;s most recent periodic reports filed with the SEC, which may be obtained for free at the SEC&#8217;s website, www.sec.gov. Although Lifecore believes that the expectations reflected in its forward-looking statements are reasonable, the Company does not know whether its expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today&#8217;s date. Lifecore does not undertake any obligation to update, amend or clarify these statements or the &#8220;Risk Factors&#8221; contained in the Company&#8217;s reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Contact</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeff Sonnek</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(646) 277-1263</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">jeff.sonnek&#64;icrinc.com</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>lndc-20240628.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9de62c0c-edcd-4a54-9604-66eca7237ca7,g:0bc9d023-c4e8-4328-9407-a0fa005fd734-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lndc="http://landec.com/20240628" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://landec.com/20240628">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lndc-20240628_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lndc-20240628_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://landec.com/role/DocumentandEntityInformationDocument">
        <link:definition>0000001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>lndc-20240628_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9de62c0c-edcd-4a54-9604-66eca7237ca7,g:0bc9d023-c4e8-4328-9407-a0fa005fd734-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_89e6aa0d-7a15-417f-8522-da6e88a73692_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0f512739-d913-4a69-a6a0-51b3c2457906_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_f02d632a-81ca-4427-ac40-9c6341767ad8_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_698fda83-ef77-49e3-ab88-664111a1ea65_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_92eae6cd-5ea4-49d3-85ed-6d07c88c7527_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_111fa455-9c89-41e3-9219-dab3dbe43610_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a214dc0f-3846-463f-939c-f0117928a0cc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_0c9d3e0b-90f6-4ca5-9538-2a0778be1da8_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ee772ac8-3966-4d4a-b799-93cd58c563ce_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_5ef6dddb-e8ed-45c9-b325-a28aca35fcae_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_02b7791c-0d1b-4c60-a36f-cdecac8d1278_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_650dc347-06a0-4e05-8de4-df431b0494b2_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_50b6125e-5343-42dc-98f6-6251d4b381d6_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6908f25f-2810-4d81-82c4-7b397b0b3331_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c063436a-f7ac-4f64-92a6-5c1d4cdb8d42_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_28e15abb-7a19-4762-b5f5-cf9ad7497b2a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_16593722-ba33-4011-975e-82deb80c8bff_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_1a31ebd6-f11a-4635-a04e-0488bbd4537f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_1ec485f0-e7a0-4b7b-b1e5-85956f692c20_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e033f51e-0a76-4e42-806c-d4f82190bc4e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_34cedcde-8d79-4e95-80b4-2d742775010b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6f99bb57-b2b2-4280-b6d4-485f05e079ff_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c308f2a8-1e4f-4d21-b657-55cb24ed75c6_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>lndc-20240628_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9de62c0c-edcd-4a54-9604-66eca7237ca7,g:0bc9d023-c4e8-4328-9407-a0fa005fd734-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://landec.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="lndc-20240628.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://landec.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3c942efd-695a-4a95-8961-0ee0f5438191" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_DocumentType_3c942efd-695a-4a95-8961-0ee0f5438191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_78018d69-b220-4d4f-8864-b7daa66859cf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_DocumentPeriodEndDate_78018d69-b220-4d4f-8864-b7daa66859cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a6e75bcd-5f6a-4b2f-8732-a2afdd66409a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_EntityRegistrantName_a6e75bcd-5f6a-4b2f-8732-a2afdd66409a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_af5b6b66-046c-4aaa-a9b4-8dc6ef3da933" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_EntityCentralIndexKey_af5b6b66-046c-4aaa-a9b4-8dc6ef3da933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_545f6c6b-b1b6-4fd4-b52b-d66324f3cdc6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_EntityIncorporationStateCountryCode_545f6c6b-b1b6-4fd4-b52b-d66324f3cdc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_819e42af-b646-4f20-8be5-ba64360b81da" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_EntityFileNumber_819e42af-b646-4f20-8be5-ba64360b81da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_dd6566fd-d9a7-4e29-9a2a-6e6a34fb10ae" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_EntityTaxIdentificationNumber_dd6566fd-d9a7-4e29-9a2a-6e6a34fb10ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2ec6094e-3d52-433a-8b73-4c55ebd665f7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_EntityAddressAddressLine1_2ec6094e-3d52-433a-8b73-4c55ebd665f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_41a46edb-d877-43c3-8b1b-8db03fbf3423" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_EntityAddressCityOrTown_41a46edb-d877-43c3-8b1b-8db03fbf3423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ffdc7718-0cd9-43e7-8b45-62444c2a3e7d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_EntityAddressStateOrProvince_ffdc7718-0cd9-43e7-8b45-62444c2a3e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_62b87dde-cda7-4a59-9521-e4144be78770" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_EntityAddressPostalZipCode_62b87dde-cda7-4a59-9521-e4144be78770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_be9f94de-2c52-4dd3-ab92-585060a5ed10" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_CityAreaCode_be9f94de-2c52-4dd3-ab92-585060a5ed10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_66272a07-2579-41e3-97ef-063e7f6603f1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_LocalPhoneNumber_66272a07-2579-41e3-97ef-063e7f6603f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_ec2bc388-831a-43c4-a8e2-25a546098ea9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_WrittenCommunications_ec2bc388-831a-43c4-a8e2-25a546098ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_e1d99a59-c80a-4b99-a944-3230e1595348" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_SolicitingMaterial_e1d99a59-c80a-4b99-a944-3230e1595348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_c4f0a9b1-33be-43b4-9c52-e10ea7fe38dc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_PreCommencementTenderOffer_c4f0a9b1-33be-43b4-9c52-e10ea7fe38dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_6a616f60-6f36-455a-931e-b7c2fab46be5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_6a616f60-6f36-455a-931e-b7c2fab46be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1a3c1536-b04c-4d22-a195-9d3810aef960" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_Security12bTitle_1a3c1536-b04c-4d22-a195-9d3810aef960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b164a8a6-5ed0-4aad-9e9a-bcb5738a792b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_TradingSymbol_b164a8a6-5ed0-4aad-9e9a-bcb5738a792b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_dc2c1d0b-4167-45b5-8f21-e8142a294aca" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_SecurityExchangeName_dc2c1d0b-4167-45b5-8f21-e8142a294aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_894a105e-ed27-4aee-bccb-3e7ea686be64" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_EntityEmergingGrowthCompany_894a105e-ed27-4aee-bccb-3e7ea686be64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e803c290-b3d6-4a87-8bcd-fad810aae0a4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d37a1c44-fa6c-459e-b3ce-9a90def9e7bb" xlink:to="loc_dei_AmendmentFlag_e803c290-b3d6-4a87-8bcd-fad810aae0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140684612546720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 28,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIFECORE BIOMEDICAL, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001005286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-27446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3025618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3515 Lyman Boulevard<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Chaska,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">55318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">368-4300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LFCR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ G4+A6)>*NQS
M    $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y
M 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/
M:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O
M.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_
M'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "=
M0N%8'#AEZC\!   \ @  #P   'AL+W=O<FMB;V]K+GAM;(U1RV["0 S\E=5^
M0!-0BU1$N)0^D*H6E8K[DG6(Q3XBKP,M7U\G452D7GKR>FR-9V87YTC'?8Q'
M]>5=2(6NF9MYEJ6R!F_236P@R*2*Y U+2X<L-03&IAJ O<NF>3[+O,&@EXN1
M:T/9=1,92L88!.R '<(Y_<Z[5ITPX1X=\G>A^[<#K3P&]'@!6^A<JU3'\TLD
MO,3 QFU+BLX5>C(,=D",Y1]XVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R!
M+ ]=R_$)'0.M#,,SQ;;!<.AHQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E<
M)S"D&IND53 >"CVN*!.L>@PL(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-:
M"Q4&L&]R( DNR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%
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MO-9.&G_FB^$_7G\!4$L! A0#%     @ G4+A6 =!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "=0N%8
M*IBUIN\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " "=0N%8F5R<(Q &  "<)P  $P              @ '-
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( )U"X5BM@Q%M100
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M2P$"% ,4    " "=0N%8)!Z;HJT   #X 0  &@              @ &Z$0
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "=0N%899!Y
MDAD!  #/ P  $P              @ &?$@  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     "0 ) #X"  #I$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lndc-20240628.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://landec.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="lndc-20240628.htm">lndc-20240628.htm</File>
    <File>lndc-20240628.xsd</File>
    <File>lndc-20240628_lab.xml</File>
    <File>lndc-20240628_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lndc-20240628.htm": {
   "nsprefix": "lndc",
   "nsuri": "http://landec.com/20240628",
   "dts": {
    "inline": {
     "local": [
      "lndc-20240628.htm"
     ]
    },
    "schema": {
     "local": [
      "lndc-20240628.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "lndc-20240628_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lndc-20240628_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://landec.com/role/DocumentandEntityInformationDocument",
     "longName": "0000001 - Document - Document and Entity Information Document",
     "shortName": "Document and Entity Information Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lndc-20240628.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lndc-20240628.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://landec.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001005286-24-000081-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001005286-24-000081-xbrl.zip
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M]@"T69X]N<DY;*47M1<@7 '778?VI''-EG7_3W$#B=MTVHPF#HM\[$'J&OU
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M$/\-.<SOZ?E\?%=G6QI?DYG0Q:>574;>AD$7>/>:E8CAW#W-&$,J%+MX!DK
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MHD/B8E]\D[.P,:O'4FT, S>SP85"5P?E$P;U1^:7+AEW0*<VZL=T1&H@!'_
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M)!/ER<OJ:DOY\A*J!/D8&B7&^[*<9G%B, 3\5 Q4&S3+%BYD#1!1428'E^^
M/-B*M[<.6AV0LQ"8A6B2!B9&^N&UR,/ &#::W%9U,>AW5N!,?7:YQQD_A%54
M$I#1A73-]L!;Q@H#BV7SR4(9'-$/?C+Z=I<!%1O2)TLJL.'!ZAX/5LL>,RP4
M>P<O?6)]73*,H+M>>6R]:T78-)[H")B9/7\+NKA)WXG,OF_P35"4%12&I"1=
MF%\W1T:0->!DW+1>%6*5;B0IIU)H!DUN>^2U2[_/3>2Q%-(P,GT$&FDS6!)C
MX0O,2TY86:!6K*^"W"4(K%:0.;,7*YCB4>[!S,DF8X0.(?BBV[+&K+6HZ"<2
M_7..YU1=(V CC9)Q&\RO08H@%50%-&) +!9@H_&NFQB[B;%_G5(*FQC[MY]*
M"^)F*PL1TK1N'7"<]O:T<17@30Q1D>L_<\-M],'.*S]=R&[LV) L71_4R&OM
MB(&M6)="V4&G/-?6$K,7K6':\+0[37$H7>P+[=YINZ]#[V!VX)BO^ZJZ58HE
M!)G9/C15JG()W#6%4^XZTO$LE7&Q&Z=.U;JI6-W1L9Y+/,H0<^F0IF22HLS'
M&D-N0%YPSEBG#CFT0<ON4^59] -R.5K2I0FBQ8_C !4G8X2Z8DE(X&0G8Q65
M]1:'AX0PO?,%3PLWEJJCIWSR#(=1HJ-BFN#*\9H43K)I8S7KJGCM?*$D^\OO
MPPKHT!I]*J$K [[7,5(.R(P3$\^R-<RI4JVUX?1TK0!VY'"I?)$>KS[8U]<C
MXN%J]YN;C6'PQKA]N(*E>!H< 6$J:G(Q"Y#LUTH3!FIB0(*%PQ?7\@8=$:0#
M:+VV6)<PE=K0;J)+!N@T4I2CP@G:,)@Q1H8I6$7'=-1'J/VT00[0(BDW6^^N
MK>>P9^KCV"%NF,UKF-TZ=R7CXET<RS+!LWQ0-\HIGQS[2AWGIN!%F&%S#3J;
ML=N<5TN,^\^\+K((<R#"AG./ZA4V*#'A!$^G9;7-()=Y*H*G(:""R$HIAL8%
M^V3R8 HA$21$ TVSL45-9HQYF5FDLZ>YH7CZ\AVQV0H/W@KK12+SJ4."7@=&
M;1YCR\$^2["HF0=::UQ$XRB]AO_PIR8W;=@DKW58.D);YYHSP"8PK?EP&+*"
M3D0&[/.M LP8EJ2Q!;4P'#Z$88+Y= SJ,2FZC9R.]M(9^5QJW/720+J$K36N
M_A9<)(=U9A%@\V+?>(_&C=G$27[2O.<T0.UM6"[">?F5[IP+&Q#)EPII)")F
MLL@-M(7\'GPZP;9 GSX?#$YFL39NV-MBF+GV=W7;7JHTNL6(VVL%UCATY=@!
M8[Z);ATDGU-UG"(?SEF$%'A%+*7L)K;R7C_//W+,"QE5B]C)N-09KZ5+%44P
M/#SO[<_;S<FY8T/![VNTI[JSJ;1O1[,S,==QV$Z$[.PY#.W64>S1->6"^"!0
M:%,I<I>O+6XXZT-Q# 1;>F5-2G#T.S/M)GWG+*]PV V9) R_\0FO@@JZ[-H9
MN.;G5R,)9USL30 @2-M1TD\JQBRBHC-HD)XX<E2*7^-S*@3O(II!."#.^U39
MM-AFDI2M1%@!'*4-[K2^6K_PIR-]V^#7)N9F#P0+[_; %>2/;WB --B+[+98
MP_SA\+!.H+DNXE"C*%U%U/4##=M>&7(5:]M;?Q3$#.7.)HCYL]6]$ THE%:F
MKQX# /%'4;JP3NNYB9*4SD_G[JYQBW8B(LFNOWE+1,/FB11$E@,6-L^&7#,W
M8H/9<?P1^:XL+@M6=]:2'VN8]9S$M%!@I?CKX\XT1GRQY#'.Q#P,''(#^#"
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M^VH<DJY#L@LKWQ8+C".O9D<0!9=151?P=1A<0@^BJ4/F2^Y4G=9.SM=BP-5
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ML P$+N&Z/7G_3^4=>6DTE6P9]A'*DES0NX;X^.+=$WZF)/"WU[W'P* T16+
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MEV9>Y^_G<3J=!<F\ ]NUXS/-!\,)$CKN'/#3/$UR+XYR5"7@\FE1>.1-@#,
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MM[NWUT=;F@=9 Y(XYJ5<X5(Z0PN]J&7CKV!P>.<1? ''"3KL(%;>.V.W7&W
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MG64J$81[T/P#I)<=NNEE:W #:,K=2YC:]2C#G4];&R.4T D4_:B 5WJ@+T7
M$&\#H,:<W6Q1 /+,>A DV!RJ(,0W>4#Y8%M%^80OA9:>^[N/-7D?H0:@V!2[
MQ,<Q ^+E/ YN\W47>;R*+IRM&-B);#\=5UZ"_1I:2H3SORH'?['#QY<$?#!7
M\3NL@YZA48S)6]HH'LPK/B\X+#<T9L8EQ6Z!4<N/V1:ORH@O$PS5'*<<7IV/
M@J'K3*@K5(9S.>R(E3+4PWCA7\[5:)K1%.\L? ]6?L6OW, #UN!"M\HN[__
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M1YDAU[2'LW>X4@<VGI*<17G7,511$NM\'[.REIHP1@R(Y;+,4C$(/>HFB,M
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MX[&YE_(G#I(-.^WN''?_F4#A:9Y7X7354Q:7=X%=-PD2!G7G2FX5 S&0-RI
M#I:%TEO":MN%]'JDU T9V:2*&?^3;R"-X*+0>,)/3=Y'5$T@KPZH;R@F:&1<
M@>US])3,%%MEZ2#L5%-&-@TIKDM=(71+T-N 3[Q!&IK\20JYSPHG8]BR"[YG
MK3S#H]Q2MX:@Z9X1B$A:9L-F.8US)$"EU5['3?$[C3IS"T'E8\:W#+:NWK_#
MA.S@&+4?V:2-+7C/E]0PZ*0X9;JA<V"!T,M1"1UQ7E:EUL%W,"?0DXGI;I*-
MY8Q'KA[J0,)#M IB='@S7!FL:QP)U 25_R!V)U?C8#X_8NLD]6 !\_4 B^!G
MF&;(!14.S@6E\+D0'8Q.A:V(."D7JYRIF4-.3GM#6A-6P@FY@]1KAUII<50$
M1(B2OAM-K2(N.;,TNTZQFLB6#[EO<@*?C8V0"&E.U)QZ5Z4["E;N&IOOT3;S
MQF3>]+>9-QN2>;.,.5;(*\KKX(X6R)+"A$XL\#Z\1H*1(\%>PPX2+C,UC%;P
MI%QXJ@I3<3&-$0#,Q;SR!3.<<&=#9=*RF4V![6RPCS5DEJYBL#/)=[VKMK>9
M<'4+7ZFS,^JQ> ]>T]+&VP41M2 7%MJDQEJ)5QO()MPVIY@/9O[3CX=/7Z 2
MEP6A8+%CLF\\YX":_LM4A*!V\LD;E:BT61@T^#'*!?ITH)+A!&[[1_G;HK,'
M^4=%7A<'E(GC#PT3GY!*)]-Q)\."';'F;K#@Q(:%)<^[NC&2[LTWPL88[X2'
MVI@JB57FW+1DBSBDU''7V4IK3'00OI[]16PT5VU,I.-;NM)"6&:C%M*G_PRK
MF<&L\$@WX(P3C;7FIO!01CFS^3C(B[L37GKXZ-J$6/!:73N9B(@0V(%0R\Z&
MP" ]7AL8I".C 6I4JXL%+G-E9>99<)MW\W9_IQUOX3,G=Y?V+:C:$\JFRR=4
M@,J]/.2G6L7F@K+IS 4*?Y^0M^NJH JXD0JI^8>CUF#?<J?JR]%=,4T.B$4P
M/*=8\CWDQWNP43$7S\;B/^DT*^O,C;2<BUWOXIZ!$P/CA=R0IBHQ29/%A!9!
MI@XLF+2HUD/3]'9Y6DWEJG"=L;872%[)A,@J$ /)=,5AM-^J1JQQUTU#>?IE
M%?J\R;-JRS#EC<PZJ@7N5!M)Z4=2U6_JU_%JYDIQ@,/@O\M06 P=?42[$=N2
M&&1C7@(_:1=QSQ3:9;5B66,4#,VX!:@N7;;B0 8$\\8T 0N/;VX$%KC<H"2N
MOLRWF;ADL=1W.T_U)!TH\- 6N7U&)0,VV(*!T>>F@#<P:Q#32D,8NA>X(25K
M 7V\RJ!JC&G7JZ14ZP)G6*L/$XEC:DGC+:(7T\1,]*$>R&S29JI>8-./HZ4T
MVJ><[J"PW7 5!]2,Q[@.GZ A=$P'C&@4J7#'!7NH74*G1-KFK)O6'NE,);I=
MIS;.86^3,+WUPI+A"=ETQFGA:NP,ZI72F7(0QJG[;A"J&BJ/Q8%PNW0*>%0D
MIR])#X$WB(&$D%/-J);]BV94"]7H-=XYK0W1"9^LC4YX62FVX&OQ@<LM%OTF
MJP7(=)F)J1'A&4N!B*$TB[)---T+=BI7=")]"H;21@TN;'I+L/ZATQ$ F])^
M@IM)C7D7 A&(T!$13 $'.U% ]P8[]4?Q50.E$J B ;ZBYK*Q:3WP'T7.-GI/
M*%[+&)O>+@@FW^'4F.A$ W%9<<0>5R=V:2 EM*J_('0H[=_ L,/# 7*":F7
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M!4D219UT;M]\&$?!("*4>=,9H9('#A8^U1GZ8& #4_ -*)=X$%R0,N/-8Z>
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MHP2/7UQ3>H2$JGL+.'LA&J\<'?RN&Z G*VU>_HO76)S%.7.%Z:;25+CE6"V
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M/NPZ:/><@3/.%6%S2Q_L^JVCANNHX1='#>ES<>&[=Z1MJHH%'"EK4SG=")B
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M')H.RH7'$+"5Q7P:E=7]8)(-O'1ITA>XK2X=E!^2F/4@C;&Y(MQ#CY>&>^C
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M8+[*N#@Z#%[1:B]64ZQ(95K_>N^>>J#/<5X7P<;>9J-)QQ=I9R2GQ];;XF^
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MC6FDPKY# \7%) X\N"MX12X FN!(I4X%V2@B^3IL%G4>%;N4>-:0#;PH[XB
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M$%OE': JQG(<8O2@9Q.9>97H2J:5+NE= #2,!>BL0BS!5HYG"A(NPG0 T@R
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M16@/O*#@3&.ATJXKA?N6A-RK7Z'F!D$\62L<B =!;A'S_6[#JDYLEOY.$WA
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MP3G>WMLT'.6/G65@R!>2O.@4@IU(^K,R]HOAQ:EO,0,P8B"J^9:[M7SK;?=
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M(Q ,'$E>(S"9TXS>ZGFL)V-.<QBE/XU,AY):-G8_X[1)H0EM9.VN-K6"WZW
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MD[*F4[SRC4#!D*"$7"Z]*[!D+$HL6=/0:9>.OEF.(WPWX(]F\O<)MD,*7[E
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M7-SR%"Y!XODSPX#AXR#P%"!S!D2,#U<U$VHNV234H:QS4_!@3-@D+&K$*1C
M]SP#)N7*E(/@EO'?:SL]ZKTMB$H (JE,2>(BY0VE.L.<\1 "R]W%*3E5DN'C
M!73D,B</5FCD.14QF=KN7"1MS0R4)'=8UM;*_33N%O%?;'4K*";-Y4#BFQ&B
M&VJ-<H4LXGC"M,#F4*@LXRKJ#)[XAM6QD%<%1@&[Q2/2J)_Z8<HSE%R=5-@)
M^J1N:R@T(Y7C$!A1SPJY1 :1""5ND,(11O?0D!3XI :34<_^:3>**Z*?04P#
M*4):FQ8)/8,BH]./,&M*R4>H\I+& G$)Q6!E!!;Y>^+$+O?H^""_X-C1#/\I
MM1BR$EGDB5/)LE[[V#61B@-'5%J(!!$S1OSW'M$N*'9YQ!OC*9P36ADJ$(8.
MI>!.X#%U:RH$_!5[;4!U^]E[BB6*)1/[COM9G1V?U;F0*V<R1UA4[3A2*-+'
M&_X=N4\MFF9?>EPP+AJ?%Q4:KBHT2@:Z36Z+9!\)=S9JC? .IVLQFMF25?N5
MWU @)S-[E/1^@>04;_SZ2*1Y38DTJZ]$VL<KD1)S?G8"BIK8!.R/3?;WO?5-
M1L>P@$XC!_B4CF4$II7./;RY/1L818W\*P+&\/8&Y==2:\/"B>4%N[,1% 0!
MJ(C0>$4/6&SDMMOK[FK_D7>(W5"42]Y02'[KF>=8_EBYJX'$,;.[X<6178JF
M!<#\0-4 9_,,U]8#4'H[,7I*ST-ZGG9#WRAZ\E&]RC24$%\0.E%0!V$,Z%ST
M&1/HBF[..X@B+LOOORS3BB$##7)]2#6=8HZ4!T9F@0&WXMFF\5TBBH=C8)=_
MF6>Z77%O $S"1Y%3&"P\%!40@_C,4N@ 76$"F"?5$[D=4W;D.53+2^K5-K+:
M672I8E\A6@5.B:LVVD#]:JF0+Y([YNZ/,$SI354VLP@'3( S5D(@,.C1BU2/
M1RJGLZE7DFXPCO&2!Z);P;P]/O5%1_UQB#YUF\\[ED.]I8\.)QSO'JV$( L1
M3.8*:2*H?!V#FVI- ISP%O2PY?!U%5[MY3RO50\:C=Q7M:JVT7.]NJ^U-OJB
MJ%,'C6JMD?\J457.5=R*F&!RB_5+;?OJ^,"=/K\NHZE7R]^%&\OPZHO+:SBL
M8G(M&3]> /M"MYOG$^ DCH^L08 G89=0TH$).D MC+5:)E,CWY"6DI/6L*%R
MZ#P</MDM\K+;)OJ"",!U")=@*>@.5WU)W3 ;JMK#%^\@&WMXE7;8'ZVF5>S0
MJW5O$.*OC@/@7CR>ZM,>SUJ'CQ:F)^&.#QYX$AXH</!G+X+)Q*H&<^EIFKB
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MLD_#?;R/)/*"7?Z6S-J]@6O.X7_C8&(?_1=02P,$%     @ G4+A6#IPS .
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MF"UY"WF#2$E-V_IXWBZL5VE;8>C+=F_CP\7=?.\MMQ=L;HQQYP]02P,$%
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M[*Z4;?\WV+]7^^=JW:/WVVML0.O7'7?DSF^ON=W&;__PP7W?=M]"(ZAD2&(
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M%P_M2*,!T6E@FXCN ;X+MU,3J.3S3[G2]__2#S/$0Z2%HB!%B-=GJ"+ (=$
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MG0P@[5G D2'KMK/+5\^X/K2V*VY@_'[R:O-,MOJTSI-7_P-02P,$%     @
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MCQG7-B>2]97AB*O>24#H_;9H2J/(;^%B*O1>,K!&L#1/N>:0HD_&X?"EM6$
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M4$L! A0#%     @ G4+A6.Q9RZ2%;P  XV4# !X              ( !
M &5X:&EB:70Q,#$M;&EF96-O<F5X8V]O<&5R+FAT;5!+ 0(4 Q0    ( )U"
MX5B%<+LH %P  )_@ @ >              "  <%O  !E>&AI8FET,3 R+6QI
M9F5C;W)E>&-O;W!E<BYH=&U02P$"% ,4    " "=0N%8?0RB%>E@  "]%@,
M'@              @ ']RP  97AH:6)I=#$P,RUL:69E8V]R97AC;V]P97(N
M:'1M4$L! A0#%     @ G4+A6+KO>I'$%   8U,  !X              ( !
M(BT! &5X:&EB:70Y.3$M;&EF96-O<F5X<')C;V]P+FAT;5!+ 0(4 Q0    (
M )U"X5A_%.TG5B   -OI   1              "  2)" 0!L;F1C+3(P,C0P
M-C(X+FAT;5!+ 0(4 Q0    ( )U"X5@Z<,P#@ (  +\'   1
M  "  :=B 0!L;F1C+3(P,C0P-C(X+GAS9%!+ 0(4 Q0    ( )U"X5C?TB-]
M*0H  'U5   5              "  59E 0!L;F1C+3(P,C0P-C(X7VQA8BYX
M;6Q02P$"% ,4    " "=0N%8K8&+3K(&   O,0  %0              @ &R
M;P$ ;&YD8RTR,#(T,#8R.%]P<F4N>&UL4$L%!@     (  @ - (  )=V 0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>lndc-20240628_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lndc-20240628.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001005286</identifier>
        </entity>
        <period>
            <startDate>2024-06-28</startDate>
            <endDate>2024-06-28</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001005286</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-06-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">LIFECORE BIOMEDICAL, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-27446</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">94-3025618</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">3515 Lyman Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Chaska,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">55318</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">952</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">368-4300</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">LFCR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
